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Introduction 
 
 
 
- The need for a broad based set of health care standards to 
guide the provision of health services to prisoners has been 
identified in various reports, specifically in various Annual 
Reports of the Director of Prison Medical Services and in 
the Report of the Group to Review the Structure and 
Organisation of Prison Health Care Services (ch. 2.3).  
Recognising this, the Prison Service Strategy Statement for 
2001 - 2003 has identified (Target 8.2) as a core target in the 
care area the need to define a set of health care standards. 
 
- This document specifically refers to prisoner health care.   
 
- These standards have been developed by a multidisciplinary 
group representing the various health related interests 
involved in prisoner health care. 
 
- The standards recognise not only the need to define the 
services to be provided but also that the effectiveness of 
such services should be measurable. 
 
- These standards are based on health care activities which 
are operationally essential taking account of the prison 
context, reflect good clinical practice within the general 
community, and are cost effective.  It is desirable that all 
such activities are undertaken by staff who are 
professionally accountable. 
 
- It is intended that these standards will provide Governors 
and other managers with clear guidance regarding the 
health services to be provided and the facilities required to 
provide them.  The various criteria and targets outlined will 
assist in assessing whether or not the standards are being 
met.   
 
- The standards outlined in this document are intended to 
assist in the formulation of the health care aspects of local 
Business Plans. 
 
- For various health care staff - Doctors, Nurses, Dentists, 
Medical Orderlies, etc., the standards provide guidance 
regarding the range of health care services to be provided in 
accordance with good practice guidelines. 
 
- Similarly, prisoners are provided with an outline of the level 
of service which they may expect to receive. 
 
- These standards are intended to take account of similar 
approaches elsewhere as well as reflecting good clinical 
practice in the general community.  They are set nationally 
in order to achieve consistency of care for all prisoners, 
regardless of location, which reflect the standards of care 
available to citizens covered by the General Medical Scheme 
(GMS) in the general community.   
 
 
- It is recognised that the health care currently provided to 
prisoners is generally of a high standard.  The purpose of 
defining various standards, etc., is to facilitate the 
implementation of a consistent level of care across the 
prison estate and to provide a mechanism whereby 
excellence can be acknowledged and any deficits addressed. 
 
- Local prison business plans should outline envisaged time 
scales, targets, etc.. 
 
- The standards outlined in this document will constitute 
envisaged targets which will be audited on an annual basis.  
These standards will be reviewed annually and revised 
accordingly. 
 
 
 
 
 
Health Care Services :   Core Aims and Underpinning  
     Philosophical Values 
 
Aim of Health Care 
 
- The aim of Health care within the Irish Prison Service is to provide 
prisoners with access to the same quality and range of health services as 
that available to those entitled to GMS services in the community 
 
- Priority is given to the promotion of health through the positive 
intervention of staff. 
 
 
 
Philosophical Values 
 
-  Given the nature of imprisonment it is accepted that in the interests of 
overall prison operation it is essential that those detained be treated in a 
fair and consistent manner. In the context of custodial health care 
provision all prisoners, regardless of personal means, are regarded as 
citizens covered by the General Medical Scheme. 
 
- The Prison Health Care Service is committed to treating all prisoners with 
dignity accepting that, notwithstanding the limitations on personal 
autonomy imposed by imprisonment, they should be directly involved in 
their health care.  (See HC Policy A/1 - ‘Complaints from Prisoners 
regarding Medical Treatment’) 
 
- All prison health care is provided on the basis of the same standards of 
consent and confidentiality as exist in the general community. (See HC 
Policy A/2 - ‘Guidance for Healthcare Staff in Relation to the 
Responsibility to Safeguard the Confidentiality of Medical Information 
concerning Prisoners’). 
 
- In relation to the involvement of prisoners in health research projects 
please refer to HC Policy A/3 - ‘Health Research Projects involving 
Prisoners’. 
 
 
 
 
 
 
 
 
 
Notes on Format and Terminology 
 
Each section of this set of health care standards  
 
 - defines the particular standard,  
 
- outlines the criterion or criteria by which the particular standard is 
measured, and  
 
 - may indicate a target which would be reasonable to achieve. 
 
These are defined as follows -  
 
Standard : An item in relation to a particular aspect of Health Care by which the 
quality of that item may be measured. 
 
Criterion : A single variable selected to facilitate the measurement of an element of 
care. 
 
Target : The specification of the expected level of achievement. 
 
 
Example : 
 
To illustrate the above terms the following examples are offered :  
 
Reception Assessment - 
 
Standard : All prisoners to be medically assessed on reception. 
 
Criterion :  A nursing assessment be undertaken in the reception area.   
 
Target : All receptions should have a thorough clinical assessment by a medical 
practitioner within 24 hours of entering prison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health Care Standard 1 : 
 
Health Assessment on Initial Reception into Prison from the 
Community 
 
Standard 
 
1. All prisoners on reception will undergo a clinical assessment. 
 
2. Initial Committal assessment will be carried out on the day of reception in the 
reception area or other appropriate clinical area. It is desirable that this initial 
committal assessment be undertaken by a qualified nurse in view of the various 
healthcare issues which may arise.  In those prisons where nursing staff are not 
consistently available this function can be undertaken by medical orderlies.   
 
3. Within 24 hours of reception a doctor will undertake a clinical assessment of the 
prisoner's physical and mental health.  
 
4. Suitable interview and examination rooms which are properly equipped and 
maintained will be provided within the reception area and/or other suitable area 
within the prison. 
 
 
1.1 Criteria: Organisational Matters 
 
1.1.1 The reception process should be organised in such a way as to allow 
adequate time for initial screening by a Nurse. 
 
1.1.2 The Governor, or other officer deputed by him, will be responsible for 
ensuring that any prisoner who is to undergo medical examination and 
assessment is produced for that purpose.  He is also responsible for 
ensuring that information received from outside sources at the time of 
reception concerning the health status of a prisoner is relayed to the Nurse 
or Doctor. 
 
1.1.3 The Governor is responsible for the maintenance of good order in any 
designated health care area of the prison. 
 
1.1.4 A Nurse or, where a nurse is not available, a Medical Orderly will be 
available to assess and attend to the immediate health care needs of any 
prisoner on reception.  
 
1.1.5 Initial health care screening will be carried out on the day of reception by 
a Nurse or Medical Orderly.  This should occur in the Reception area or 
other appropriate clinical area prior to any cell allocation. 
 
1.1.6 A Doctor will be available for consultation, either in person or by 
telephone, to address any urgent clinical concerns arising in relation to a 
newly received prisoner. 
 
1.1.7 All prisoners will receive within 24 hours of reception a physical and 
mental health assessment by a Doctor.  This should include examination 
of Heart, Lungs, Abdomen, CNS, and any other examination deemed 
appropriate by the doctor.  
 
 
 
1.1.8 Any prisoner who refuses healthcare assessment will be required to sign a 
disclaimer to this effect. This disclaimer should be placed on his/her 
health care record and should be brought to the attention of the responsible 
doctor and be followed up by a nurse who should continue to offer 
medical assessment. 
 
1.1.9 The weight (in kilograms) of the prisoner will be recorded at the time of 
each admission.  The height (in centimetres) will be recorded on first 
admission only. 
 
1.1.10 Each prisoner will be provided with information in a format 
understandable to him/her to explain how health care services are 
provided and how to seek help. 
 
1.1.11 All health care interviews will be carried out in such a manner as to ensure 
the privacy and confidentiality of the interaction except where in the 
opinion of the health care staff, and based on advice from other prison 
staff, the prisoner requires an escort on the grounds of security. 
 
1.1.12 Properly equipped and maintained interview/examination rooms will be 
provided within the reception area and/or other agreed place in the prison. 
 
1.1.13 All health care records will be completed promptly and maintained 
accurately in computerised format.  Such records will be kept in 
accordance with legal requirements and any professional ethical guidance. 
 
 
 
 
 
 
 1.2 Criteria: Initial Nursing Screening 
 
Please refer to Standard – Item 2 above (relating to Initial Committal 
Assessment). 
 
1.2.1 Sufficient time and adequate privacy will be allowed for each initial 
screening. 
 
1.2.2 The Nurse will assess the prisoner’s general health and will encourage 
discussion with the prisoner regarding health care matters. 
 
1.2.3 The Nurse will assess the prisoner’s self-injury/suicide risk and, if 
necessary, advise on appropriate immediate precautions. 
 
1.2.4 If the prisoner is considered to be in urgent need of treatment the Nurse 
will consult the responsible Doctor immediately.  Any action taken will be 
recorded in the health care record. 
 
1.2.5 The Nurse will ensure that the initial screening record, together with any 
other related documentation, is made available to the Doctor carrying out 
the clinical examination of the prisoner. A summary of the nursing 
assessment must be documented in the Nurses notes. This summary must 
indicate conclusion as to the patient’s health status. 
 
   
 
1.3 Criteria: Doctor’s Examination 
 
1.3.1 The Doctor will carry out, in conditions appropriate to safeguard 
confidentiality, an assessment of the physical and mental state of every 
new prisoner, having due regard to information obtained during the 
committal interview. 
 
1.3.2 Urgent cases will be seen on the day of reception.  Under normal 
circumstances medical assessment will be undertaken on the day 
following reception.  Adequate time should be available to enable a 
thorough consultation. (See HC Policy A/4 - ‘Medical Assessment of New 
Receptions’). 
 
1.3.3 The Doctor will take a medical and psychiatric history together with a 
history of substance misuse, including details of alcohol use, misuse of 
prescribed medication and/or illicit drug use and record the information on 
PMRS. 
 1.3.4 The Doctor will make specific enquiry regarding signs or symptoms 
relating to suicide or self-injury behaviour, depression, infectious diseases, 
and substance misuse and record the information on PMRS. 
 
1.3.5 Any necessary or appropriate physical examination will be carried out.  
The physical examination will include examination of Heart, Lungs, 
Abdomen, CNS, and any other examination deemed appropriate by the 
doctor. 
 
1.3.6 If further investigation or specialist examination is required this will be 
arranged by the Doctor. 
 
1.3.7 Examination of a prisoner’s mental health status should include account of 
any known psychiatric history, particularly in-patient admissions, alcohol 
and substance abuse, and any history of self-injury. 
 
1.3.8 Where appropriate the Doctor will refer those with psychiatric illness to 
the visiting Psychiatrist for further assessment.  Prisoners deemed to 
require psychiatric in-patient care should be transferred to an appropriate 
location under the terms of the appropriate legislation. 
 
1.3.9 The Doctor will assess the prisoner’s self-injury/suicide risk and, if 
necessary, advise on appropriate immediate precautions. 
 
1.3.10 In the case of those prisoners suffering from chronic diseases (e.g.  
Asthma, COPD, Diabetes, Hypertension, Ischaemic Heart disease, 
Epilepsy, etc.), the Doctor will carry out a review of the management of 
the condition and compliance with treatment, and will consider the need 
for specialist review and other investigations. 
 
1.3.11 Appropriate screening for communicable diseases (TB, HIV, Hepatitis) 
should be carried out (See HC Policy C/1 - ‘Screening for Infectious or 
Communicable Diseases’ and Appendix 2 - ‘Protocol for the Management 
of Tuberculosis in Prison’) 
 
1.3.12  As in the general community there is an obligation on Prison Doctors to 
notify statutory public health authorities of any cases of a notifiable 
disease occurring in the prisoner population. (See HC Policy C/2 - 
Notifiable Diseases’). 
 
1.3.13 In relation to the conditions listed above (and any other relevant illnesses) 
a programme of regular review will be commenced. 
 
1.3.14 On the basis of clinical assessment the Doctor will advise in relation to the 
prisoner’s health care needs and location within the prison. 
 1.3.15 The Doctor will advise in relation to the prisoner’s fitness for work and 
other occupation within the prison. 
 
1.3.16 Requests from prisoners for access to healthcare on a private basis should 
be guided by HC Policy A/5 - ‘Private Medical Arrangements by 
Prisoners’ 
 
 
1.4  Criteria: Facilities and Equipment 
 
1.4.1 Each room provided for Nursing/Medical interview or examination will be 
of sufficient size to accommodate at least three people in comfort together 
with fixtures, furnishings and equipment. 
 
1.4.2 Each interview/examination room will be equipped with a desk/table, 
three chairs, examination couch, wash basin, PMRS access, and secure 
storage for confidential papers.  In addition each room used for medical 
examination will be equipped with a sphygmomanometer, scales, 
stethoscope, ophthalmoscope, auroscope, and eyecharts. 
 
1.4.3 All rooms will be cleaned according to current infection control standards, 
well maintained and comfortably heated to current building and design 
standards. 
 
1.4.4 All health care locations will be provided with a telephone with direct 
dialling facilities to the outside that can be disconnected when necessary. 
 
1.4.5 Each Health Care Centre will have a Fax Machine, photocopier, and 
shredder. 
 
1.4.6 Each clinical consulting room will be provided with access to the Prisoner 
Medical Record System (PMRS). 
 
1.4.7 Requests for the provision of Medical Equipment should be in line with 
HC Policy A/6 - ‘Acquisition of Medical Equipment’.  
 
  
 
 
 
 
 Health Care Standard 2: 
 
Primary Care 
 
Standard 
 
1. Primary Care Services will be provided to a standard equivalent to that available 
in the general community (GMS standard). 
 
2. Suitable, properly equipped accommodation and facilities for the delivery of 
primary care will be provided. 
 
3. Access to specialist services appropriate to the health care needs of prisoners will 
be provided within the prison. 
 
4. Efficient arrangements for referral to external outpatient facilities will be in place. 
 
2.1 Criteria: Organisational Matters 
 
2.1.1 A Primary Health Care Service will be provided on a 24 hour basis in 
closed prisons. A close working relationship will be developed between 
Health Care staff and relevant prison management.  Appropriate 
arrangements will be made to ensure that all relevant staff are aware of the 
care plans for prisoners for whom they are responsible, and of their part in 
carrying out the plan. 
 
 
2.1.2 A Nurse will be available to undertake nursing assessment on a 24 hours 
basis where appropriate. 
 
2.1.3 A Doctor will be on call and available for consultation at all times outside 
normal hours of attendance and will attend as necessary. 
 
2.1.4 Appropriate administrative support will be provided. 
 
 
2.1.5 All aspects of primary health care will be provided as clinically 
appropriate (See HC Policy A/7 - ‘Recruitment / Engagement of Medical 
or Therapeutic Staff’ and HC Policy A/8 - ‘Provision of Para-Medical 
Therapies at State Expense’) 
 
2.1.6 Urgent cases will always be seen as appropriate. 
 
2.1.7 Requests for Healthcare interventions can be undertaken by a member of 
the health care team and any necessary follow-up arranged.   
 
2.1.8 The Governor will ensure that prisoners who are required to see a 
Healthcare professional attend the Health Care Centre in good time.  In 
the case of open centres the onus lies with the prisoner to make 
him/herself available to see the Healthcare professional. 
 
2.1.9 Accurate Health Care Records will be maintained on all prisoners.  
Records should be maintained in the Prisoner Medical Record System 
(PMRS). 
 
2.1.10 All health care record entries will be signed and dated by the health care 
staff directly responsible for providing treatment as appropriate. 
 
2.1.11 Prisoners will be allowed access to their personal health care records in 
accordance with good clinical practice guidelines and any legislative 
provisions pertaining. 
 
2.1.12 In relation to requests for medical reports concerning prisoners guidance is 
available in the following -  
 
HC Policy A/9     - ‘Requests for Medical Reports on Prisoners’ 
HC Policy A/10   - ‘Requests for Medical Information on Prisoners by the 
Parole Board.’ 
HC Policy A/11   - ‘Freedom of Information Act’. 
HC Policy A/12   - ‘Repatriation of Prisoners under the terms of the 
European Convention on the Transfer of Sentenced 
Prisoners’. 
HC Policy A/13   - ‘Annual Medical Reports’ 
 
 
 
2.2 Criteria: Referral to External Hospitals 
 
2.2.1 Prisoners will be referred to external specialist services as clinically 
indicated.  Referral will be on the same basis as for citizens in the general 
community covered by the GMS (Medical Card) scheme. 
 
2.2.2 Where a prisoner is committed with existing medical appointments 
procedural guidance is provided in HC Policy A/14 - ‘Extant Medical 
Appointments on Committal’. 
 
2.2.3 Decisions regarding where a prisoner should be referred should be a 
matter for clinical judgement, taking into account operational 
considerations. 
 2.2.4 Referrals should be accompanied by all relevant information. Where 
practical extracts from the prisoner’s Health Care Record, including a 
clinical summary, will be provided to the receiving hospital. All referral 
letters will be generated on PMRS. 
 
2.2.5 Any emergency attendance at an outside hospital will be effected with 
appropriate urgency. 
 
2.2.6 Arrangements will be made by the Governor to ensure that prisoners keep 
appointments. In the event for operational reasons that such appointments 
are cancelled, the Governor is responsible for consulting or informing 
Healthcare.  
 
2.2.7 It is important to keep prisoners appraised of the status of any external 
hospital appointment while bearing in mind the need to maintain security 
around exact dates. 
 
 
2.3 Criteria: Prison-Based Specialist Services 
 
2.3.1 Where appropriate, arrangements will be made with local H.S.E. or other 
health service providers, or with individual practitioners for the provision 
of specialist advice and treatment. 
 
2.3.2 Prisoners will be referred to specialist services on the same basis as would 
apply to individuals holding Medical Cards in the general community (See 
HC Policy A/15 - ‘Referral for Specialist Medical Assessment’). 
 
2.3.3 Arrangements will be made by the Governor to ensure that prisoners keep 
appointments. 
 
2.3.4 Visiting Specialists will be provided with suitable accommodation and 
clinical facilities for their consultations.  Arrangements will be in place to 
ensure that they are not unreasonably delayed either on arrival at the 
prison or in the course of consultations. 
Health Care Standard 3:  
 
Mental Health Services 
 
 
Standard 
 
1. To provide an integrated service that meets the needs of prisoners suffering from 
mental disorder.  Services should include appropriate implementation of, a) policy 
on preventing self-injury among prisoners and, b) relevant mental health 
legislation. 
 
 
3.1 Criteria -  Organisational Matters 
 
3.1.1 Suitable arrangements will be made for the provision of appropriate 
mental health services, including consultant psychiatric and other related 
services.  The psychiatrist will attend the prison for assessment of 
referrals, routine reviews, etc.   
 
3.1.2 The care regime available to prisoners will be multidisciplinary.  Good 
working links should be established with relevant health and social 
services. 
 
3.1.3 Appropriate use will be made of voluntary agencies such as the 
Samaritans or a counselling service. 
 
3.1.4 Co-ordination of throughcare with local (Health Service Executive) 
mental health services will be developed. 
 
 
3.1.5 The Governor will make arrangements to ensure that prisoners are 
available to be interviewed by visiting psychiatrists or CPNs at the 
appointed time, that such visiting psychiatric professionals are accorded 
speedy access to patients and their records, and that facilities for a 
confidential consultation are available. 
 
3.1.6 Appropriate administrative support will be provided. 
 
3.1.7 Any prisoner considered unfit to remain in prison will be referred to an 
appropriate specialist for assessment and opinion. 
 
3.1.8 Health Care staff will be familiar with pertinent mental health legislation 
and its application in the prison context.   
  
3.2 Criteria - Aspects of Care 
 
3.2.1 A Mental Health Nurse should be available to provide specialist nursing 
care and advice where necessary. 
 
3.2.2 Continuity of care will be provided. 
 
3.2.3 A close working relationship will be developed between Health Care staff 
and relevant prison management.  Appropriate arrangements will be made 
to ensure that all relevant staff are aware of the care plans for prisoners for 
whom they are responsible, and of their part in carrying out the plan. 
 
3.2.4 Individualised care plans should be developed and maintained. 
 
3.2.5 Any referrals to the visiting psychiatrist must be made either through, or 
in consultation with, the Prison Doctor.  
 
 
 
3.3 Criteria - Suicide and Self-Injury Strategy 
 
3.3.1 The prison Suicide Review Group will prepare and keep under review a 
local strategy for the care of the suicidal and the reduction of self-harm.  
This strategy should reflect national guidelines.   
 
3.3.2 Membership of the prison Suicide Review Group should include members 
of the health care team. 
 
3.3.3 All health care staff will be aware of, and follow, documentary procedures 
required by the IPS in the event of an incident of suicide or self-injury. 
 
3.3.4 It will be a recognised duty of all members of staff to be alert to the 
feelings and actions of prisoners which may be indicative of suicide or 
self-harm risk and to take appropriate action.  
 
3.3.5 In all cases of deliberate self-harm a Doctor or appropriate clinician will 
interview the prisoner in depth, seek to establish the reasons for the action, 
and organise any appropriate further clinical intervention. (See HC Policy 
C/3 - ‘Food Refusal within Prison - Management Protocol). 
 
3.3.6 Prisoners considered to be suicidal will be cared for in appropriate 
accommodation. (See HC Policy A/16 - ‘Special Observation Lists 
(Medical)’) 
 3.3.7 Seclusion should be used strictly in accordance with the Prison Rules 
2007 and best clinical practice and in the case of prisoners considered to 
be at risk of suicide only as a short-term measure of last resort.  
           
3.3.8 Appropriate shared accommodation should be available to facilitate the 
support and observation of vulnerable prisoners. 
 
3.3.9 Arrangements should be made for the Samaritans or other suitably trained 
voluntary helpers (who may include prisoners) to be involved in 
befriending and supporting prisoners at risk. 
 
3.3.10 Where a prisoner considered to be at risk of suicide or self-injury is 
transferred within or to another institution for any reason, suitable 
arrangements will be made to ensure that appropriate contact and 
monitoring is maintained. The Nurse Manager will ensure that an 
appropriate system is in place to notify the Healthcare staff at the 
receiving institution.                 
 
 
3.4 Criteria - Facilities 
 
3.4.1 Where appropriate there should be specific accommodation for those with 
mental health problems.  The design of such accommodation should be 
such as to enable disturbed or noisy prisoners to be separated from others.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health Care Standard 4: 
 
Transfer, Release and Throughcare 
 
Standard 
 
1. To ensure that the health care needs of prisoners are considered and taken into 
account before transfer to another prison and that these needs are provided for 
during transfer and on reception at the receiving prison. 
 
2. To ensure that all prisoners with ongoing health care needs are assessed by a 
Doctor or Healthcare professional prior to planned release (and appropriate 
arrangements made for follow-up). 
 
 
 
4.1 Criteria- Transfer to another prison 
 
4.1.1 Prisoners being considered for transfer will be assessed regarding their 
health care needs and fitness to travel. 
 
4.1.2 The Health Care Team of the sending prison will have access to data 
regarding the planned transfer of a prisoner and will arrange the 
assessment accordingly. (See HC Policy A/17 - ‘Notification of the 
Impending Transfer of a Prisoner to Healthcare Staff’). 
 
4.1.3 The Nurse Manager will ensure that a system is in place to ensure all 
relevant clinical information will be communicated to the receiving prison 
to ensure continuity of care. 
 
4.1.4 Prisoners requiring special nursing care or supervision while being 
transferred to another prison establishment will be accompanied by a 
Nurse. 
 
4.1.5 In considering planned transfers due attention will be given to the issue of 
outstanding hospital appointments or pending in-patient procedures. 
 
            4.1.6    A prisoner’s medical file must be transferred with him/her.  (See HC 
Policy A/18 - ‘Access to Medical files on Transfer’). 
 
4.1.7 Where medication has been dispensed for a patient, this will be transferred 
with him/her. 
 
4.1.8 For transfer or release of prisoners availing of drug treatment services 
reference Healthcare Administrative policy A/24.                                          
  
 
4.2 Criteria -  Reception following Transfer 
 
4.2.1 All prisoners received on transfer will have a Nursing assessment 
undertaken on reception (analogous to that outlined in HCS 1 above). 
 
4.2.2 All transferred prisoners will receive within 24 hours a physical and 
mental health interview and assessment by a Doctor. 
 
4.2.3 Any prisoner on ongoing medical treatment will have the treatment 
reviewed by the receiving Doctor and appropriate follow-up arrangements 
made as necessary. 
 
 
4.3 Criteria: Release and Throughcare 
 
4.3.1 The health care record of all prisoners under clinical supervision and/or 
receiving treatment immediately prior to release will be reviewed by the 
Doctor. 
 
4.3.2 Any prisoner on prescribed medication will be provided with a 
prescription to maintain his/her treatment until s/he can consult his/her 
own General Practitioner.  
 
4.3.3 Where there is a need for continuing care this will be communicated to the 
relevant agencies (GP/Hospital/Clinic) in the general community. 
 
4.3.4 Any prisoner who, at the time of release, has pending hospital 
appointments will be given written notice of these on release. 
 
4.3.5 A discharge summary will be prepared as necessary by the Prison Doctor. 
A letter signed by the doctor should be prepared providing information on 
the current treatment provided to the prisoner, any medication supplied to 
the prisoner on release and any outstanding medical appointments. This 
letter should be given to the prisoner on release to furnish to their GP. 
Health Care Standard 5:  
 
Clinical and Related Services for Promoting Health 
 
Standard: 
 
1. To provide services to prisoners which may prevent illness and promote health. 
 
2. To provide prisoners with the information and opportunity to enable them to make 
reasoned choices regarding the adoption of a healthy lifestyle. 
 
 
5.1 Criteria: Services to be Provided 
 
5.1.1 These services will be delivered to prisoners by staff trained in relevant 
aspects of clinical practice and health promotion or by outside 
specialists/external agencies with relevant expertise. 
 
5.1.2 Subjects addressed by the services will include (but not be confined to) 
those relevant to the prevention of: 
 
  - HIV/AIDS 
  - Hepatitis 
  - Drug addiction/dependency 
  - Misuse of Alcohol 
  - Coronary Heart Disease & Stroke 
  - Smoking 
  - Mental Illness & Stress 
  - Sexually Transmitted Diseases 
  - Cervical Cancer 
  - Dental disease 
 
5.1.3 Health care staff will offer regular screening to defined prisoner groups 
(e.g. Women; Men over 45 years, etc.) which mirrors recommended 
clinical guidelines in the general community. 
 
5.1.4 The Irish Prison Service will aim to promote a healthy lifestyle by 
including the implementation of a ‘No-Smoking’ policy.  (See HC Policy 
C/4 - ‘Nicotine Replacement Therapy’). 
 
5.1.5 Relevant external agencies will be accessed to ensure that all staff 
involved in health promotion keep up to date with current theory and 
practice and have access to appropriate teaching materials. 
 
5.1.6 Staff involved in health promotion will encourage the provision for staff 
and prisoners of physical environments (including no smoking areas) 
conducive to health. 
 
5.1.7 Self-help and peer support group initiatives will be encouraged and 
supported. 
 
5.1.8 Active use will be made of community wide health promotion events 
(such as National Healthy Eating Week, World AIDS Day, etc.) to support 
local initiatives targeted at staff and prisoners. 
 
5.1.9 Prior to release prisoners will be provided with information about how to 
make best use of health services in co-operation with community health 
agencies. 
 
5.1.10 Prisons with female prisoners will develop Health Promotion services 
relevant to the needs of women’s health. 
Health Care Standard 6  
  
Communicable Diseases      
 
In keeping with statutory requirements doctors must inform the local Public Health 
services of all cases of notifiable diseases (See HC Policy C/2 - ‘Notifiable Diseases’ and 
Appendix 1 - ‘List of Notifiable Diseases’). 
 
A. Tuberculosis 
 
Standard: 
 
1. To provide prisoners with appropriate screening facilities based on current public 
health advice. 
 
2. To provide appropriate diagnostic and treatment facilities to prisoners considered 
at risk. 
 
3. To provide throughcare and arrange appropriate aftercare where required. 
 
6.1 Criteria  
 
6.1.1 Care will be provided in a multidisciplinary context by prison health care 
staff, relevant visiting specialists and services, and external specialist 
services in line with good practice guidelines (See Appendix 2 - ‘Protocol 
for the Management of Tuberculosis in Prison’). 
 
6.1.2 Appropriate hygiene and infection control procedures will be maintained. 
 
6.1.3 Where possible shared-care protocols will be developed between prisons 
and relevant community health care services. 
 
6.1.4 The appropriate confidentiality of clinical information will be maintained 
by health care staff. 
 
                      
B. HIV 
 
Standard: 
 
1.  To provide prisoners with an appropriate clinical assessment and treatment of 
HIV related illness. 
 
2. To provide information and guidance to prisoners regarding the advantages and 
disadvantages of testing where appropriate. 
 
3. To provide throughcare and arrange appropriate aftercare. 
 
 
6.2 Criteria 
 
6.2.1 Care will be provided in a multidisciplinary context by prison health care 
staff, relevant visiting specialists and services, and external specialist 
services in line with good practice guidelines. 
 
6.2.2 Appropriate hygiene and infection control procedures will be maintained. 
 
6.2.3 Where possible shared-care protocols will be developed between prisons 
and community health care services. 
 
6.2.4 The confidentiality of clinical information, including that relating to 
HIV/AIDS, will be maintained by health care staff. 
 
6.2.5 A test for HIV disease will be undertaken only when requested by a 
prisoner or where, following consultation, a prisoner gives informed 
consent to a test on the clinical recommendation of the doctor involved.  
This does not preclude the use of voluntary anonymised testing for 
research or survey purposes.   
 
6.2.6 Irrespective of actual result all prisoners receiving the result of a HIV test 
should receive counselling from an appropriately knowledgeable person in 
relation to the medical, psychological, and social implications of the 
result. 
 
6.2.7 Any HIV test result should be provided to a prisoner in a situation suitable 
to facilitate appropriate post-test counselling. 
 
6.2.8 Any newly-diagnosed HIV positive prisoner will be offered early 
specialist assessment by an appropriate clinician. 
 
6.2.9 Appropriate arrangements will be in place to facilitate clinical review and 
support by both general and specialist practitioners. 
 
6.2.10 Any special arrangements for the care of pregnant prisoners with HIV 
disease will be addressed. 
 
6.2.11 Treatments available to GMS patients in the community will be made 
available to prisoners. 
 
 6.2.12 Condoms/Dental dams should be made available where appropriate. 
 
6.2.13 In the interests of health maintenance sterilising tablets and instructions on 
their use should be provided to prisoners. 
 
 
 
C. Hepatitis B 
 
Standard 
 
To provide prisoners with clinical services which include -  
 
1. Advice regarding Hepatitis B infection and, where clinically indicated, testing for 
Hepatitis B. 
 
2. Immunisation against Hepatitis B where appropriate (See HC Policy C/5 - 
‘Hepatitis Vaccination Policy’). 
 
3. Appropriate treatment for those who are carriers or are suffering the effects of 
Hepatitis B. 
 
 
6.3 Criteria 
 
6.3.1 Hepatitis B testing will be offered where clinically appropriate.  Testing 
will be undertaken only when requested by a prisoner or where, following 
consultation, a prisoner gives informed consent to a test on the clinical 
recommendation of the doctor involved.   
 
6.3.2 Prisoners who are identified as Hepatitis B carriers will be given 
appropriate advice and treatment. 
 
6.3.3 Immunisation against Hepatitis B will be offered to those at risk.  
 
                         
D. Hepatitis C 
 
Standard 
 
To provide prisoners with a health care service which includes - 
 
1. General health information in relation to Hepatitis C. 
 
2. Advice and testing for Hepatitis C where clinically indicated. 
 
3. Referral to appropriate specialist services. 
 
4. Treatment and support for those infected with Hepatitis C. 
 
 
 
6.4 Criteria 
 
6.4.1 Hepatitis C testing will be offered where clinically appropriate.  Testing 
will be undertaken only when requested by a prisoner or where, following 
consultation, a prisoner gives informed consent to a test on the clinical 
recommendation of the doctor involved. 
 
6.4.2 Prisoners who are infected with Hepatitis C will be given appropriate 
advice and treatment (See HC Policy C/5 - ‘Hepatitis Vaccination 
Policy’). 
 
 
E.  Rubella 
 
Standard 
 
1. In prisons holding women all practical steps will be taken to minimise the risk of 
exposure of pregnant prisoners to Rubella. 
 
2. All possible steps will be taken to ensure that female prisoners of childbearing age 
are immune. 
 
 
6.5 Criteria 
 
6.5.1 Information and discussion about the importance of rubella immunisation 
will be included in all health promotion programmes, especially those 
organised in female prisons. 
 
6.5.2 Where appropriate tests to check an individuals immune status will be 
offered. 
 
6.5.3 All female prisoners of childbearing age who are shown not to be immune 
to Rubella will be offered immunisation. 
 F. Scabies 
 
Standard  
 
1. To ensure that any affected prisoners and their close contacts are treated at the 
earliest opportunity. 
 
2. To ensure that all recommended Public Health measures are taken to prevent 
spread of infections.  
 
 
6.6 Criteria 
 
6.6.1 All prisoners, at time of reception, will be routinely questioned as to the 
presence of a rash or itch. 
 
6.6.2 Any prisoner suspected of suffering from scabies will be referred to a 
Doctor for assessment, diagnosis, and treatment. 
 
6.6.3 The Doctor will record the presence or absence of burrows in the Health 
Care Record. 
 
6.6.4 Once a diagnosis is made the prisoner, together with any identified close 
contacts, particularly cell mates, will be treated simultaneously. 
 
6.6.5 Choice of treatment will be in line with current Public Health guidelines. 
 
6.6.6 Application should follow product instructions 
 
6.6.7 Any prisoner undergoing treatment for scabies should have a change of all 
bed linen and clothing following treatment. 
  
6.6.8 The prisoner should be informed that the itch may take some time to 
settle.  Similarly, prisoners should be informed that in a proportion of 
cases further spots may break out and require a further course of 
treatment. 
 
6.6.9 All staff involved in the treatment of patients with infection should act in 
accordance with recommended infection control policies. 
 
 
 
 
G. Routine Immunisation 
 
Standard 
 
1. All programmes of immunisation offered to prisoners will be in line with national 
guidelines recommended by the Department of Health & Children or by local 
Health Boards. 
          
 
6.7 Criteria 
  
6.7.1 Hepatitis B immunisation will be offered to prisoners in line with 
prevailing policy guidelines. 
 
6.7.2 Hepatitis A vaccination will be offered to prisoners who are Hepatitis C 
positive and do not show evidence of previous Hepatitis A infection. 
 
6.7.3 Meningitis C vaccination will be offered to prisoners under the age of 23 
years who have not previously received this immunisation. (See HC 
Policy C/6 - ‘Meningococcal C Immunisation Programme’). 
 
6.7.4 Young offenders who have not completed their programme of school-
based immunisation will be offered the opportunity to complete these. 
 
6.7.5 Other immunisation programmes will be offered in line with pertaining 
Public Health guidelines.  (See HC Policy C/7 - ‘Influenza Vaccination for 
Prisoners’). 
 
 
 
Ref:   Immunisation Guidelines for Ireland - 2002 edition 
             
Available on:   
 
www.doh.ie/publications/immuguid.html 
www.ndsc.ie/Publications/Immunisation/ImmunisationGuidelines 
                       
 
Anaphylaxis packs, containing Adrenaline, must be available at all times before giving 
vaccines. 
 
See Appendix 3.3 - “Best Practice Guidelines in the Management of Anaphylaxis” 
 
 
 
Health Care Standard 7  
 
The Use of Medicines 
 
 
Standard 
 
1. To provide pharmaceutical services to prisoners that are efficient, cost effective, 
meet legal and professional requirements, and reflect good professional practice. 
 
2. To provide a safe and effective system for enabling prisoners to hold prescribed 
medicines in their possession for self-administration. 
 
3. To provide a system of management for controlled drugs which complies with the 
relevant legislation and regulations. 
 
 
7.1  Criteria: Organisational Matters 
 
7.1.1  The service will meet the requirements of the Misuse of Drugs Act 1977 
and 1984, Misuse of Drugs Regulations 1998 and (Amended) Regulations 
1993, Misuse of Drugs (Supervision of Prescription and Supply of 
Methadone) Regulations 1998 and Medicinal Products (Prescription and 
Control of Supply) Regulations 2003, and all relevant regulations together 
with any other statutes controlling the use of medicines. 
                       
7.1.2 Arrangements will be made to allow for the dispensing of medicines to be 
carried out by appropriately qualified pharmacy staff under the direct 
supervision of a registered Pharmacist.  There will be no secondary 
dispensing. 
 
7.1.3 The administration of medicines will follow current good practice 
guidelines as advised by An Bórd Altranais and IPS.  All health care staff 
will be aware of, and will adhere to these guidelines. 
                         (See HC Policy C/8 - “Policy on Medication Administration”) 
 
7.1.4 All prescribing will be undertaken by fully registered Medical or Dental 
practitioners in accordance with DOHC good practice guidelines. 
 
7.1.5 Prescribing will reflect the guidance contained within a national Prison 
Service Medicines Formulary, when developed by a Drugs and 
Therapeutics Committee. 
 
7.1.6 Each prison will have a supply of treatments to include analgesics and 
simple antacids, available to prisoners under protocol.  
                        (See Appendix 3.1 - “Administration of Medicines under Protocol”) 
 
7.1.7 All pharmaceutical products will be stored in appropriate conditions of 
security.   
 
7.1.8 Controlled Drugs will be stored and handled as required under the Misuse 
of Drugs Act and related regulations. 
 
7.1.9 Any In-Possession (I/P) policy will be in accordance with Standard 7.6.  
 
7.1.10 Equipment, medicines, and dressings will be available for use in an 
emergency situation and such supplies will be regularly monitored to 
ensure that equipment is in working order and that other supplies are not 
time expired. 
 
7.2 Criteria: Pharmaceutical Services  
 
7.2.1 Pharmaceutical practice within the prison system will adhere to practice 
guidelines issued by the Pharmaceutical Society of Ireland. 
                     
7.2.2 Advice and information to ensure safe and appropriate use of medicines 
will be made available to Health Care staff. 
 
7.2.3 Professional pharmacy advice will be utilised to promote the cost effective 
purchase of medicines and other equipment; and advice on medicine 
budgets and comparative costs to achieve a rational and economic use of 
medicines. 
 
7.2.4 Prisoners will be effectively informed regarding the pharmaceutical 
management of their condition. 
 
7.2.5 Pharmacy staff will advise on all aspects of the security of pharmaceutical 
products. 
 
 
7.3 Criteria: Acquisition, Storage and Disposal of Medicines 
 
7.3.1 The range and quantity of medicines within prison establishments will be 
determined by consultation between the medical, nursing, and pharmacy 
staff. 
 
7.3.2 Any medicines due for disposal on the grounds of expiry, completion or 
discontinuation of treatment, etc., will be returned to the pharmacy.  
  
            7.3.3    The pharmacist will be responsible for the disposal of medicines. 
 
7.3.4 In the event of the death of a patient who was on a course of medication, 
the medication(s) concerned must be retained until clearance is given. 
 
 
 
7.4 Criteria: Prescribing 
 
            7.4.1    All prescribing will be undertaken by fully registered Medical or Dental 
practitioners in accordance with DOHC good practice guidelines. 
                     (See HC Policy C/9 - “Use of Benzodiazepine Hypnotics”) 
 
7.4.2 The purpose of, and any known risk from, prescribed medicines will be 
explained to the patient at the time of initial prescription. 
 
7.4.3 All prescriptions will be recorded on the PMRS. 
                        (See Appendix 4.1 - “Prescription Writing Guidelines”) 
 
7.4.4 Prescribing will reflect guidelines contained within any national IPS 
formulary once this is developed. 
         
 
7.5 Criteria: Administration of Medicines 
 
7.5.1 Administration of prescribed medicines will follow an agreed policy. 
                        (See HC Policy C/8 - “Policy on Medication Administration”) 
 
7.5.2 The patient will be correctly identified before administration of 
medication. 
 
7.5.3 Arrangements will be in place to ensure that simple OTC antacid and 
analgesic preparations are available to prisoners.  Records will be kept of 
such medicines issued. 
                        (See Appendix 3 - “Administration of Medicines under Protocol”) 
 
7.5.4 The prescriber will be contacted if there is any doubt regarding the 
prescription. 
  
            7.5.5   On return from temporary release, where concern exists regarding the 
safety of medication administration, reference should be made to HC 
Policy C/10 -”Administration of Medicines to Prisoners following return 
from Temporary Release” 
 
7.5.6 The patient will be fully informed about his/her medication when it is 
prescribed and when it is first administered. 
 
7.5.7 A contemporary, signed, legible record in electronic format will be made 
of each medicine administered, withheld, refused by the patient, or not 
given for whatever reason. 
 
7.5.8 The person administering the medication should do so under appropriate 
health care supervision. 
 
7.5.9 Where a medicine is not available or is refused the prescriber will be 
informed and the same will be recorded on the PMRS. 
 
7.5.10 Medication will only be given to prisoners with consent, except where 
indicated in an emergency situation. In such emergency circumstances 
medication will be administered in accordance with an agreed clinical 
protocol. 
 
  
7.6 Criteria: Self-Administered Medication 
 
7.6.1 It will be the responsibility of the prescriber in consultation with 
healthcare staff and Prison Management to decide which prisoners should 
be allowed have medication in their possession. 
 
  
 
7.7 Criteria: Controlled Drugs 
 
7.7.1 Drugs controlled under the Misuse of Drugs Acts 1977 and 1984 and 
subsequent regulations will be kept in a locked, safe cabinet which meets 
professional and legal guidelines.  This cabinet should be in a location 
which is designed to prevent unauthorised access to such drugs. 
 
7.7.2 Prescriptions for Controlled Drugs will conform to the requirements of the 
relevant legislation - Misuse of Drugs Act 1977 and 1984, Misuse of 
Drugs Regulations 1988 and 1993, and Misuse of Drugs (Supervision of 
Prescription and Supply of Methadone) Regulations 1998. 
                        (See Appendix 4.2 - “Prescription Writing Requirements”) 
 
7.7.3 A register, as required by legislation, will be kept at each location where 
Controlled Drugs are kept. 
 
7.7.4  All Controlled Drugs received from prisoners, at time of committal or 
otherwise, will be recorded, witnessed and destroyed.  (See HC Policy 
A/19 - ‘People entering Prison with Methadone Supplies’) 
 
 
 
References:  
 
Misuse of Drugs Act 1977 
Misuse of Drugs Act 1984 
Misuse of Drugs Regulations 1988 and (Amendment) Regulations 1993 
Misuse of Drugs (Supervision of Prescription and Supply of Methadone) Regulations 
1998 
Medicinal Products (Prescription and Control of Supply) Regulations 2003 
  
 “The Practice of Pharmacy Guide”, P.S.I. 1999 
  “Pharmaceutical Society of Ireland Best Practice Guidelines on the Provision of 
Pharmacy Services to Residential Homes by Community Pharmacies” 
  “Pharmaceutical Society of Ireland Best Practice Guidelines on the Use of Dosage 
Compliance Systems” 
 
 
   Relevant Medical Council Guidelines 
   Bord Altranais Guidelines on Medication Management 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health Care Standard 8 
 
Dental Services 
 
Standard 
To provide dental treatment to prisoners of an equivalent standard to that normally 
available to citizens in the general community covered by the GMS Dental Schemes. (See 
Appendix 5 - “Dental Services for Prisoners - Operational Policy”) 
 
8.1 Criteria: Treatment 
 
 8.1.1 Every Prison will have access to the services of a qualified dentist. 
 
8.1.2 A prisoner requesting treatment should normally be seen by the prison 
dentist within a reasonable period of time. 
 
8.1.3 A prisoner with severe dental pain that has not responded to initial 
analgesic treatment should be seen at the next available clinic.  
 
8.1.4 Any treatment that is available under the GMS/Social Welfare public 
dental schemes will be provided to a prisoner if he/she requires it. 
 
8.1.5 The dentist will maintain a full clinical record of all treatments undertaken 
on prisoners. 
 
8.1.6 The dentist will have ready access to the prisoner’s medical history. 
 
8.2  Criteria: Accommodation and Equipment 
 
8.2.1 Every dental surgery should be equipped to current professional standards, 
with the appropriate fixtures, furnishings, and equipment. 
 
8.2.2 All dental equipment must be serviced and checked according to current 
standards, including any applicable legislation. 
 
8.2.3 Effective cross-infection prevention procedures will be in place. 
 
8.2.4 Each dental surgery will have sufficient instruments, hand pieces, etc., to 
allow all sterilisation procedures to proceed without hindering treatment. 
 
8.2.5 All prison dental surgeries will be provided with a telephone and adequate 
means to summon other staff in case of emergency. 
 
Health Care Standard 9 
 
Drug Treatment Services 
 
 
Standard 
 
1. To provide clinical services for the assessment, treatment, and care of substance 
misusers comparable to those available in the community, and which are 
appropriate to the prison setting. 
             
 All Methadone Treatment delivered to prisoners will be based on IPS Methadone 
Guidelines as derived from the European Methadone Guidelines - see Appendix 
6. 
 
9.1  Criteria: General Principles 
 
9.1.1 If a prisoner has been on a treatment programme (e.g. methadone) in the 
community immediately prior to entering prison, then, if clinically 
appropriate, this treatment should be continued. 
 
9.1.2 Substitute or detoxification prescribing practice will be in line IPS policy 
based on best practice guidelines. (See Appendix 6 - “Methadone 
Guidelines”) 
          
9.1.3 Any prisoner seeking treatment for substance misuse may be required to 
enter into an agreed contract. 
 
9.1.4 Where drug use becomes problematic during the course of a sentence, etc., 
a detoxification may be considered subject to the prevailing clinical 
criteria. 
 
9.1.5 All drugs prescribed as part of a drug treatment programme must be 
administered on a supervised, individual dose basis, within a safe and 
secure environment. 
 
9.1.6 Initiation of methadone maintenance while in prison for a prisoner who 
has not previously been on such a programme in the community should 
only be undertaken following consultation with the relevant substance 
abuse specialist, so as to ensure continuity of treatment after leaving 
prison. 
 
9.1.7 Subject to accepted clinical criteria treatment using other appropriate 
pharmaceutical agents (e.g. Lofexidine) may be considered.  Any such 
treatment should be based on specialist advice and supervision. 
  
9.2 Criteria: Initial Reception 
 
9.2.1 All drug misusing prisoners will be assessed by a Nurse as part of the 
general reception process.  A specific history of drug use, including 
method of administration, duration of use, previous treatment contacts, 
etc., should be elicited. 
 
9.2.2 Opioid use should be confirmed by means of urinalysis.  It is important to 
remember that urinalysis will only confirm the presence of a drug.  It will 
not provide any information regarding the extent of use or dependence. 
(see HC Policy A/20 - ‘Potential Contamination of Urinalysis Results for 
Drugs of Abuse’). 
 
9.2.3 Methadone supplies accompanying new receptions to prison will be 
confiscated (See HC Policy A/19 - ‘People Entering Prison with 
Methadone Supplies’). 
 
9.2.4 Prior to commencing any form of treatment it is essential that a full 
clinical assessment be undertaken by a doctor.   (See Methadone 
Guidelines, page 73 below) 
 
9.2.5 Prescribing is the sole responsibility of the doctor who signs the 
prescription.  This responsibility cannot be delegated. 
                         (See Appendix 4.2 - “Prescription Writing Guidelines”) 
 
9.2.6 A new committal into prison should not receive methadone until the day 
following reception (See HC Policy C/11 - ‘Precautions in Relation to 
Initiating Methadone Treatment for Opiate Abusers’) 
 
9.2.7 Detox should be carried out in line with the Methadone Guidelines 
Document (see P.76 below). 
 
9.2.8 Methadone should, where possible, be administered in the morning to 
allow for monitoring of clinical condition during the day. 
 
 
9.3 Criteria: Prisoners considered for Maintenance Therapy 
 
9.3.1 In line with current Department of Health and Children policy, Prisoners 
who  
- have been on a recognised maintenance programme immediately 
prior to reception,  
 -          have a verified place on a community treatment programme  
 available to them on release  
 - are addicted pregnant women 
 - have a recent diagnosis of HIV 
 -           are juveniles in need of drug treatment (See HC Policy C/12 -  
 ‘Prescription of Methadone to Patients under 18 years’) 
   
 may be considered for continuation of maintenance while in prison. 
 
9.3.2 A doctor can, in consultation with a consultant specialist in substance 
misuse, initiate treatment in cases falling outside the above criteria. 
 
9.3.3 Continuation of maintenance treatment will require regular clinical 
assessment by a Doctor. 
 
9.3.4 Verification of prior treatment, dosage, etc., should be obtained from the 
Central Treatment List and the community prescriber. 
 
9.3.5 Detoxification and unstable service users should be seen by a Doctor 
weekly and, if as they achieve stability, fortnightly and then monthly. 
 
9.3.6 Detox and unstable Methadone maintenance patients should have random 
twice weekly urine screens. 
 
9.3.7 Prisoners stable on methadone maintenance should have random weekly 
urine screens. 
 
9.3.8 Any prisoner receiving methadone maintenance may be expected to sign a 
contract agreeing to comply with the regime associated with such 
treatment within the prison situation. 
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APPENDIX 1 
 
LIST OF NOTIFIABLE DISEASES 
Infectious Diseases (Amendment)(No.3) Regulations 2003 (SI No. 707 of 2003) 
 
 Acute anterior poliomyelitis 
 Acute infectious gastroenteritis 
 Ano-genital warts 
 Anthrax 
 Bacillillus cereus food-borne infection/intoxication 
 Bacterial meningitis (not otherwise specified) 
 Botulism 
 Brucellosis 
 Campylobacter infection 
 Chancroid 
 Chlamydia trachomatis infection (genital) 
 Cholera 
 Clostridium prefringens (type A) food-borne disease 
 Creutzfeldt Jakob disease 
 Nv Creutzfeldt Jakob disease 
 Cryptosporidiosos 
 Diphtheria 
 Echinococcosis 
 Enterococcal bacteraemia 
 Enterohaemorrhagic Escherichia coli 
 Escherichia coli infection (invasive) 
 Giardiasis 
 Gonorrhoea 
 Granuloma inguinale 
 Haemophilus influenzae disease (invasive) 
 Hepatitis A (acute) 
 Hepatitis B (acute and chronic) 
 Hepatitis C 
 Herpes simplex (genital) 
 Influenza 
 Legionellosis 
 Leptospirosis 
 Listeriosis 
 Lymphogranuloma venereum 
 Malaria 
 Measles 
 Meningococcal disease 
 Mumps 
 Non-specific urethritis 
 Noroviral infection 
 Paratyphoid 
 Pertussis 
 Plague 
 Q Fever 
 Rabies 
 Rubella 
 Salmonellosis 
 Severe Acute Respiratory Syndrome 
 Shigellosis 
 Smallpox 
 Staphylococcal food poisoning 
 Staphylococcus aureus bacteraemia 
 Streptococcus group A infection (invasive) 
 Streptococcus pneumoniae infection (invasive) 
 Syphilis 
 Tetanus 
 Toxoplasmosis 
 Trichinosis 
 Trichomoniasis 
 Tuberculosis 
 Tularemia 
 Typhoid 
 Typhus 
 Viral encephalitis 
 Viral meningitis 
 Viral haemorrhagic fevers 
 Yellow Fever 
 Yersiniosis 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 2 
 
PROTOCOL FOR THE MANAGEMENT OF TUBERCULOSIS IN PRISON 
 
Many of the issues relevant to the management of tuberculosis in a prison setting are 
dealt with in the Report of the Advisory Committee On Communicable Diseases In 
Prison (May, 1993).  Sections 1.4-1.7 and 6.5 are of particular relevance.  The following 
is intended to complement the recommendations of the Advisory Committee and assist in 
their implementation with a view to enhancing the quality of medical care for persons in 
prison.   
 
This protocol is based on advice received from the Department of Public Health, ERHA. 
 
As circumstances change, these recommendations may have to undergo periodic revision. 
 
Index of suspicion 
Transmission of tuberculosis in prisons presents a health problem for the institution and 
may also be a problem for the community into which the inmates are released.  The 
incidence of tuberculosis is likely to be higher in prison inmates than in the general 
community.  In order to prevent or contain tuberculosis, it is essential that there is a high 
index of suspicion for the disease.   
 
Screening of inmates 
All inmates should be screened on committal.  As part of the screening process, it is 
desirable that all inmates complete a screening questionnaire (see suggested Screening 
Form appended) eliciting symptoms of current illness, any relevant previous illness, 
present medication together with a history of contact with tuberculosis or other infectious 
disease. 
 
Initial screening would include review of the prisoner’s questionnaire response with 
particular reference to symptoms suggestive of infectious disease, documentation of BCG 
status including the presence of vaccination scar, recording of weight and temperature.  
Any diagnostic tests should be undertaken in consultation with local Public Health 
Services.  This preliminary screening examination could be carried out by a suitably 
trained nurse. 
 
Inmates with known or suspected HIV infection should ideally receive a chest radiograph 
as part of their initial screening at the time of first committal, regardless of tuberculin 
skin-test or BCG status. 
 
All inmates should, if possible, be housed in single cell accommodation until such time as 
they have been medically assessed. 
 
Role of nurse 
The nurse would be responsible for 
 
 Organising a formal record system for each individual.  This should contain 
records of tests carried out and their results, together with medical notes 
 
 Prioritising patients to be seen by the prison doctor 
 
 Ensuring that inmates suspected of having an infectious disease are isolated in 
appropriate accommodation pending confirmation of the diagnosis 
 
  Ensuring inmates are receiving prescribed mediation, including directly 
observing therapy (DOTS) where indicated 
 
  liaison with the Public Health Department on cases of notifiable disease 
occurring in the prison (suspected and confirmed, including denotification where 
appropriate). 
   
Nursing personnel should have specific training in relation to tuberculosis, with an 
understanding of the issues involved in the control of the disease.  Such training should 
include placement in a TB hospital and a community based clinic.  Nursing personnel 
should also have the skills required to deal with the particular client group encountered in 
a prison setting. 
 
It would be desirable to have a nurse on duty during office hours on a Monday to 
Saturday basis. 
 
Nursing personnel should report to the Prison Doctor on all matters relating to the 
inmates health status and liaise with the relevant Public Health Department as 
appropriate. 
 
Diagnosis of tuberculosis 
Provision must be made for appropriate diagnostic measures e.g.. Sputum smear and 
culture and/or chest radiograph for all persons who are symptomatic.   
 
Confirmed tuberculosis 
Confirmed cases will normally be under the care of a consultant physician.  Inmates with 
pulmonary involvement should remain in hospital accommodation until confirmed non-
infectious. 
 
All inmates with confirmed tuberculosis must be monitored by trained personnel for signs 
and symptoms of adverse reaction during chemotherapy.  Therapy should be directly 
observed where possible.  Ideally those with drug-resistant organisms should not remain 
in prison.  Where it is not possible to release them, special emphasis must be placed on 
their close supervision and care. 
 
All confirmed cases should be notified in writing by the Prison Doctor to the local 
Medical Officer of Health so that contact tracing can be put in place. 
 
To ensure continued mediation and follow-up, if an inmate is to be released before 
completion of therapy, the local Medical Officer of Health should receive prior 
notification of the release. 
 
Chemoprophylaxis 
Prisoners on chemoprophylaxis should also have directly observed therapy.  To ensure 
continued medication and follow-up, if an inmate is to be released before completion of 
chemoprophylaxis, the local Medical Officer of Health should receive prior notification 
of the release. 
 
 
Repeat skin tests 
Repeat testing of prisoners or staff should be based on Public Health advice.  If data from 
previous screening and TB case finding are available, the frequency of repeat skin testing 
should be determined based on the need for timely surveillance information. 
 
It is important to remember that the tuberculin test is merely a screening test.  A negative 
test does not rule out tuberculosis, nor does a history of previous BCG.  Where there is a 
high index of suspicion e.g. cough, weight loss, night sweats, a chest X-ray should be 
performed and the individual referred for specialist opinion.  Individuals with 
documented evidence of a previous positive tuberculin test (Heaf>2, Mantoux>10mm) 
should not be retested. 
 
Assessment 
Inmates are transferred frequently.  Thus, record systems for tracking and assessing the 
status of persons with TB and tuberculous infection in the prison facilities are essential.  
These systems must be maintained by using current information on the location, 
treatment status, and degree of infectiousness of these persons.  Prompt action must be 
taken to reinstitute drug therapy should treatment lapse for any reason. 
 
Further advice 
The Public Health Department or local Medical Officer of Health may be contacted for 
further information an any aspect of tuberculosis prevention and control. 
 
TUBERCULOSIS SCREENING FORM 
 
1. NAME: 
 
 
2. ADDRESS: 
 
 
3. AGE: 
 
 
4. Do you have a cough? 
 
4(a) If yes, how long have you had this cough? 
 
 
5. Have you ever been treated before for tuberculosis? 
 
5(a) If yes, what hospital did you attend? 
 
 
6. Have you been in close contact with anyone who has been diagnosed with  
 tuberculosis? 
 
 
 
 
(In terms of initial screening it is considered that questions 4 & 4a are the key questions). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BCG vaccine 
 
Bacille Calmette Guerin (BCG) vaccine, contains a live attenuated strain derived from 
Mycobacterium bovis.  The efficacy of BCG in preventing tuberculosis has varied in 
reported studies over the years, but is probably most consistently effective against 
tuberculosis meningitis and miliary tuberculosis, with protection lasting approximately 15 
years.  Irish studies have indicated a protective efficacy against childhood tuberculosis.  
Indications for BCG vaccine continue to be re-evaluated but at present it is recommended 
that neonatal BCG be continued. 
 
Dose and route of Administration 
 
BCG vaccine may be given concurrently with another live vaccine, but if they are not 
given at the same time an interval of at least three weeks should be allowed between such 
vaccines.  When BCG is given to infants there is no need to delay primary 
immunisations. 
 
Adults and children over three months  
 
The recommended dose is 0.1 ml, by intradermal injection, reconstituted with 1 ml of 
sterile ‘Water for injection’ or normal saline which has been allowed to stand for one 
minute.  Subjects who give a history of previous BCG immunisation should only be given 
BCG if there is no characteristic scar and they are tuberculin negative.  If reimmunisation 
with BCG is being considered expert advice should be sought. 
 
Infants of three months of age or less 
 
The recommended dose is 0.05 ml, by intradermal injection in two divided doses in 
adjacent sites.  Babies up to three months of age may be immunised without prior skin 
testing. 
 
The vaccine should be given in the arm, over the insertion of the deltoid muscle. 
 
Once reconstituted and prepared, any vaccine remaining at the end of the session 
(maximum four hours) should be discarded safely.  No further immunisation should be 
given for at least three months in the arm used for BCG vaccination because of the risk of 
regional lymphadenitis. 
 
Indications  
 
The vaccine is indicated for prophylactic immunisation in tuberculin negative individuals. 
 
Those at normal risk 
   
a) New born babies 
b) Children or adults where the parents or individuals themselves specifically request 
BCG immunisation, unless contraindicated 
c) Schoolchildren between the ages of 10 and 14 years who have not previously been 
immunised or who are tuberculin negative and who have no characteristic scar  
d) Students in teacher training colleges 
e) Members of the travelling community - due to the logistical difficulties of providing 
alternative control measures and follow-up of contacts 
 
Those at higher risk 
 
a) Health care staff who may have contact with infectious patients or their specimens 
b) Veterinary staff who handle animal species known to be susceptible to tuberculosis 
c) Contacts of cases with active respiratory tuberculosis.  Children under five years of 
age in contact with smear positive tuberculosis should be given chemoprophylaxis 
and then immunised with BCG on completion of the course if tuberculin negative 
d) Newborn infants where there is a positive family history of tuberculosis 
e) Immigrants from high incidence countries and their children 
f) Those intending to visit high incidence countries for more than one month 
 
Contraindications  
 
BCG vaccine should not be given to those: 
    
1. Receiving corticotrophins or systematic corticosteroid therapy (other than as 
replacement) 
2. Receiving other immunosuppressive treatment including x-irradiation 
3. Suffering from blood dyscrasias, lymphoma, or malignant neoplasms involving bone 
marrows or the lymphoreticular system, or with gamma globulin deficiency or 
abnormality 
4. With pyrexia 
5. With generalised eczema or infected dermatosis.  The effect of BCG vaccine may be 
exaggerated in these patients, and a more generalised infection is possible 
6. Who are pregnant 
7. With positive tuberculin tests 
 
HIV positivity 
 
BCG vaccine should not be given to HIV positive persons. 
 
Adverse reactions 
 
Local: side effects include local induration, pain and occasionally ulceration, lupoid 
reaction, inflammatory and suppurative adenitis. 
 
General: rash, fever and rarely generalised lymphadenopathy can occur. 
 
Interactions 
 
The vaccine should not be given within three months of blood or plasma transfusion or 
administration of human serum globulin in excess of 0.01 ml/kg body weight. 
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POLICY ON THE ISSUING OF PARACETAMOL TO PRISONERS 
 
 
POLICY 
 
The Irish Prison Service policy is to make available to prisoners Paracetamol tablets or 
liquid within the terms of the protocol as stated below. 
 
Introduction: 
 
Within the community, a number of medications including Paracetamol, can be 
purchased at a Pharmacy without consulting a Doctor, and so on the basis of equity of 
care, within a prison setting Paracetamol should also be made available, without the need 
to consult the Doctor. 
 
Paracetamol, when used properly, is a very effective and safe treatment to relieve mild to 
moderate pain associated with such conditions as headache, toothache and minor injuries 
etc. It can also be used to reduce temperature. 
 
However, Paracetamol has the potential to be a very dangerous medication, if not used 
properly. 
Overdose of Paracetamol can result in liver damage, and possibly death, therefore the 
following protocol must always be used. 
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POLICY ON THE ISSUING OF PARACETAMOL TO PRISONERS 
 
 
 
 
PROTOCOL PRINCIPLES 
 
1. A nurse or medical orderly may issue Paracetamol, on request of a prisoner  in 
accordance with this protocol. 
 
2. All relevant staff must read, and sign to confirm that they have read this protocol 
before they are authorised to issue Paracetamol. 
 
3. Prisoners must initiate the request for painkilling medication such as Paracetamol. In 
issuing the medication, staff are not expected to make a medical judgement or diagnosis. 
 
4. The issuing of Paracetamol in this way does not remove the right of access to 
healthcare services. 
 
5. The imperatives of security must be taken into account at all times. 
 
6. Responsibility for the implementation of the protocol lies with the Governor. 
 
7. Responsibility for arranging local training in the protocol lies with the Governor. 
 
8. Staff must only administer Paracetamol in accordance with this protocol. 
 
9. This policy will be reviewed annually. 
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POLICY ON THE ISSUING OF PARACETAMOL TO PRISONERS 
 
PARACETAMOL: 
 
1. CLINICAL CONDITION: 
Mild to moderate pain (e.g. headache, toothache etc.), pyrexia. 
 
2. CRITERIA FOR EXCLUSION: 
It is the responsibility of the Healthcare team to ensure that the prisoner knows if he/she 
should not take Paracetamol. 
DO NOT USE IF PATIENT IS ALLERGIC TO PARACETAMOL. 
 
3. TREATMENT: 
 
Paracetamol 500mg tablets or Paracetamol 250mg/5ml suspension 
 
Dose: 1-2 tablets (500mg to 1g) taken orally, every six to eight hours or 
             10-20ml, taken orally every six to eight hours 
 
Max. Daily dose: 8 tablets (4g) or 80ml (4g) in 24 hours 
 
Max. Period of treatment (before G.P. Consulted) 48 hours 
 
Paracetamol must NOT be given to any patient already receiving a medicine containing 
paracetamol e.g. Kapake, Solpadol, Tylex, Paramol, Solpadeine, Uniflu plus etc. - check 
in MIMS/B.N.F. 
 
4. ADMINISTRATION 
If the authorised staff member is satisfied that there are no contra-indications, and in 
his/her opinion administration is appropriate, he/she may administer the drug. 
 
Following details must be recorded in the patient’s PMRS file ; 
 
- symptom 
- name of preparation, dose, date and time 
 
 
The medication must be administered with a glass of water, and prisoner must be 
observed to ensure that the medication has been swallowed. 
 
5. FOLLOW-UP 
 
If problem persists or 48 hours treatment is insufficient, this should be brought to the 
attention of the Doctor, whose advice should be sought. 
Prisoners who make repeated intermittent requests must be referred to the Doctor. 
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POLICY ON THE ISSUING OF PARACETAMOL TO PRISONERS 
 
 
 
RECORDING SHEET FOR THE ISSUE OF PARACETAMOL 500mg TABLETS  (PARALIEF 
500MG  / PANADOL 500MG) 
 
Notes: 
1. Prisoners may only be issued with two Paracetamol tablets at any one time. 
2. No more than 2 Paracetamol tablets should be issued every 6 hours. 
3. No more than 8 Paracetamol tablets should be issued in any 24 hour period. 
 
 
Issue 
No. 
Date Time Prisoner 
Name & 
Number 
Dose Reason Issued 
By: 
Entered in 
kardex  
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POLICY ON THE ISSUING OF PARACETAMOL TO PRISONERS 
 
 
 
 
RECORDING SHEET FOR THE ISSUE OF PARACETAMOL 250MG/5ML LIQUID  
(PARAPAED 250MG/5ML) 
 
Notes: 
1. Prisoners may only be issued with 20ml Paracetamol liquid at any one time. 
2. No more than 20ml Paracetamol liquid should be issued every 6 hours. 
3. No more than 80ml Paracetamol liquid should be issued in any 24 hour period. 
 
 
Issue 
No. 
Date Time Prisoner Name 
& Number 
Dose Reason Issued 
By: 
Entered 
 in kardex 
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NALOXONE 
 
Introduction: 
 
These Guidelines refer to the administration of Naloxone, where indicated, by clinical 
staff i.e. Prison doctors and nurses. 
This means that Narcan may be administered by a nurse, in an emergency, without 
prescription, as outlined in these guidelines. 
 
The signs and symptoms of overdosage with Methadone parallel those for other opioids, 
namely profound respiratory depression, pinpoint pupils, hypotension, circulatory failure 
and pulmonary oedema and coma. 
 
 
The specific antidote Naloxone is indicated for the reversal of coma and the 
restoration of spontaneous respiration. 
 
 
 
NARCAN 400micrograms/ml ampoules contain Naloxone HCl 400micrograms/1ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NARCAN (Naloxone ) 400micrograms/1ml amps. 
 
ADMINISTRATION: Naloxone may be given as outlined in these guidelines, where 
indicated, by prison doctors and nurses. 
 
CLINICAL INDICATIONS: 
Narcan may be used for the complete or partial reversal of opioid depression, including 
mild to severe respiratory depression induced by natural and synthetic opioids, including 
Dextropropoxyphene and Methadone. 
It may also be used for the diagnosis of suspected acute opioid overdosage. 
Narcan is not effective against respiratory depression caused by non-opioid drugs. 
 
CONTRAINDICATIONS: 
Not to be used if patient known to be hypersensitive to Naloxone. 
 
ADMINISTRATION: 
In the prison setting, Narcan should be given by i.m. or s/c injection. Duration of action 
is dependent on dose and route of administration. The i.m. route produces a more 
prolonged effect. 
 
A full record of administration must be made in the patient’s PMRS file. 
 
DOSE: 
Opioid overdose: 
Initial dose of 400 - 2000 micrograms (1 to 5ml of 400microgram/ml amp.) i.m. or s/c. 
 
This may be repeated at 2 - 3 minute intervals, to a maximum of 10mg if respiratory 
function does not improve. 
 
Since Naloxone has a shorter duration of action than many opioids, including Methadone 
and Dextropropxyphene,  repeated injections may be necessary according to the 
respiratory rate and depth of coma. 
 
If no response after 10mg administered, diagnosis of opioid induced or partial opioid 
induced toxicity should be questioned. 
 
Partial recovery from Methadone overdose may be seen, but relapse can frequently occur 
if respiratory depression returns as the effects of Naloxone wear off.   
(Methadone has a half-life of 15 - 20 hours initially and the half life increases with 
continued administration. The half life of Naloxone is approximately 64 minutes, 
therefore repeated doses of Naloxone may be required.) 
 
Heroin has a much shorter half life and so the response to Naloxone administration is 
rapid. 
 
In patients where respiratory depression is caused by Methadone, and who do not respond 
to repeated doses of Narcan, immediate transfer to hospital is required to allow for the 
administration of an i.v. infusion of Narcan, to produce sustained antagonism to the 
opioid, where the rate of administration can be adjusted according to the response and 
based on close monitoring of vital signs. 
 
In addition to Narcan, other resuscitative measures such as maintenance of a free airway, 
artificial ventilation, cardiac massage and vasopressor agents should be available and 
employed when necessary in a hospital setting. 
 
Any patient who has been treated with Naloxone should not be given any further 
medication, particularly respiratory depressants, until the patient has been reviewed by 
the doctor. 
 
 
SPECIAL WARNING/CAUTION: 
 
Narcan should be administered with great caution to patients who have received large 
doses of opioids or to those physically dependent on opioids, since too rapid reversal may 
precipitate an acute withdrawal syndrome in such patients. 
 
Caution should be exercised when Narcan is administered to patients with renal 
insufficiency/failure or those with liver disease. 
Should be used with caution in patients with pre-existing cardiac disease or patients who 
have received potentially cardio-toxic drugs. 
The safety of Narcan for use in pregnancy has not been established, it should therefore be 
used with caution in pregnancy. 
 
 
ADVERSE EFFECTS: 
Abrupt reversal of opioid depression may result in a range of symptoms from nausea, 
vomiting, sweating, tachycardia to pulmonary oedema and cardiac arrest, which may 
result in death. 
 
 
OVERDOSE: 
No reports of acute overdosage.  Has not been shown to produce tolerance or to cause 
physical or psychological dependence. 
 
 
FOLLOW -UP: 
 
Patients who have responded satisfactorily to Narcan should be referred to hospital for 
assessment, as they should be monitored closely for 48 hours after apparent recovery, in 
case of relapse. 
 
  
Ref:  Narcan Summary of Product Characteristics,    Bristol Myers Squibb, Jan 2002 
and Irish Pharmaceutical Healthcare Association Data Sheet and Summary of 
Product Characteristics Compendium 2001-2002, 11th edition 
British National Formulary 43, March 2002, British Medical Association and 
Royal Pharmaceutical Society of Great Britain. 
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 ANAPHYLAXIS: 
 
The following guidelines should be followed by qualified clinical staff.  
In situations where such staff are not present, current practice in the management of 
anaphylaxis should be maintained. 
 
Introduction: 
 
Anaphylaxis is an acute generalised allergic reaction that can lead to asphyxia and cardiac 
arrest. It can vary in severity and rapidity of onset. 
 
While the incidence of anaphylaxis is rare, it requires immediate intervention. 
 
 
 
Recognised risks: 
 
1.   Medicinal products - those mainly used in prisons include 
Vaccines 
Antibiotics 
Aspirin and other NSAID's 
 
2.   Insect stings - particularly wasp and bee stings 
 
3.   Certain foods, including 
Nuts, peanuts 
Eggs, fish 
 
In the case of medication, anaphylaxis is more likely after parenteral administration: 
resuscitation facilities must always be available for injections associated with special risk. 
Anaphylaxis packs should be available in every surgery. 
 
When exposed to a particular antigen, antigen specific immunoglobulin E (IgE) 
antibodies cause the release of histamine. Other vasoactive mediators are released from 
mast cells and basophils producing circulatory, respiratory, cutaneous and gastrointestinal 
effects.  Anaphylactic reactions can vary in severity and can be slow, rapid or (unusually) 
biphasic. Occasionally the onset may be delayed by a few hours and even persist for 
longer than 24 hours. 
  
Type Signs and Symptoms 
Mild Uriticarial rash 
Pruritis 
Rhinitis 
Nausea and vomiting 
Severe Tachycardia 
Dyspnoea and cough 
Wheezing 
Malaise 
Laryngeal oedema 
Angioedema 
Hoarseness 
Hypotension 
Tachycardia 
Cold and clammy 
Sub-sternal or abdominal pain 
Collapse 
 
 
 
 
 
  
Emergency Treatment of Anaphylaxis in Adults 
 
1.Clinical features of severe allergic-type reaction 
| 
v 
Discontinue Administration of the Suspected Drug/Substance 
| 
v 
 Call Medical Staff 
| 
v 
Recline Patient into a Comfortable Position (If unconscious, insert airway) 
| 
v 
Administer Oxygen (10-15 L/min) 
 
2. Stridor, wheeze, respiratory distress or clinical features of shock 
| 
v 
Administer Adrenaline 0.5ml of 1:1,000 solution I.M. 
 
3. No clinical improvement after 5 min or deterioration 
| 
v 
Repeat Adrenaline 0.5ml of 1:1,000 solution I.M. 
 
4. Administer Antihistamine (Chlorpheniramine) 10-20 mg I.M. 
 
IN ADDITION 
| 
v 
For all severe or recurrent reactions and patients with asthma give hydrocortisone 100-
500mg IM/or slowly IV 
and/or 
If clinical manifestations of shock do not respond to drug treatment give 1-2 litres IV 
fluid. Rapid infusion or one repeat dose may be necessary 
 
 If profound shock is considered to be immediately life threatening, start 
CPR/Advanced Life Support if Necessary 
 
  
ANAPHYLAXIS PACKS: 
 
 
10 X 1ML ADRENALINE 1 IN 1000 AMPS (1MG/ML) FOR I.M. USE 
 
5 X SOLU-CORTEF 100MG + 5 X 2ML W.F.I. 
 
5 X 1ML PIRITON 10MG/ML AMPS 
 
1 X 1ML SYRINGE + 2 X 2ML SYRINGE 
 
2 X 21G NEEDLES + 5 X 23G NEEDLES 
 
2 X 21G NEEDLES + 5 X 23G NEEDLES 
 
6 X MEDI-SWABS 
 
RANGE OF GUEDAL AIRWAYS (2,3,4) 
 
 
 
A complete record of any intervention or treatment given must be recorded in the 
patient’s PMRS file. 
 
 
CHECKING AND RECORDING: 
 
At least one anaphylaxis pack, with contents as outlined above, should be available in 
every surgery. 
 
The contents of this pack and the expiry date of each item should be checked and 
recorded weekly. 
Any product within one week of it's expiry date should be replaced. 
 
As soon as any item is used, it should immediately be replaced. 
 
 
 
 
 
 
 
 
 NOTES: 
 
 
1. An inhaled beta-agoinst such as salbutamol may be used as an adjunctive measure if 
bronchospasm is severe and does not respond rapidly to other treatment. 
 
 
CAUTIONS: 
 
1.  Patients who are taking tricyclic antidepressants (especially amitriptyline or 
imipramine) or M.A.O.I.'s are considerably more susceptible to adrenaline and should 
receive only 50% of the usual dose of adrenaline. Administration of adrenaline may cause 
potentially dangerous hypertension and arrythmias. Cocaine may also sensitise the heart 
to adrenaline and so the use of adrenaline is contraindicated. 
 
2.  Beta-blockers may increase the severity of an anaphylactic reaction and antagonise the 
response to adrenaline, calling for the use of salbutamol. Adrenaline may cause severe 
hypertension in those receiving beta-blockers. 
 
 
 
Ref: Project Team of the Resuscitation Council (UK) Jan. 2002 
         B.N.F 41, Mar. 2001 3.4.3 
         Immunisation Guidelines for Ireland 2002 
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 EXPLANATORY NOTE REGARDING USE OF CONTROLLED DRUGS 
 
This memo outlines the more common Controlled Drugs in Schedules 2 and 3 of the 
above regulations, with a description of the requirements relating to prescribing, storage, 
recording and dispensing. This note does not purport to be a legal interpretation, rather it 
is an explanatory note. 
 
SCHEDULE 2 DRUGS: 
 
CLASS OF CONTROLLED DRUG PROPRIETARY PRODUCTS 
Buprenorphine Temgesic, Transtec  
Cocaine  
Codeine Preparations containing more than 100mg or 
2.5% per unit dose 
Dextromoramide Palfium 
Dihydrocodeine DF118, DHC Continus 
Fentanyl Durogesic, Sublimaze 
Hydromorphone Palladone, Palladone SR 
Methadone Pinadone, Phymet 
Methylphenidate Ritalin, Concerta XL 
Morphine Cyclimorph, Oramorph, Sevredol, 
MST Continus, MXL, Morstel SR, 
Oxycodone Oxycontin, Oxynorm 
Pethidine  
Pholcodine  
 
SCHEDULE 3 DRUGS 
 
CLASS OF CONTROLLED DRUG PROPRIETARY PRODUCT 
Amylobarbitone Amytal, Sodium Amytal 
Butobarbitone Soneryl 
Flunitrazepam Rohypnol 
Methohexitone Brietal 
Phenobarbitone Gardenal Sodium 200mg 
Temazepam Normison, Tenox, Nortem, Euhypnos 
This is not an exhaustive list of Controlled Drugs, but lists those that are more commonly 
used and it may be amended from time to time. If you are unsure, always check before 
use whether a drug is controlled or not, by reference to the current legislation. 
 
SCHEDULE 2 DRUGS 
These drugs must be stored in the Controlled Drugs Safe. 
Every transaction involving Schedule 2 drugs must be recorded in the register. 
Full prescription writing requirements apply. 
 
 SCHEDULE 3  DRUGS: 
These drugs must be stored in the Controlled Drugs Safe. 
Full prescription writing requirements apply 
 
 
Notes: 
 
1. The following are controlled under Schedule 4 and 5, and so the requirements as 
outlined for Schedule 2 and 3 controlled drugs do not apply: 
 
a. Preparations containing not more than 100mg per dosage unit of 
phenobarbitone(calculated as base) e.g. Phenobarbitone 15mg, 30mg, 60mg tablets 
   
b. Preparations (other than injections) containing not more than 100mg per dosage unit 
of codeine or in undivided preparations not more than 2.5% of either drug e.g. 
Codeine Phosphate 30mg tabs, Codeine Linctus 15mg/5ml(Codinex), Benylin with 
Codeine(5.7mg/5ml of Codeine Phos), Dimotane Co(10mg/5ml Codeine Phos), 
Pholcolin (Pholcodine 5mg/ml), Expulin (Pholcolin 5mg/5ml). 
   
c. Preparations (other than injections) containing not more than 10mg per dosage unit of 
Dihydrocodeine or in undivided preparations not more than 1.5% e.g. Paracodin 
syrup(0.1%), tablets (10mg) or drops(1%) 
   
d. Preparations of dextropropoxyphene, for oral use, containing not more than 135mg 
per dosage unit e.g. Distalgesic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NOTE:  
Where a nurse is on duty, s/he will be held responsible for the safe custody of 
Controlled Drugs and compliance with the regulations. 
 
 
1. RECORDING OF CONTROLLED DRUG USAGE (for CD2 Drugs) 
 
1.1 REGISTER: 
 
Every transaction involving CD2 drugs must be recorded in a register kept for that 
purpose in the form specified. The register must be retained for 2 years after date of last 
entry and must be available for inspection. 
Entries must be in ink, in chronological sequence and be made on the day of the 
transaction. 
 
A running stock balance must be made at each transaction. 
 
1.1a. Opening balance: 
On commencement of the use of the register, a stock balance should be carried out i.e. 
The total stock in the surgery should be counted - to include all full bottles and any stock 
in open bottles (e.g. Methadone) or the number of tablets in stock (e.g. DF118). 
 
This should be entered as “Opening Stock balance” on the first line of the register. 
 
1.1b. Daily Issue: 
1. Daily Issue Sheets: 
a. As a daily record of the administration of Methadone is kept, to comply with record 
keeping requirements it is acceptable to make a single entry in the register for the 
total amount of Methadone dispensed each day i.e. on 7.7.2005, total of 2,500mls 
administered, therefore entry in register is 2,500mls used on that day. 
b. The daily sheet must state each individual prisoner's name, DOB, PRIS, quantity 
administered to each patient. In addition it must state the total quantity issued on each 
day and must signed by two healthcare staff members. 
c. A stock check should be carried out at the end of each daily administration.  
d. The total quantity administered as per daily sheet should be subtracted from the 
opening balance. This is the calculated balance. 
e. The actual balance is then measured - this is the actual quantity left in stock. 
f. The calculated balance and the actual balance should be identical, however due to the 
viscosity of the liquid, a slight discrepancy is acceptable. The adjustment should 
always be minimal and must be recorded also. 
g. The balance forward is the actual amount in stock at the end of the day and this is 
then carried forward as the opening balance for the next day. 
   
 
  
1.1c.   Register: 
a. An entry is then made in the CD register, stating the actual balance remaining at the 
end of each day. 
The register and the daily issue forms constitute the complete record for the use of   
Methadone. 
 
 
1.1d. Receipt of new supplies: 
a. Each new supply of Methadone received in the surgery must be recorded in the 
register and the stock balance adjusted accordingly. 
 
Although it is not acceptable practice and should not happen, in the event of an 
emergency supply being loaned to or borrowed from another prison surgery, such 
transactions must also be recorded in the CD Register. 
 
No cancellation, obliteration or alteration is permitted. Corrections, where necessary, 
must be made by way of marginal note or footnote in ink which must specify the date on 
which the correction was made. 
 
2. STORAGE: 
 
Schedule 2 and 3 Controlled Drugs should be stored in a locked safe. 
No other items, except controlled drugs, should be stored in this safe. 
 
The key of this safe should at all times be kept on the person of one accountable staff 
member who is accountable for the controlled drugs and should be passed on to the staff 
member taking over on the next shift. It should be kept separate from all other keys and 
should never be left in the lock, in a drawer or any other area. No other person should 
have access to this key. 
 
The stock should be checked and signed off at each change over of staff by two 
healthcare staff. 
 
3. ADMINISTRATION: 
Schedule 2 and 3 drugs should only be dispensed on foot of a written prescription by a 
doctor. 
The administration of CD2 drugs should be conducted by two healthcare staff members. 
The checking, preparation, administration or destruction of these drugs should be 
witnessed. 
Any wastage of these drugs should be recorded and the entry witnessed. 
A signed record should be appropriately entered on the patient’s file on PMRS and in the 
CD register, which must be signed by two healthcare staff members. 
 
 
  
4. PRESCRIPTION: 
 
The prescription for Schedule 2 and 3 drugs must: 
a. be in ink or otherwise so as to be indelible and signed by the practitioner with his 
usual signature and dated by him. 
b. specify in the prescriber’s handwriting, the name and address of the person for whom 
the treatment is issued - ( in the case of a prison, the address of the patient need not be 
specified provided the prescription is written on the patient’s kardex) 
c. clearly indicate the name of the person issuing it and state that the person issuing it is  
a registered medical practitioner 
d.  specify a telephone number at which the prescriber may be contacted 
e. specify (in the prescriber’s handwriting)  
• the dose to be taken, 
• the form  
• the strength (when appropriate) 
• in both words and figures either the total quantity of the drug or 
preparation or the number of dosage units to be supplied 
f.  in the case of a prescription for a total quantity intended to be dispensed by 
instalments, specify the quantity, the number of instalments and the intervals to be 
observed when dispensing 
 
An electronic prescription recorded on PMRS is acceptable for use within the IPS. 
 
5. REQUISITIONS/ORDERING PROCESS: 
a). Ordering: 
 A book of pre-printed requisition forms is available in each surgery, in duplicate 
form. 
 A new requisition form must be used for each order. This may be completed by a 
healthcare staff member but must be signed by a doctor. 
 The completed and signed requisition is then sent to the stores department, where it is 
assigned an order number and is then faxed to the supplier. 
   
b). Receipt of Supplies: 
 Ideally any supplies of methadone should then be delivered to the doctor and the 
delivery note signed by the doctor. This task can however be delegated by the doctor 
to another staff member, who has been named as an authorised messenger and who 
can accept delivery on behalf of the doctor. 
 The order will then be accepted by an authorised member of the healthcare staff who 
will be required to sign the delivery note and return the top copy to the delivery 
person. 
 The duplicate requisition must also be signed by the healthcare staff member who 
accepted the new supply. 
 All new supplies received must then be recorded in the CD Register as per 1.1.d 
above 
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Appendix 4.1: 
 
PRESCRIPTION WRITING GUIDELINES: 
 
All prescriptions should be recorded on the patients’ file on PMRS 
 
The following guidelines refer to hand-written prescriptions and are now 
incorporated within PMRS 
 
Prescription kardex should have completed patient details, including PRIS and 
D.O.B. 
 
All patient known allergies should be ascertained and recorded by both the Doctor 
and Nurse, on the front of the kardex 
 
Prescriptions must be written legibly, in capital letters, using a ball-point pen. 
 
Each prescription must be signed and dated by a registered medical practitioner, using 
their normal signature. 
 
The prescription should specify the name, strength and form of the medication, and 
the route, dose and the frequency of administration. 
 
The decimal point should be used when prescribing less than 1mg of a drug, i.e. place 
a "0" before the decimal point, e.g. 0.25mg. 
 
Abbreviations are not to be used when writing the drug name. 
 
Doses should follow the normal convention: 
      g for grams, mg for milligrams, micrograms written in full. 
 
The period for which the prescription remains valid will be clearly indicated by the 
prescriber. All prescriptions must be reviewed at no less frequency than 28 days. 
 
Where an instruction "as required" is used by a prescriber it must be qualified by a 
clear statement indicating the maximum dosage and frequency allowed per day, and 
the maximum period for which the prescription remains valid. 
 
When discontinuing a drug, a line should be drawn through the prescription and 
a similar line through the administration recording panel, directly after the last 
dose given. This should be initialled and dated. 
 
Only one chart and kardex should be in use for a patient at any one time. 
 
Single dose drugs should only be prescribed on the lower section of the kardex. 
 
 
 
Appendix 4.2 
 
CONTROLLED DRUG PRESCRIPTION  
WRITING REQUIREMENTS: 
 
All prescriptions for Controlled Drugs should be recorded on the 
patient’s file in PMRS. 
 
The following guidelines refer to hand-written prescriptions and are  
now incorporated or taken account of within PMRS. 
 
 
As it is unlawful for a practitioner to issue, or for a pharmacist to dispense a prescription 
for a Schedule 2 or 3 drug unless it complies with the legal requirements, in addition to 
the guidelines set out above, to meet such legal requirements, a prescription for a 
Schedule 2 or 3 drug must: 
 
 
 
 
a. Be in ink or otherwise so as to be indelible and signed by the practitioner with his 
usual signature and dated by him 
b. Except in the case of a GMS prescription, specify the address of the person issuing it. 
c. Clearly indicate the name of the person issuing it and state that this person is a 
registered medical practitioner 
d. Specify a telephone number at which the prescriber may be contacted 
e. Specify in the prescriber’s handwriting the name (including the given name) of the 
person for whose treatment it is issued 
f. Specify in the prescriber’s handwriting: 
i. The dose to be taken 
ii. The form in the case of preparations 
iii. The strength (when appropriate) 
iv. In both words and figures either the total quantity of the drug or preparation or the 
number of dosage units to be supplied 
g. In the case of  a prescription for a total quantity to be dispensed by instalments, 
specify the amount of the instalments and the intervals at which the instalments may 
be dispensed 
    
    
 
 
 
 
Ref: Misuse of Drugs Acts, 1977 and 1984 
        Misuse of Drugs Regulations 1998 and (Amended) Regulations 1993 
 APPENDIX 5 
 
DENTAL SERVICES FOR PRISONERS  -  OPERATIONAL POLICY 
 
This policy has been drafted on the basis of advice received from Dublin Dental Hospital 
regarding appropriate treatment provision in the context of community norms. 
 
  
1. EMERGENCY  TREATMENT 
 
1.1 This refers to acute trauma, pain, or infection and will be referred for treatment 
by the Medical Officer, Prison Nurse, or Medical Orderly alone in the various 
prisons. 
 
1.2 The patient will be seen as soon as possible, preferably on the day of referral, and 
treatment will mainly consist of extractions, fillings, or prescriptions 
(medication).  Except in exceptional clinical circumstances, e.g., acute traumatic 
episode, emergency dental treatment will be limited to treatment on one tooth.  
 
2. GENERAL  TREATMENT 
 
2.1 Routine basic dental treatment will be made available to prisoners.  This will 
consist principally of examinations, x-rays, extractions, fillings, scaling, root 
filling of single rooted teeth only, and dentures (plastic).  
 
2.2 This treatment will be available only to those sentenced to a period of 16 
months or longer (see 2.3 below for exceptions) or where a prisoner has been 
on remand for 12 months or more.  With the standard remission of 1/4 of 
sentence this means any prisoner who might be expected to spend more than a 
year in prison. 
 
2.3 If , in the clinical judgement of the dentist, routine basic treatment is required for 
a prisoner serving less than 16 months prior approval should be sought from the 
IPS Healthcare Directorate (through the Governor) outlining the reasons for such 
treatment.  (In those prisons serviced by the Dublin Dental Hospital treatment in 
such cases will require the approval of the Consultant in Charge. 
  
2.4 A waiting list will be in operation on a first come first served basis. 
 
2.5 Only prisoners referred for dental treatment by the Medical Officer or Prison 
Nursing or Medical Orderly staff will be treated. 
 
 
 
 
3. GENERAL RULES 
 
3.1 A prisoner who is given an appointment but who subsequently refuses treatment 
twice, for no acceptable reason, will not be given a further appointment during 
his/her sentence.  If a dental emergency as defined above arises, or if a special 
approach is made to the Consultant in Charge (or visiting dentist where 
appropriate) this bar on treatment may be lifted. 
 
3.2 Scaling and polishing is only available to prisoners on an annual basis.   
 
3.3 A prisoner will only be provided with one set of dentures in any given calendar 
year except in exceptional circumstances and with the approval of the Consultant 
in Charge.  
         
3.4 Except in exceptional circumstances (see below) no advanced restorative 
treatment, e.g., chrome cobalt dentures, crowns or bridges will be undertaken 
within the Prison Dental Service for prisoners. 
 
4. ORTHODONTIC TREATMENT  
 
4.1 Orthodontic treatment (straightening of teeth) is not available within this service. 
 
  
 
Advanced restorative Treatment 
 
If it is thought necessary by the treating dentist that some form of advanced dental 
treatment is clinically necessary, this should be discussed with the Consultant in Charge, 
Dublin Dental Hospital. Only in extenuating circumstances should such a procedure be 
contemplated, for example, if a natural or artificial crown has been damaged whilst in 
prison. This should be discussed with the Consultant in Charge before an application is 
made to the relevant prison governor. (This is similar to the procedure adopted under the 
DTSS in terms of extenuating circumstances but it is not usual for such requests to be 
granted). Prior to any discussions, the following records should be collected in order to 
make a decision: 
  
1. Upper and lower models of the mouth. 
2. A full periodontal screening (to determine the condition of the gums and bony 
support of the whole mouth). 
3. The bleeding index for the whole mouth - that is the level of gingival bleeding, 
which indicates the level of plaque control. 
4. The plaque index, that is the amount of plaque and the number of surfaces of the 
teeth, which are covered in plaque.  This can be worked out by staining the plaque by 
using a vegetable dye, counting the surfaces and then getting a ratio. In any patient 
with a plaque score of over 20%, this in itself is a contra- indication for proceeding 
with advanced  restorative treatment, as in all likelihood the proposed treatment will 
be unsuccessful.  In cases where the score is over 20%, the treatment itself may well 
cause further deterioration of the gingival condition and so make things worse. 
5. Is the patient a smoker.  There is a very close association in the dental literature 
between smoking and periodontal disease and as such, may compromise the 
prognosis for any advanced restorative care. 
6. The reasons why the request for this particular treatment is being proposed.  It 
should not be sought on the basis that the patient just wants it 
7. The overall level of active dental disease ( both active and recurrent carious 
lesions) present in the patient’s mouth at the time of the assessment. 
8. The degree of difficulty/skill required to undertake the proposed treatment and 
whether this is available from within the Prison Dental Services, or what other 
considerations must be taken into account. 
9. It would also be necessary to have access to recent, relevant readable 
radiographic images.  
 
 
On the basis of the above, the Consultant in Charge will discuss the findings with the 
treating dentist and make a decision as to whether or not to approve the proposed 
treatment on the merits of the case presented, after which approval will be sought from 
the governor. 
 
 
 
 
Healthcare Directorate 
July 2007 
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Methadone Treatment Programme Guidelines for the Irish 
Prison Service. 
 
 (based on the European Methadone Guidelines) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
 
 
In most good programmes psychosocial interventions are considered a central part of 
methadone treatment.  Research from the USA has demonstrated that there are several 
programme characteristics associated with treatment success such as comprehensive 
services and the integration of medical, psychosocial, counselling and administrative 
services (Ball & Ross, 1991).  McLellan et al (1993) described that service users who 
receive counselling and other psychosocial services with their methadone had better 
outcomes than those who only received methadone. 
 
The importance of creating and maintaining a therapeutic context in which 
methadone treatment programmes are delivered as part of the treatment of opioid 
dependence is widely accepted.    As is the case with any other service user populations 
receiving any kind of treatment, individual methadone maintenance service users may 
vary in their needs and they may differ in their responses to components of treatment.  
The need for counselling and other interventions should therefore be assessed for each 
service user individually.  Some service users need more assistance than others to get 
their lives in order.  On the other hand, there is no reason why stable service users without 
major life problems should require counselling at all. 
 
Service users with psychiatric disorders could benefit from psychotherapy.  However, 
there is no reason to believe that psychotherapy is a treatment for all opioid dependants. 
Individual assessment is the key to good service delivery. 
 
 
Assessment of addiction and the degree of dependence is essential before prescribing 
methadone.  Induction, treatment plan and initial dosage should all be determined with 
care. Service users need to be informed not only about the actual pharmacological effects 
of methadone and the dangers of using other substances when on methadone, but also 
about the potential risk of overdose. 
 
It is highly recommended that new entrants start receiving methadone in the morning and 
preferably early in the week, so that the peak blood methadone concentrations occur when 
the health care area is still open and staff are available for consultation and intervention. 
 
 
In general, the initial dose will be between 10 - 20mg.  In cases where tolerance to opioids 
is high, the normal dose will be between 25 - 40mg.  When tolerance is low or uncertain, 
a dose between 10-20mg is more appropriate.  If in doubt perhaps it is best to ere on the 
side of caution and prescribe a lower dose.  While too much methadone can be fatal, 
insufficient methadone is unlikely to be effective. 
 
During the first week of induction scheme, service user should be seen daily where 
possible so that a stabilisation dose can be established.  Where doses need to be increased 
during this first week, the daily increase should be a maximum of 5 to 10mg and not 
exceeding 20mg within a week of the initial dose. 
 
 
Careful consideration should be given if a dose increase exceeds 20mg per week.  It can 
take up to six weeks or more to be properly stabilised on methadone treatment.  
Compliance will only be maintained if both service user and doctor agree that a reduction 
scheme is desirable. 
 
The majority of individuals in maintenance treatment will treatment will require 60 - 
120mg per day.  Although some individuals can be successfully maintained on lower 
doses, an average heroin dependent person will use less heroin and remain longer in 
treatment, if maintained on higher rather than lower doses of methadone. 
 
Some groups such as pregnant women, people with HIV disease, service users with 
young children etc. (see emergency criteria for treatment), should be given priority to 
enter methadone treatment.  They may also need special attention.  Liaison should be co -
ordinated with specific services as antenatal, infectious diseases, so that their immediate 
problems can be addressed. 
 
Methadone treatment should not be seen as an isolated intervention but as part of a 
comprehensive programme of care.   It is important to identify and address other 
problems such as medical, social, mental health or legal problems.  This can be done 
either by the staff within the methadone programme or through liaison with other services 
and institutions.  A multidisciplinary approach to methadone treatment is essential. 
 
Prescribing is the sole responsibility of the doctor who signs the prescription. This 
responsibility cannot be delegated. 
Apart from methadone, a range of other substitution medication is prescribed in different 
countries with success, such as Bruprenorphine, long acting morphine and heroin. 
 
People working in methadone treatment will require specific training which 
addresses the pharmacological, toxicological, medical and psychosocial aspects of 
treatment of opioid dependence.  The attitude of the staff needs to be non-judgmental.  
Supervision and regular team meetings are important elements of good practice.  To 
ensure high quality of the services delivered, continuous training is highly recommended. 
 
Keeping records of prescribing and of any activity surrounding a service user is necessary 
as in any medical practice, this may be computerised, hand written and combination of 
both.  A central list of service users in methadone treatment may prevent double 
prescribing.  The information contained on this is confidential and access to the list is 
restricted to doctors and clinical team who provide the treatment. 
 
A methadone treatment programmes should be a safe place.  It should be easily accessible 
centrally located and clean.  At all times, service users should be assured of the 
confidentiality of their information and that it will not be used for non-medical purposes 
(see policies regarding confidentiality).  A good rapport between the staff and the service 
user is vital for the success of the treatment. 
 
When planning and designing a new treatment service, it is important to involve users of 
this service in the process as well were possible. 
 Monitoring activities and evaluation of outcomes should be undertaken on a regular 
basis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter One. Introduction 
 
Of critical importance is the recognition that, as in every other area of medicine, treatment 
must be tailored to the needs of the individual service user. 
 
These guidelines are not intended to dictate, but rather provide guidance and 
recommendations for good clinical practice of methadone treatment programmes. 
 
 
Methadone Substitutions Treatment in Europe 
 
The type of methadone programmes varies from low threshold programmes in some 
countries to high threshold ones in others.  Both high and low threshold are formed in the 
Northern Area Health Board. 
 
 
Low threshold programmes: 
 
 
- Are easy to enter 
- Harm reduction oriented 
- Have as primary goal to relieve withdrawal symptoms and craving and improve 
the quality of life of service users 
-          Offer a range of treatment options 
 
 
 
High threshold programme 
 
 
·          Are more difficult to enter / may have selective intake criteria 
·          Abstinence oriented (including methadone abstinence) 
·          Have no flexible treatment options 
·          Adopt regular (urine) controls 
·          Inflexible discharge policy (illegal opioid use not consented) 
·          Compulsory counselling and psychotherapy 
 
Most countries have seen a rapid expansion in the provision of substitution services, 
especially in Spain, France, and Greece and in some Central and Eastern European 
countries.  A rapid expansion is even more evident in countries like Luxembourg, Finland 
and Greece, which had lower baseline levels of provision.  The impetus for the expansion 
has largely been a response to the HIV disease epidemic among drug users.  Whilst most 
countries have experienced few problems during this growth period, concern has been 
expressed in some member states.  It concerned the lack of training and skills of some 
practitioners who are now involved in substitute prescribing.  This is particularly notable 
among specialist services, including general practitioners and pharmacists (Department of 
Health UK guidelines, 1999; Farrell et al., 1999). There is also concern about controls on 
prescribing and the risk of possible diversion of methadone onto the black market (Farrell 
et al., 1999). 
 
 
Chapter Two:         The evidence for the effectiveness of methadone 
 
 
Pharmacology 
 
Methadone (methadone hydrochloride, or 6-dimethylamino -4, 4-dipheny1-3-hepatone 
hydrochloride) is a synthetic opioid agonist that has effect on humans similar to those 
observed with morphine.  Methadone is well absorbed from the gastro -intestinal tract, 
irrespective of formulation type (e.g.  syrup vs. tablet).  It has very good bioavailability of 
80 to 95%.  The elimination half-life of methadone has been estimated to be 24 to 36 
hours, with considerable variation across individuals (10 to 80 hours). 
 
The rate of metabolism of methadone by the CYP3A4 enzyme affects the clearance of 
methadone from the body.  The expression of the CYP enzyme is influenced by genetic 
and environmental factors and by certain medications.  It is highly variable which can 
result in methadone toxicity and at the other extreme, in opioid withdrawal.  Certain 
medications interact with the blood level concentration of methadone and special attention 
has to be given to people using other medications such as HIV medications, antibiotics, 
some anti -epileptics and medications that treat tuberculosis.  For more information on the 
interaction of methadone and other medications we refer to appendix 14 of the UK 
Guidelines and to the Methadone Briefing by Andrew Preston, 1996.  The UK Guidelines 
can be consulted on the Internet: http://www.doh.gov.uk/drugdep. The Drug Misuse and 
Dependence -Guidelines on Clinical Management. 
 
Side effects of methadone occur in the neuro -vegetative and psychological area.  The 
most common side effects include: increased transpiration, constipation, and disturbances 
of sleep, sex drive and concentration.  Such undesirable side effects may persist over 
longer periods of treatment, but mostly remain without medical consequences.  In total, 
these side effects affect less than 20% of methadone service users (Swiss Methadone 
Report, 1996). 
 
Methadone treatment with full tolerance and stable doses does not usually impair the 
ability to drive or operate mechanical machinery.  All service users that are not stable are 
strongly advised not to drive or operate mechanical machinery, and should be informed 
that if deemed at risk to others, confidentiality may be broken.  Where service users are 
being prescribed further psychotropic medication, further consideration to their ability to 
drive or operate mechanical machinery should be questioned.  However, before issuing or 
reissuing a driver's license, careful checking is advisable to determine whether the service 
user's situation is stable; whether there are any chances of relapse, and whether there is 
consumption or misuse of other substances.  Especially the simultaneous use of alcohol 
and/or medications (e.g. benzodiazepines) should be taken into consideration (Swiss 
Methadone Report, 1996). 
 
 
 
 
 
 
Research 
 
Most research on methadone has been done in the USA.  The National Institute on Drug 
Addiction (IDA) has funded and co -ordinated several studies which have examined 
various treatment outcomes of methadone maintenance treatment in the United States.  
Some of these research projects were: the Drug Abuse Reporting Programme (DARP) 
studies with a 12-year follow-up; The Treatment Outcome Perspective Study.  (TOPS) 
gathered data before, during and after treatment on a nationwide scale and The Methadone 
Research Project (The Ball and Ross Studies) looked at the effectiveness and status of 
MMT in six programmes in three cities (International Forum, 1994). 
 
Opiate addiction is complicated and that has both metabolic and psychological 
components.  It is important to deal with both aspects of this condition.  Since it is a 
condition where a service user is prone to relapse, careful risk assessment of this 
possibility should preclude any decision to stop methadone prescribing. 
 
Another important study is the British follow-up study of the National Treatment 
Outcome Research Study (NTORS), which monitored the progress of 1075 service users 
in residential and/or community treatment services over five years (Gossip et al., 1998). 
 
In conclusion, research supports the conclusion that methadone maintenance is more 
effective than no treatment or placebo in retaining people in treatment, reducing use of 
Heroin and other illicit drugs, preventing HIV infection, improving the health -related 
quality of life, and reducing involvement in criminal activity and imprisonment rates.  
Detoxification alone is seldom effective in producing long -term change.  The benefits of 
methadone maintenance programmes can be maximised by retaining service users in 
treatment, prescribing higher rather than lower dosages of methadone, orientating 
programmes towards maintenance rather than abstinence, offering counselling, 
assessment and treatment of psychiatric co-morbidity and social treatments and the use of 
contracts and counselling to reduce the use of additional drugs (Preston, 1996; Farrell, 
1994; Ward, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter Three:            Outline of Best Clinical Practice 
 
 
Criteria for Treatment 
 
There are two internationally accepted diagnostic criteria that cover drug dependence: the 
first criteria of ICD 10 which defines Dependency syndrome as: "A cluster of 
physiological, behavioral and cognitive phenomena in which the use of a substance or a 
class of substances takes on a much higher priority for a given individual than other 
behaviours that once had a greater value………"(WHO Expert Committee on Drug 
Dependence, 1998). 
 
Substance dependency is diagnosed if at least three of the following criteria had been 
present in the previous year: 
 
 
Psychological: 
 
 
·          Strong desire or compulsion to take the substances 
·          Difficulty in controlling behaviour regarding the onset, termination or levels of use 
 
 
Physiological: 
 
 
·          Characteristic withdrawing syndrome or the substance if not taken 
·          Evidence of tolerance and need of increased dose to achieve effect 
 
 
Social: 
 
 
·          Progressive neglect of alternative interests/pleasures and increased time necessary 
to obtain, take or recover from substance 
·          Persisting with substance use despite the negative harmful consequences 
 
 
The criteria for entering methadone treatment differ widely between programmes. 
 
 
High threshold programmes adopt strict criteria, such as: 
 
 
·          A minimum age of 18 (under in some cases) 
·          History of failed treatment attempts 
·          Strong motivation to enter treatment 
·          One of the international diagnostic criteria for opioid dependence 
 
Some methadone programmes only accept heroin addicts for treatment if they suffer from 
illnesses, such as HIV disease or tuberculosis. 
 
At the other end of the scale there are low-threshold programmes, which would welcome 
anybody with a proven addiction to opioid who wish to enter a treatment programme. 
 
The criteria differ according to the type of treatment (maintenance or detoxification) 
because of the length of time a service user is expected to be in treatment.  Other factors, 
such as the availability of places, may influence inclusion criteria.  In areas where there 
are no waiting lists, programmes can adopt looser criteria than in places where there is a 
larger demand than supply of treatment possibilities. 
 
In general, the best situation is where everyone who is opioid dependent and in need of 
treatment can enter methadone after appropriate assessment and treatment induction.  It is 
recommended that the availability of treatment places be taken into account when 
adopting admission criteria.  A minimum age, length of opioid addiction, physical and 
mental health and personal motivation of the service user, could all be taken into 
consideration.  Some groups, such as pregnant women or service users with HIV/AIDS or 
other illnesses, should be given priority over the general opioid addicted population.  
This, however, should not entail compulsory HIV - antibody testing of service users. 
 
 
 
Assessment 
 
It is recommended best practice that all service users receive an initial nursing, 
counselling and doctors assessment before starting treatment.  Before starting any type of 
methadone treatment it is necessary to determine whether the service user is taking 
opioids and to establish the presence and severity of opiate dependence.  The doctor 
should conduct a personal interview with the service user and carry out a physical 
and mental state examination and urine for toxicology.  The final decision for the type 
of treatment should be taken on the basis of the needs of the individual service user and 
the options open to the clinician.  To ensure a successful treatment programme, the 
clinician or assessor is required to give the service user information on the full range of 
treatment options.  It should be ensured that the service user is matched to the most 
appropriate treatment for their current needs. Further, when starting methadone or 
psychoactive substances, the doctor should give to the client detailed information on the 
treatment, on the possible side effects of the medication and the potential social 
consequences (such as long -term dependency and increased tolerance). 
 
Part of the assessment process for new committals must include a minimum of one urine 
with specific test for heroin metabolites (6 A. Morph).  The doctor before their initial 
assessment of the service user should review Nursing and counselling assessments. 
 
Urinalysis can be helpful in confirming opioid use, however, this should be 
considered with care.  It may encourage the use of opioids prior to an assessment.  
Furthermore, it can only confirm opioid use, but it does not provide any information 
about the extent of use or dependence.  Its main usefulness may be in determining the use 
of other substances presently being used by the applicant (Ward et al., 1998). The results 
of any urinalysis should be considered only with a thorough clinical examination. 
 
 
 
 
 
Treatment plan and treatment goal (duration and dosage) 
 
Although these guidelines cannot modify potential local restrictions in therapeutic 
options, it can be stressed that the international literature, as well as the experience 
overtime in different parts of the world, underline the importance of the availability of a 
room for individual treatment assessment.  Restrictions in availability of places, in 
dosages and duration or type of treatment are counter-productive in the effective 
treatment of opioid dependent service users.  Making decisions about the treatment of 
individual service users has to be based as much as possible on a thorough assessment of 
what will work for that person and on reliable information about what works (Preston, 
1996).  The decision about what treatment to offer is based on what treatment is available 
locally, on the service user's previous history, current situation, social support network 
and expressed wishes.  The decision is also based on the clinician's judgement of the 
required degree of structure, monitoring and support of the service users needs. 
 
Opioid use and dependence is associated with a range of medical, legal and psychosocial 
problems.  Additional problems should be addressed from the very beginning, either by 
the methadone programme itself or through referral to an appropriate service. 
 
 
 
Induction 
 
 
The calculation of the right starting dose should take the following factors into account: 
 
 
·          That the right dose varies according to the treatment aim; 
·          That illicit heroin varies in purity from area to area and from time to time; 
·          That methadone is a long acting opiate; 
·          That too much methadone can be fatal but insufficient methadone is unlikely to be 
effective. 
 
Starting service users on a dose of methadone that is too high may result in toxicity 
and death.  However, there is some danger inherent in the administration of a dose of 
methadone that is too low, in that withdrawal may occur.  The experience of withdrawal 
symptoms may prompt service users to seek relief from other sources, such as illicit 
opiates and benzodiazepines.  The combination of methadone with other substances may 
result in toxicity and death.  Furthermore, some service users may metabolise methadone 
quite rapidly and may also be in danger of withdrawal and self- medication (Humeniuk et 
al., 2000).  There is evidence that people entering treatment have a higher risk of dying 
during the first month than before they entered treatment (Caplehorn, 1999). 
 
Once opioid dependence has been confirmed in a service user, tolerance and methadone 
dose need to be assessed.  The usual way to determine tolerance is by clinical assessment 
of the service user's medical and drug use history upon presentation.  Accuracy of clinical 
assessment may be improved by using corroborating evidence such as examining veins 
for evidence of injecting opioid use or urine tests.  A good rapport with the service user is 
vital in obtaining the necessary information.  It is important that enough time is allocated 
for the clinical interview as well as communication with other practitioners whom 
[service users may have seen. 
 
The absolute condition for an effective start of methadone treatment is to provide the 
service user with relevant information, which should include the following: 
 
 
·          The delay of 2 to 4 hours before methadone has a peak effect; 
·          The accumulation of methadone over time resulting in a greater effect over 3 
 to 5 days or more, even on a fixed dose; 
·          The risk of poly-drug use while on methadone, particularly other opiates, cocaine, 
 benzodiazepines and alcohol; 
·          The effect of medications that induce or inhibit activity on subsequent methadone 
concentrations. (for more information we refer to appendix 2). 
 
 
One more of the following criteria can identify service users with a higher risk of 
methadone toxicity: 
 
·          It is their first presentation to that practitioner and their medical and drug use 
history is unclear; 
·          They are at high risk of poly-drug use of dependence 
·          Their degree of neuro-adaptation is uncertain 
·          There is risk of overdose on methadone or any other drug 
·          They have a clinically significant respiratory disease 
·          They have clinical evidence of the end stage of liver disease 
·          They are currently being administered drugs that inhibit the CYP3A4 enzyme(*). 
 
 
Clinical titration of dosage needs to keep in mind the possibility of liver disease. 
 
It is highly recommended that methadone is commenced in the morning and preferably 
early in the week, so that the peak blood methadone concentrations occur when health 
care area is open and fully staffed enabling staff to intervene.  It is not recommended to 
start a new service user immediately before a holiday period. 
 
 
The aim of induction is to eliminate withdrawal.  In general, the initial dose is between 10 
- 20mg.  If tolerance of opioids is high the usual dose is between 20 - 40mg.  In cases 
where tolerance is low or uncertain, a dose between 10 - 20mg is more appropriate.  If in 
doubt it is best to err on the side of caution. 
 
Where possible in the first week of induction the service user should be seen daily in 
order to establish stabilisation dosage. 
 
For a longer period of detoxification and for maintenance treatment, it is recommended 
that increased doses to not exceed 20mg per week up to a total of between 60 - 120mg.  
The time needed to properly stabilise on methadone treatment can take up to six weeks or 
more. 
 
 Induction 
 
In general, the initial dose will be between 10 - 20mg.  In cases where tolerance to opioids 
is high, the normal dose will be between 25 - 40mg.  When tolerance is low or uncertain, 
a dose between 10-20mg is more appropriate.  If in doubt perhaps it is best to err on the 
side of caution and prescribe a lower dose.  While too much methadone can be fatal, 
insufficient methadone is unlikely to be effective. 
 
During the first week of induction scheme, service user should be seen daily where 
possible so that a stabilisation dose can be established .  Where doses need to be increased 
during this first week, the daily increase should be a maximum of 5 to 10mg and not 
exceeding 20mg within a week of the initial dose. 
 
Careful consideration should be given if a dose increase exceeds 20mg per week.  It can 
take up to six weeks or more to be properly stabilised on methadone treatment.  
Compliance will only be maintained if both service user and doctor agree that a reduction 
scheme is desirable. 
 
The majority of individuals in maintenance treatment will treatment will require 60 - 
120mg per day.  Although some individuals can be successfully maintained on lower 
doses, an average heroin dependent person will use less heroin and remain longer in 
treatment, if maintained on higher rather than lower doses of methadone. 
 
 
 
 
Detox regime suggestions 
 
The present policy in the IPS is to detox clients with a proven drug history unless they fall 
into the following categories. 
 
·    Currently on methadone maintenance. 
·    HIV positive. 
·    Pregnancy. 
 
On committal to the institution the individual must be assessed by the nurse, if there is a 
history drug use, particularly if the person has not been treated with methadone before, a 
urine must be taken for toxicology specifically testing for heroin metabolites (6 Acetyl-
Morphine ), the results of which must be available to the doctor examining the person 
prior to prescribing methadone. 
 
 
·    The day of committal the person will not receive methadone. 
·    Day 2. -  The individual will be seen by the doctor with the results of the test. A                                    
maximum of  20 mgs Methadone to be dispensed. 
·    Day 3. -  Following assessment 20 mgs will be administered. 
·    Day 4.  - Reassessed by the doctor and dose triturated based on clinical findings. 
 
Extreme caution to be used in concurrent prescribing of benzodiazepines and other 
psychotropic drugs. Caution should also be exercised when assessing the 16 – 19 y.o. 
During this induction period the person should be kept under regular nursing and medical 
observation. 
 
Many service users, despite requesting detoxification, are more suitable for maintenance 
treatment.  Options should be sensitively explored with the service user, and the overall 
goal should be to maximise the service user’s potential health gain. 
 
Undertaking a regular clinical review will ensure that the potential goal of abstinence can 
always be reconsidered.  Yearly case plan review is strongly recommended for all service 
users. 
 
 
Maintenance programme suggestions 
 
Research suggests that the majority of individuals require 60-120mg per day.  Although 
some individuals can be successfully maintained on lower doses, an average heroin 
dependant person will use less heroin and stay in treatment longer, if maintained on higher 
rather than lower doses of methadone.  In situations where high daily doses fail to prevent 
withdrawal during the full 24 dosing cycle, it should be determined if the individual is 
taking enzyme - inducing drugs concurrently, or if the individual metabolises methadone 
at a faster rate than average and higher methadone doses will be needed (Humenuik et al, 
2000; Preston, 1996; Ward et al, 1998).  Methadone levels should be performed on any 
service user receiving more that 100mgs. 
 
Although the majority of service users can be adequately treated with a daily dosage of 
between 60-120mg there are no objective data (include methadone plasma concentration) 
to suggest an adequate daily dose for an individual service user.  Asking the service 
user’s opinion about methadone dosage can have a positive effect on the treatment. 
 
Caution needs to be observed about high doses if there is associated alcohol/ 
Benzodiazepine dependence that could be the result of an under-medication with 
methadone.  In this case the stabilisation dosage needs to be reconsidered (Maremmani & 
Shinderman, 2000) 
 
In the prison setting when an established methadone maintenance patient is committed 
the following procedure should be followed. 
 
 
• Verify with the Central Treatment List (CTL) where the patient is registered 
as receiving his/her methadone. 
• Having verified where the patient is attending, contact should be established 
to ascertain the current dose of methadone, when it was last administered and 
any other relevant medical information. 
• This information should be furnished to the doctor and continuation of 
his/her prescription should ensue as appropriate. 
• Urine should be screened for methadone and other illicit drugs. 
 
 
Initially, service users may need to be seen by the doctor weekly and if stable fortnightly 
and then monthly.  A more thorough review may be useful every three months to consider 
what has been achieved and to set new goals.  Twice weekly urines are recommended in 
the initial stages and thereafter weekly.  Co-existing physical, social, psychiatric and 
legal problems should be addressed as much as possible. 
 
 
 
Detoxification from Methadone Maintenance Treatment 
 
The available research suggests that the slower the course of diminishing doses, the 
better. However, like all other decisions regarding the treatment plan, this can best be set 
individually in consultation with the service user.  One option is to reduce the dose 
blindly, as some people may prefer not to know the reduction details in order to prevent 
anxiety or expectancy effects. Supportive counselling is also considered an important part 
of withdrawing for maintenance and this should be continued after service users have 
finished the reduction regime because of the post-methadone syndrome.  This syndrome is 
associated with mild symptoms of the protracted withdrawal phase as well as with issues 
related to leading an opioid -free life.  The development of aftercare services in some 
places is an answer to these problems and involves a mix of education, skills training and 
features derived from self-help groups like Narcotics Anonymous (Ward et al; 1998). 
 
 
 
 
Specific Groupings 
 
 
 
Pregnant Women 
 
Attracting and maintaining pregnant women in treatment services is vital.  Where possible 
the partner should be taken on as well.  It is advisable to give pregnant women priority to 
enter Methadone treatment because of the health risks for both the mother and the foetus 
associated with substance abuse, such as premature labour.  Multiple drug use, poor 
nutrition and unsafe injecting can damage the foetus.  The long term outcome of women 
who enter methadone treatment programmes during pregnancy is better in terms of their 
pregnancy, childbirth and infant development, irrespective of continuing illicit drug use.  
Women attending treatment services usually have better antenatal care and better general 
health than drug -using women not in treatment, even if they are still using illicit drugs 
(Finnegan, 2000) 
 
Once a stable treatment programme has been established, liaison with other medical 
services, particularly for antenatal care, can be initiated. This can be facilitated particularly 
through the Drug Liaison Midwife. 
 
Although many women would wish to detox, long -term methadone maintenance 
treatment is considered the best option for most opioid dependant pregnant women.  In the 
third trimester, many women will need higher doses because of weight gain and other 
physiological changes. 
 
If a woman wants to detoxify, it is recommended not to do this in the period prior to week 
12 or after week 32 of pregnancy (Council of Europe, 2000).  Withdrawal symptoms 
should be avoided but particularly during the first trimester of pregnancy because of the 
risk of premature labour in this period.  The normal maximum reduction in the daily dose 
is between 1 –5mg weekly, fortnightly or monthly, depending on the woman’s response.  
Women should not be encouraged to detox in the final trimester of pregnancy. 
 
If detoxification is unsuccessful and the service users drug use becomes uncontrolled, 
methadone dosage should be re -assessed until stability is regained. 
 
 
 
Neonates of Opioid Dependant Women 
 
Over 60% of neonates born to opioid dependant mothers have symptoms of neonatal 
abstinence syndrome (NAS) that tend to occur 24-74 hours after delivery and include the 
following: high-pitched cry, rapid breathing, hungry but ineffective sucking and excessive 
wakefulness.  Hypertonicity and convulsions can also occur.  The intensity of the NAS 
does not directly correlate with the dose of the methadone or other opioids used by 
pregnant women. The use of Benzodiazepines by the mother in the anti -natal period and 
diarrhoea in the neo-nate can considerably prolong the period of withdrawal and may 
result in respiratory depression. 
 
They can usually be cared for in a normal maternity environment on condition that in case 
of emergency, they could be transferred to special care units. 
 
 
If medication is required, a range of opioid and non-opioid drugs can be used.  An oral 
morphine concentrate is the drug of choice and phenobarbitone may be used if the mother 
had been taking other substances, such as benzodiazepines. 
Breast feeding is encouraged not only because of its general advantages but also because 
some methadone may pass to the baby in very low doses and this in turn may help to 
reduce any withdrawal symptoms of the baby.  In case of HCV infection, the benefits of 
breast-feeding should be considered according to the mother’s viral load (Council of 
Europe, 2000).  Contra- indications for breast-feeding however are: if the mother has HIV 
disease or if she uses high doses of Benzodiazepines or if she continues illicit drug 
consumption. 
 
Finally, because pregnant women and young mothers may suffer from severe guilt 
feelings, psychosocial care and counselling is highly recommended. 
 
 
 
 
 
Parents of young children 
 
Drug use is not a reason to introduce care proceedings.  The needs of young children of 
drug dependant parents are, however, paramount. Workers in methadone programmes will 
need to include the care of the children in their treatment plan and have some means of 
supervision. There are special programmes co-ordinating the care of the parents and 
young children, case management of these service users is a key issue and the specific 
needs of the children should be considered explicitly (Children First, Department of 
Health & Children - September 1999) 
 
 
 
Young People 
 
Methadone is unlikely to be an appropriate treatment for people under 16 years of ages as 
they are unlikely to fit the criteria of: 
 
 
·    Long term opioid use 
·    Significant tolerance 
·    Level of problematic opioid use which would not be possible to treat with another 
form of treatment and help. 
 
If methadone treatment was nevertheless considered, specialist assessment and 
management is advised.  Parental consent is required.  In very rare circumstances 
treatment may be initiated after multidisciplinary/specialist revue and legal opinion. 
 
 
 
People with HIV Disease 
 
 
It is strongly recommended that all people in treatment should be tested for Hepatitis B 
and those without protective antibodies, should be vaccinated (See Vaccination Schedule 
– ERHA Publication March 2001).. 
 
Hepatitis C is a serious health problem for injecting drug users, both in terms of 
prevalence and its clinical effects.  There is a great need for improved methods of 
diagnosis and management of people with hepatitis C.  The dose of methadone will have 
to be reviewed and analysed, according to the liver function of the service user.  
Specialist referral should be arranged for assessment and possible treatment of HCV.  
People who are stable on methadone can be very compliant with HCV treatment.  Finally, 
as is in the case of people with HIV, it is important to reiterate the avoidance of sharing 
injecting equipment. 
 
 
 
People with mental health problems 
 
A significant percentage of opioid users may suffer from mental health problems, 
including anxiety and depression.  A percentage of opioid users presenting at services 
have suicidal and self-harm risk.  Entry into treatment has a significant positive impact on 
their psychological well being.  A minority (circa 10%) have severe enduring mental 
health problems that require close collaboration with mental health services (Marsden, et 
al., 2000). 
 
Dually diagnosed opioid dependant service users who survive early attrition, tend to stay 
in treatment longer than those without psychiatric co-morbidity do, when treated with 
higher methadone doses during the stabilisation phase (Maremmani et al, 2000). 
 
 
 
Poly Drug Users 
 
 
In order to deal with additional substance misuse, the health worker must be aware of 
other poly substance misuse including alcohol and benzodiadepines, so appropriate 
intervention can be made. It is vital to establish a good therapeutic relationship if these 
issues are to be addressed.  A good rapport based on trust and co-operation between 
prescriber and service user makes for good treatment. 
 
Strategies to reduce risk behaviour include: increasing the methadone dose and possibly 
other medication, the frequency of collection, supervised consumption, setting realistic 
treatment goals and finally, in some programmes, the suspension of methadone 
prescribing. 
 
 
Minority ethnic groups 
 
 
In many areas, opioid dependence can be a problem among ethnic minorities.  Often, 
services are developed for and run by people from the mainstream population and culture.  
In order to make services more attractive to ethnic minorities, it is important to offer 
culturally appropriate services. 
 
 
People in hospital 
 
It is important that general hospitals recognise and treat service user with opioid 
dependence. After proper assessment and communication with the drug treatment service, 
service users should be able to continue their methadone medication and all other 
medications in such a way as to ensure the completion of the medical treatment for which 
the service user entered the hospital.  It is worth noting that general hospitals should not 
be considered as detox centres. The drug treatment offered in hospital should allow for 
full treatment of the medical problem. 
 
The emergency department of a hospital will mainly encounter two situations: 
 
 
·    The management of severe abstinence and or overdose; 
·    The management of other drug related problems. 
Liaison between drug services, prison drug services and emergency departments are 
essential and joint policies between the two departments should be developed at local 
level. 
 
  
 
 
 
Steps in Methadone Treatment - 
 
 
 
Individual committed to prison 
 
 
Assessment by nurse 
(day of committal) 
 
Urinalysis (6 A. Morph) 
 
Verification with Central treatment list 
 
Doctors’ assessment 
 
Treatment plan (maintenance, detoxification) 
 
Contract signed (copy to service user). 
 
 
1. Service user given detailed information on the treatment and on the risks of using other 
drugs 
 
2. Listed medications not to be used 
 
Psycho-social follow up by Counsellor / Key Worker (where possible) 
 
Stabilisation period to establish the right dose 
 
Maintenance or detoxification regimen 
 
Regular review to set new goals (depending on type of treatment) 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five  (extract). 
 
 
Role of the medical doctor 
 
A doctor prescribing controlled drugs including methadone for the management of drug 
dependence should have an understanding of the basic pharmacology, toxicology and 
clinical indications for the use of the drug, dose regime and therapeutic monitoring 
strategy if they are to prescribe responsibly. 
 
Irrespective of the composition of the staff of a methadone treatment programme, 
prescribing is the sole responsibility of the doctor signing the prescription.  The 
responsibility cannot be delegated. 
 
It is the clinicians’ responsibility to make sure that the service user receives the correct 
dose and that efforts are taken to ensure that the drug is used appropriately and not 
diverted onto the illegal market.  Particular care must be taken with induction, especially 
in case of self- reporting dosage. 
Clinical reviews of service users should be undertaken regularly. 
 
 
 
Role of the nurse 
 
As part of a multidisciplinary team the nurse provides a standard of nursing care to 
service users in a primary health care setting conforming to best practice, An Bord 
Altranais code of professional conduct. 
 
In addition to carrying out the initial assessment, prioritising for treatment, managing the 
treatment waiting lists and co-ordinating care, the nurse completes a nursing assessment, 
initiates interventions and evaluates nursing care delivery to a caseload of service users. 
 
The nurse works in a variety of settings, which can influence the degree of primary care 
delivered.  However, the following common interventions and educational inputs are 
provided by the nurse to all service users: 
 
 
Ø   Family planning and safe sexual practices 
Ø   Education on HIV/Hepatitis 
Ø   General health promotion 
Ø   Virology for HIV/Hepatitis screening 
Ø   Vaccination regime as per protocol 
Ø   Assessment, treatment and management of tissue viability 
 
 
 
The Pharmacist provides advice for clinicians and nurses on pharmacology and drug 
interactions of medications. 
 
 
 
 
Record keeping 
 
Each intervention should be properly recorded and thorough, clearly written or computer 
records of prescribing should be kept (In accordance with ERHA Guidelines).  A service 
user- held record countersigned by those involved in care, can be a useful adjunct to 
treatment. Other medical staff members who may see the service user should be informed 
of current treatment. 
There is enormous variation in regulations about confidentiality throughout Europe.  A 
central register where people receiving methadone are notified exists in some areas.  This 
register should not entail notification to any non-medical service or institution, as there 
would be repercussions for the service user, such as a loss of civil liberties.  Its main 
purpose should be to protect the service, the service users and the service providers as 
well as to prevent multiple prescribing and to facilitate research or funding decisions 
(Irish Guidelines, 1997) 
 
In areas where there is no register, there should be some form of control and monitoring 
of the prescription and supply of methadone. 
 
 
 
Physical setting 
 
A first condition for a programme is that it is safe. Safe in the sense that people can trust 
the workers and that personal information is treated according to medical standards and is 
not given to third non-medical parties.  It may seem obvious, but essential for a successful 
programme is that people are being treated with respect and that their privacy is ensured. 
A non-judgmental attitude of treatment staff is important.  Some research has shown that 
in a methadone maintenance programme where the staff can be identified as “abstinence 
orientated” service users will leave quicker than when a programme is maintenance 
orientated. This difference ensued after correcting for methadone dosage. (Vosseberg, 
1998) 
Another obvious pre -requisite for any medical service is that premises are clean.  It is 
recommended that all staff involved in the treatment of opioid dependence be immunised 
against hepatitis B and undergoes tuberculosis screening. 
 
The location of the programme should meet some important conditions.  Because service 
users will have to attend the programme regularly, and in many cases daily, it is important 
that it should be centrally located. 
 
Opening hours should be flexible to accommodate service users who work. Ideally, the 
programme should open in early morning. 
 
When starting a new service in a given area, it is recommended to seek contact with 
community groups and representatives.  Clear information should be given on the rules 
and regulations within the centre. 
 
 
 
 
CLINICAL POLICIES 
 
 
C/1. SCREENING FOR INFECTIOUS OR COMMUNICABLE 
DISEASES 
 
C/2.   NOTIFIABLE DISEASES 
 
C/3. FOOD REFUSAL WITHIN PRISON - MANAGEMENT 
PROTOCOL 
 
C/4.   NICOTINE REPLACEMENT THERAPY 
 
C/5.   HEPATITIS VACCINATION POLICY 
 
C/6.   MENINGOCOCCIAL C IMMUNISATION PROGRAMME 
 
C/7.   INFLUENZA VACCINATION FOR PRISONERS 
 
C/8.   IPS POLICY ON MEDICATION ADMINISTRATION 
 
C/9.   USE OF BENZODIAZEPINE HYPNOTICS 
 
C/10. ADMINISTRATION OF MEDICATION TO PRISONERS 
FOLLOWING RETURN FROM TEMPORARY RELEASE 
 
C/11. PRECAUTIONS IN RELATION TO INITIATING METHADONE 
TREATMENT FOR OPIATE ABUSERS 
 
C/12.  PRESCRIPTION OF METHADONE TO PATIENTS UNDER 18 
YEARS 
 
C/13. CLINICAL RISK MANAGEMENT 
 
C/14. REVISED PRESCRIPTION KARDEX 
 
C/15. HAND HYGIENE 
 
C/16. MRSA POSITIVE WOUNDS OR ULCERS 
 
C/17. ADMINISTRATION OF EXISTING PRESCRIPTION 
MEDICATION TO PRISONERS ON COMMITTAL TO PRISON 
 
C/18. AVIAN FLU - POTENTIAL RISKS 
 
C/19. PATIENT REFUSAL OF MEDICATION 
 
            
  
 
HC Policy C/1 
 
SCREENING FOR INFECTIOUS OR COMMUNICABLE DISEASES 
 
In view of the long-standing association between I/V drug use, infection with 
communicable diseases (in particular Hepatitis B,C, and HIV), and criminality with the 
risk of incarceration it has been long-standing healthcare policy and practice to regard the 
prison population as being at high risk for such conditions.  In view of the requirement on 
healthcare staff to do all possible to safeguard the health of those in their care appropriate 
screening, immunisation, and referral to specialist services has been undertaken over a 
considerable time. 
 
In this context it is recommended that -  
 
1) All persons entering prison who volunteer a background history with risk factors 
for any infectious disease should be offered any available screening for that 
condition.  In line with current clinical practice it is considered that pre-test 
counselling is not relevant when considering HIV screening of at-risk individuals.  
Irrespective of the results of any screening all at-risk prisoners should be offered 
post-test counselling and advice regarding recommended life-style changes, etc. 
 
2) Any therapeutic intervention (screening, treatment, and referral) should be 
provided on the basis of informed consent.   
 
3) Where vaccination or immunisation is available on an equivalent basis to the 
general community this should be offered to the prisoner (see HC Policy C/2 - 
Hepatitis Vaccination Policy).  Where any such process occurs over a period steps 
should be taken to ensure continuity of provision, either within the prison system 
or in conjunction with community health agencies following release. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/2  
 
Re:  NOTIFIABLE DISEASES 
 
 
As is the case in the general community there is a legal and professional obligation on 
Prison Doctors to inform the relevant local statutory public health authority of any cases 
of notifiable disease coming to notice in the prison population. A current List of 
Notifiable Diseases is available from the National Disease Surveillance Centre, 25-27 
Middle Gardiner St, Dublin 1 (Tel.: 01-8765300; Email: info@ndsc.ie;  Web:  
www.ndsc.ie). 
 
Your co-operation in this matter would be appreciated. 
 
 
 
 
 
Healthcare Directorate 
April 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/3 
 
FOOD REFUSAL WITHIN PRISON - MANAGEMENT PROTOCOL 
 
Where a prisoner informs the prison authorities that s/he intends to refuse food or does 
so: 
 
 1. The reasons for this refusal should be established. 
  
 2. Where it is considered that his/her refusal is based on delusional beliefs or other 
psychiatric illness a full psychiatric assessment (with psychiatric hospitalisation, if 
necessary) should be arranged and the underlying illness treated without delay. 
  
 3. Where there is no evidence of psychiatric illness then the wishes of the prisoner 
(in refusing food) should be respected.  Force-feeding is not an option.  This fact 
should be explained to the prisoner by the doctor with clinical responsibility for 
his/her medical care. 
  
 4. The prisoner’s medical condition should be monitored by a doctor on a daily 
basis. Monitoring should include the following:  
   
 1) Daily fluid intake and urine output 
 2) Pulse and blood pressure both lying and standing each day 
 3) Urine tested for ketones each day 
 4) Weight recorded on a weekly basis 
  
 The effects of continuing food refusal on his/her health should be explained in terms 
the patient understands.  The progress of the situation, together with any interventions 
considered appropriate on medical grounds, should be communicated by the doctor to 
the prison management without delay. 
  
5.  The prisoner should continue to be offered meals at the appropriate times and note 
made of his refusal. 
  
6.  It is desirable that the prisoner be admitted to a single room in an appropriate 
medical facility when there has been a significant loss of weight with ketonuria.  The 
prisoner should be admitted immediately if he/she refuses fluids. 
  
7.  Bearing in mind the likelihood that if the food refusal continues the prisoner will, 
at a certain stage lose consciousness, he/she should be asked at an early stage to 
nominate a legal advisor or family member to act on his/her behalf in relation to 
resuscitation in the event that unconsciousness or incoherence occurs. 
  
 
 
The prisoner should be given the opportunity at an early stage to instruct the legal advisor 
or family member regarding his/her wishes.  This is to safeguard the doctor from any 
accusations of negligence (in failing to resuscitate the unconscious patient) or assault (by 
providing treatment without the consent and contrary to the express wishes of the 
patient). 
  
           
8.   The fasting prisoner should be assessed by a psychiatrist at least twice weekly to 
establish that his/her capacity for rational judgement is unimpaired. 
  
9.   Medical supervision and advice, together with appropriate food and fluids, should 
continue to be made available to the prisoner. 
  
10.  At all times it should be made explicit to the prisoner by the responsible doctor that 
there is no rule of medical practice which requires the doctor to resort to artificial feeding 
and that the inevitable deterioration in his/her health may be allowed to continue without                
medical intervention unless he/she specifically requests it. 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/4 
 
NICOTINE REPLACEMENT THERAPY 
 
Treatments available under the GMS, including Nicotine Replacement Therapy (NRT), 
are made available to prisoners subject to clinical considerations.  Given the very high 
prevalence of smoking among prisoners we would seek to assist anyone genuinely 
motivated to give up cigarettes in any way possible.  Giving up cigarettes requires more 
than replacement therapy alone and the evidence is that combined approaches are more 
successful than single focussed ones.  In this context NRT prescription is fully justified in 
those indicating serious motivation, including active participation in any associated 
counselling programme.  Where such motivation is lacking a more cautious approach to 
prescribing NRT is recommended.   
Any decision to supply such therapy from within the prison healthcare budget should take 
this into account. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/5 
 
Re: HEPATITIS VACCINATION POLICY 
 
It is IPS Healthcare policy to offer vaccination to prisoners in line with DOHC policy.   
 
1. Hepatitis B 
 
It has been long standing policy to offer Hepatitis B vaccination to all prisoners who are 
likely to remain in prison long enough to complete a scheduled vaccination course.   
 
In the case of prisoners who are Hepatitis C positive vaccination against Hepatitis A is 
also offered.  The following vaccination schedules have been suggested by the ERHA 
Drug Treatment Services (Dr. Keating) on the basis of practice with at-risk drug users in 
the general community -  
 
Proposed Vaccination Schedules: 
 
There are four client groups who require vaccination in the Drug Clinics. They are as 
follows: 
 
 1. Hepatitis C negative, hepatitis B negative 
 2. Hepatitis C positive, hepatitis B negative, on long term program 
 3. Hepatitis C positive, hepatitis B negative on short term program 
 4. Hepatitis C positive, hepatitis B positive 
 
 
1. Hepatitis C negative, hepatitis B negative 
Present recommendations suggest vaccination against hepatitis B only - This may change 
if all drug users are to be vaccinated against hepatitis A and B irrespective of Hepatitis C 
status 
 
Give: 
Hepatitis B vaccine - HBvaxPRO (Aventis Pasteur MSD) or Engerix B 
(GlaxoSmithKline)* at elected date 
Hepatitis B vaccine - at one month 
Hepatitis B vaccine - at 6 months 
 
*The interchangeability of Hepatitis B vaccines has been demonstrated 
 
Measure anti HBsAb six to twelve weeks after the end of schedule 
 
 
2. Hepatitis C positive, hepatitis B negative, on long-term program 
 
Vaccinate against hepatitis B and A 
Give: 
Twinrix (GlaxoSmithKline - combined hepatitis A and B vaccine) at elected date 
Twinrix - at one month  
Twinrix - at 6 months 
 
Or 
 
Hepatitis B vaccine - HBvaxPRO (Aventis Pasteur MSD) or Engerix B 
(GlaxoSmithKline) and at elected date and hepatitis A vaccine - Avaxim (Aventis Pasteur 
MSD) or Havrix (GlaxoSmithKline) 
Hepatitis B vaccine - at one month 
Hepatitis B vaccine and hepatitis A vaccine - at 6 months 
 
Measure anti HBsAb six to twelve weeks after the end of schedule 
 
 
3. Hepatitis C positive, hepatitis B negative on short-term program 
 
Vaccinate against hepatitis B and A 
Give: 
Twinrix (GlaxoSmithKline - combined hepatitis A and B vaccine) at elected date 
Twinrix - at one month 
Twinrix - at 6 months - recall if not on program 
 
Or 
 
Hepatitis B vaccine - HBvaxPRO (Aventis Pasteur MSD) or Engerix B 
(GlaxoSmithKline Kline) and at elected date hepatitis A vaccine with Avaxim (Aventis 
Pasteur MSD) or Havrix (GlaxoSmithKline Kline) 
Hepatitis B vaccine - at one month 
Hepatitis B vaccine and hepatitis A vaccine - at 6 months - recall if not on program 
 
Measure anti HBsAb six to twelve weeks after the end of schedule 
 
 
4. Hepatitis C positive, hepatitis B positive (natural infection or vaccination) 
 
Vaccinate against Hepatitis A only with Avaxim (Aventis Pasteur MSD) or Havrix 
(GlaxoSmithKline Kline) 
 
Give: 
Hepatitis A vaccine at elected date 
Hepatitis A vaccine at 6-12 months 
 
 
Post Vaccination Testing (6-12 weeks after the end of the vaccination schedule): 
  
Anti-HBs level Action Required 
0 or <10miu/ml Non responder.* Exclude past infection or 
chronic carriage. 
Repeat 3 dose course of Hepatitis B vaccine 
(a different brand of vaccine may be 
considered). Double dosing should also be 
considered. 
Recheck Anti-HBs at 2 -4 mobthd post 
completion. 
10 - 99miu/ml Poor responder. 
Immediate booster and retest at 2 - 4 mothd 
using 2 assays; if both assays are > 10miu/ml, 
this indicates an adequate response.** 
The results should be discussed with the 
reference laboratory. 
100miu/ml or greater Adequate response 
 
* check anti-HBc and HBsAg to exclude past infection or chronic carriage before 
repeating 2nd course of vaccine. 
 
** For those at high occupational risk of contracting Hepatitis B, efforts should be made 
to achieve a response of greater than 100miu/ml 
 
 
 
Healthcare Directorate 
April 2004  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/6 
 
Re : MENINGOCOCCAL C IMMUNISATION PROGRAMME 
 
As you are aware in 2000 the Department of Health and Children launched the above 
national programme aimed at minimising the incidence of Meningitis C.  The aim has 
been to vaccinate, on a phased basis, all citizens up to the age of 23 years.  This process 
should have been significantly achieved by this time.  Given that prisons contain 
significant numbers of individuals between the ages of 15 and 23 (particularly between 
17 and 23) it is important that the opportunity to offer this vaccine to those within this age 
cohort while in prison is not lost.  
 
I am writing to recommend to you that as a matter of Prison Service Health policy steps 
should be taken to offer this vaccine to any prisoners under the age of 23 within your 
establishment if they have not already received it elsewhere.  Given the transient nature 
of the prison population it is important to maintain thorough records of those receiving 
the vaccine with, ideally, the prisoner’s own GP being informed on release from prison.  
 
If you have any difficulty accessing supplies of the vaccine I would suggest that you 
should contact your local health board or the Office for Health Gain (01-670 5194 or 623 
4783).  
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/7 
 
Re: INFLUENZA VACCINATION FOR PRISONERS  
 
Policy in relation to the provision of Influenza Vaccination to prisoners is as follows - 
 
It is practice to offer Influenza Vaccination to prisoners on the same basis as it is 
provided in the general community under Dept. of Health guidelines.   
 
Essentially it is DOHC policy that Influenza Vaccine should be offered to the following 
groups   
 
1) Persons aged 65 years or over (including residents of nursing homes, old peoples 
homes, and other long stay facilities); 
 
2) Younger People with chronic illness requiring regular medical follow-up (e.g. 
chronic respiratory disease, cystic fibrosis, moderate or severe asthma, chronic 
heart disease, diabetes mellitus, etc.), 
 
3) Persons with immunosuppression due to disease or treatment; 
 
4) Children and teenagers on long-term aspirin therapy. 
 (not likely to be relevant in the prison context) 
 
It is important to note that under current guidelines vaccination is not recommended for 
healthy adults.  Consequently, it is not recommended for the vast majority of prisoners 
and prison staff. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/8 
 
IPS POLICY ON MEDICATION ADMINISTRATION: 
 
• Medication may only be given as prescribed or under protocol. 
   
 Only Nurse Officers and Medical Orderlies are entitled to administer medication 
 
 Before administering a medicine to a prisoner, the nurse/medical orderly must: 
            a)   check the prisoners name, number and location 
            b)   check the medication against the prescription 
            c)   check the strength 
            d)   check the quality i.e. not defective in any way 
 
 In order to ensure the safe and effective use of medication, where possible all oral 
medication should be administered as a solid dose i.e. tablet or capsule. 
            There are a number of orodispersible formulations available now, such as Zispin   
Soltab, Zyprexa Velotab etc. and it is recommended that they be used where 
necessary to ensure compliance, particularly for medications with overdose or 
abuse potential. 
 
 All medication administration must take place in front of the Nurse/Medical 
Orderly. 
 
 To ensure that the prisoner has swallowed the medication, the following 
procedure should apply at all times: 
 
a) All medication should be administered with a glass of water - therefore a 
supply of water and plastic cups should be available during medication 
administration rounds. 
  
            b) The patient should be supervised, in so far as is possible, to ensure that the          
            medication has been swallowed. 
 
 c) The patient should be engaged in conversation following medication    
       administration, to assist in confirming that the medication has been swallowed. 
 
 If the patient cannot/will not swallow a tablet/capsule, then a properly formulated 
liquid preparation should be prescribed and used. 
 
 Solid dose medication should never be administered in water, as this practice is 
unlicensed, unsafe and ineffective. 
 
 Where there is a problem with hoarding/abuse of medication, the patient should 
be referred to the doctor, who will consider the appropriate action - discontinuing 
prescription etc. 
 • Administration of all medication should be recorded in the prisoners 'kardex'. 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/9 
 
Re:  USE OF BENZODIAZEPINE HYPNOTICS 
 
In line with the ‘Report of the Benzodiazepine Committee’ and associated 
‘Benzodiazepines: Good Practice Guidelines for Clinicians’ which were widely circulated 
to all prescribers following their publication by the Department of Health & Children in 
August 2002 IPS supports the principles contained therein. 
 
These drugs should only be used for short periods (no more than one to two weeks) for 
the treatment of acute insomnia.  The use of these drugs in high dosage for prolonged 
periods of time (especially in the prison population as it exists) is contraindicated.  It 
would be difficult to claim, were questions raised or criticism made in any forum, that the 
use of these drugs in such a fashion conformed to good practice or enjoyed the support of 
a substantial body of medical opinion. 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/10 
 
 
Re:  ADMINISTRATION OF MEDICATION TO PRISONERS FOLLOWING 
RETURN FROM TEMPORARY RELEASE 
 
Where prisoners with a background history of substance abuse are absent from the prison 
(temporary release, court appearance, etc.) and on their return concern exists regarding 
the possibility of consumption of illicit drugs then it would appear judicious to withhold 
the administration of sedative medication until medical review (usually the following 
morning). 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/11 
 
Re : PRECAUTIONS IN RELATION TO INITIATING METHADONE 
TREATMENT FOR OPIATE ABUSERS  
 
Arising from the evidence presented at an inquest into the death of a prisoner it is 
considered appropriate to again re-iterate the need for an adequate assessment and 
clinical caution in relation to the prescription of methadone for detoxification purposes.  
In particular it is advised that two particular steps be taken. 
 
1. Given the range of proprietary and prescribed drugs that can mimic a positive 
opiate urine, I would recommend that, where practical, analysis for 6-
acetylmorphine (6AM) be undertaken.  This is a specific metabolite of heroin and 
indicates that heroin was consumed recently.  Most of the laboratories 
undertaking toxicology for drugs of abuse indicate that they are able to undertake 
this test routinely where specified. 
 
2. Where a prisoner is to be detoxified using methadone the following regime is 
recommended to minimise overdose risk. 
 
 Day of committal   -  No prescription 
 Day 1 following committal  -  20 mg methadone. 
 Day 2            - 20 mg methadone 
 Day 3 et seq   - clinically appropriate dosage for detox. 
 
These steps are recommended to ensure that any prescription to a prisoner of methadone 
for detoxification minimises the risk of cumulative overdose developing.  
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/12 
 
RE : PRESCRIPTION OF METHADONE TO PATIENTS UNDER 18 YEARS 
 
Clarification has recently been sought regarding the prescription of methadone to a 
detainee under the age of 18 years.  Current advice (as outlined in the Methadone 
Guidelines) is that caution should be used in any consideration of methadone prescription 
to this age group.  In particular it would be advisable to consider obtaining parental 
agreement for treatment, though this may not always be practical in the prison context.    
In line with current community protocol such prescribing should only be undertaken 
when the prescribing doctor has sought advice from a Consultant in Substance Abuse. 
 
I would be grateful if you would bear these considerations in mind should you be 
contemplating the prescription of methadone for someone under the age of 18 years. 
 
 
Healthcare Directorate 
22/01/2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy : C/13 
 
 
Re: CLINICAL RISK MANAGEMENT 
 
As you are probably aware Healthcare is increasingly functioning in an environment 
where appropriate Clinical Risk Management (CRM) structures are required.  This 
applies right across the healthcare environment and is not in any way specific to prisons.  
Most Health Boards, Hospitals, etc., now have established mechanisms in place to 
address the issue of CMR. 
 
Clinical Risk Management is an approach to improving the quality and safe delivery of 
health care by - 
 
1) Placing special emphasis on identifying circumstances that put patients at risk of 
harm, and 
 
2) Acting to prevent or control those risks in a 'no blame' cultural environment. 
 
The reporting, monitoring, and analysis of risk incidents is best fostered within a non-
blame culture as there is good evidence that blaming individuals for adverse events does 
little to improve safety and tends to encourage staff to hide mistakes and near misses 
rather than manage them..  The purpose of clinical risk analysis is to identify 
organisational deficiencies which may have contributed to the cause of the event, to 
develop strategies which reduce the chance of a similar event occurring again, and to 
promote the development of a proactive safety culture.   
 
Clinical risk may occur in a variety of areas -  Facilities; Equipment; Procedures; and 
Organisation. 
 
To encourage and facilitate the development of an acceptable Clinical Risk Management 
environment in the prison context the following steps are recommended -  
 
1) All incidents should be recorded in the patient’s medical record.  This should 
include date, time, nature of incident, and witnesses (if any) and be clearly signed. 
 
2) Healthcare staff should report any untoward clinical incident involving a patient 
to Healthcare Directorate by e-mail.  This will facilitate analysis. 
 
3) Depending on the potential or actual seriousness of the event further investigation 
may be required. 
4) Arising from analysis of an incident it may be possible to eliminate possible risk 
or reduce the likelihood of recurrence.  This step may have resource implications. 
 
5) Arising from any remedial steps taken ongoing re-evaluation of the potential risk 
is required to assess whether the risk has been adequately addressed. 
 It is intended to undertake a process of consultation with Healthcare staff with a view to 
designing a process to facilitate the needs of Clinical Risk Management at local level and 
to clarify requirements in this respect. 
 
 
 
 
 
Healthcare Directorate 
15/10/2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy : C/14 
 
 
Re: REVISED PRESCRIPTION KARDEX 
 
Supplies of a new revised kardex to record the prescription and administration of 
medication to prisoners are currently being supplied to all prisons.  This kardex (printed 
blue on a white background) is designed to be forwarded with the patient on transfer and 
to remain valid in the receiving prison until the patient is seen by the doctor. 
 
It is essential that all staff administering medication to prisoners clearly record having 
done so and the attached guideline outlines the procedure to be followed in this respect.  
Recording of medication administration is essential to safeguard the integrity of the 
process and also to protect staff. 
 
Please ensure that all new prescriptions are entered on this new kardex form and that use 
of previous kardexes or other recording mechanisms is discontinued.  A guidance 
document on the use of the kardex is attached. 
 
Further supplies of the kardex document are available from the Print Unit, Arbour Hill 
Prison (ref. AH 0207). 
 
 
 
 
Healthcare Directorate 
19 April 2005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy : C/15 
HAND HYGEINE 
 
Hand hygiene is acknowledged to be the single most effective and most cost-effective, 
intervention to promote infection control in clinical settings (Reybrouck 1983, Voss & 
Widmer 1997). Awareness of its critical role in reducing morbidity and mortality predates 
the discovery of bacteria and the germ theory of infection (Newsom 1993). Evidence that 
hand decontamination helps to prevent cross infection emerged from the epidemiological 
studies initiated by the Obstretician Ignaz Semmelweis during the mid-19th Century 
(Newsom 1993). 
However, the timely publication of two important documents (National Audit Office 
2000, and Plowman et al 1999) has reaffirmed the importance of controlling HAI. The 
benefits of ensuring that all clinical staff adhere to hand decontamination protocols to 
safeguard infection control should now be regarded as an important component of risk 
management and clinical governance (Desai et al 2000).  
1.1 ORGANISM PRESENT ON THE HANDS MAY BE DIVIDED INTO TWO 
CATEGORIES 
 
1.1.1 Resident micro –organisms (normal Flora) 
Resident micro organisms are those that are deep seated within the epidermis and 
are not easily removed. 
1.1.2 Transient organisms 
Transient organisms; These are located on the skin surface. They are easily 
removed with hand washing.  
1.2. CHOICE OF PRODUCT 
 
As a general rule, soap and water are adequate for routine activities, but the added 
protection of an antiseptic is desirable when performing invasive procedures and 
during the care of immuno-compromised patients.  
1.2.1 Soaps have a detergent effect. They remove transient micro organisms physically, 
but have no effect on the resident microbial population unlike antiseptics. Soaps 
do not kill micro organisms or inhibit growth. Their effectiveness is limited, but 
they are perfectly adequate when performing routine hand hygiene and are 
inexpensive. Liquid soap should be used. (Bar soap is unsuitable) 
 
1.2.2 Antiseptics cause a greater reduction than soap in the number of transient and 
resident organisms on the skin, either by killing them or                               
by inhibiting their growth. They are also likely to be more effective than soap 
against potentially pathogenic bacteria. Some antiseptics have a detergent effect, 
or are marketed in a formulation that includes a detergent, and are suitable for use 
on hands that are physically soiled. The aqueous antiseptic solutions available in 
your clinical setting are likely to include Chlorhexidine gluconate, Triclosan or 
Povidone iodine as the active agent.  
 1.2.3 Hand Rubs. The active ingredients in these products are ethyl alcohol (ethanol), 
isopropanyl alcohol (isopropanol) or n-propyl alcohol. These products might 
sometimes contain other antiseptics such as chlorhexidine or triclosan. When 
combined with chlorohexidine, residual action is provided, but on their own, 
alcohols do not display this property. They should always incorporate an 
emollient to protect their skin from dryness. They have excellent bactericidal 
activity against most Gram-positive and Gram-negative bacteria, but have no 
effect on spores. Alcohols destroy bacteria more swiftly than the aqueous 
solutions described above, but have no detergent effect and are not suitable in the 
presence of heavy contamination. They are extremely useful at times when 
physically clean hands require rapid decontamination.  
 
 
 
1.3. HAND DECONTAMINATION 
 
All wrist and ideally hand jewellery should be removed at the beginning of each 
clinical shift before regular hand decontamination begins. Cuts and abrasions 
must be covered with waterproof dressings.  
Hands should be washed: 
• Before commencement of duty. 
• Before moving from one patient to another. 
• Before any aseptic procedure. 
• After handling any patient. 
• After handling any item that is or might be soiled. 
• After using the toilet. 
• Before handling food. 
• After removing gloves. 
• As soon as hands become visibly soiled. 
• Prior to leaving the work area at the end of each duty roster. 
 
1.4. TYPES OF HAND DECONTAMINATION 
 
Routine: this renders the hands socially clean and removes most transient micro 
organisms. 
Surgical: Surgical hand washing is intended to remove transient organisms and to reduce 
resident organisms by using antiseptic hand wash solution. Surgical hand wash is 
essential before all surgical or invasive procedures. 
1.4.1 Routine hand wash 
Technique A sink with elbow-or foot-operated taps should be used if possible. 
This helps to avoid direct touching and the transfer of micro organisms either to 
clean hands or the next person.  Moisten hands before adding aqueous solution 
then vigorously rub hands together. Ensure contact of the solution with all 
surfaces: the palm, dorsum, tips of fingers, inter digital spaces, wrists and thumbs. 
When using an alcoholic solution, add 3 to 5mls to your cupped hands and then 
massage thoroughly to contact all surfaces.  
Duration of routine hand wash. If all hand surfaces are to be adequately covered 
with the chosen product, the duration of decontamination must be sufficient. The 
hands must be rubbed together vigorously for a minimum of 10-15 seconds, 
paying particular attention to the tips of the fingers, the thumbs and the areas 
between the fingers has all been suggested as ideal.  
Drying. Wet surfaces transfer micro organisms more effectively than dry ones 
and organisms will be removed by friction on the paper towel. Hands should be 
dried thoroughly because they will become sore. Soft, absorbent paper towels are 
more acceptable to most people than hard ones. The use of communal towels 
should be avoided because their damp surfaces can harbour bacteria and transfer 
them between hands.  
Protecting the skin Bacterial counts rise when the skin is damaged and this 
increases the risk of cross-infection. Hands should be protected by applying soaps 
and aqueous antiseptic solutions to skin that has already been moistened; they 
should not be allowed to contact dry skin. Thorough rinsing is necessary after 
washing. Hands can be further protected by applying good quality hand cream at 
the end of the shift and before retiring, with special attention paid to areas that 
look or appear dry or red. Large, communal jars of hand cream are not desirable 
as the contents can become contaminated, promoting cross infection.  
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2. GUIDELINES FOR GLOVE USAGE 
2.1 Reasons for Glove Wearing 
Expert opinion agrees that there are two main indications for the use of gloves in 
preventing Hospital Acquired infections. (ICNA 2002, & DOH U.K. 1994)  
1. To protect hands from contamination with organic matter and micro 
organisms. 
2. To reduce the risks of transmissions of micro organisms to both patients 
and staff. 
 
2.1.1 Types of Gloves 
Disposable gloves are manufactured in a variety of materials and have to conform to 
various national and international standards. They include:  
Natural Rubber Latex. (NRL) 
 Combination NRL with hydrogel lining. 
 Synthetic materials 
 Nitrile (acrylonitrile) 
 Tactylon (multipolymer synthetic styrene-ethylene-butadine- styrene) 
 Neoprene (Polychloprene) 
 Vinyl (Polyvinyl chloride-pvc: synthetic co-polymer) 
 Polythene (ethylene co-polymer/plastic 
 
2.1.2 General principles of glove wearing. 
 
• Gloves should not be worn unnecessarily as their prolonged use and 
indiscriminate use may cause adverse reactions and skin sensitivity. (Yassin et 
al 1994) 
• Gloves should be worn as single use items. They must be discarded after each 
care activity for which they were worn in order to prevent the transmission of 
micro organisms to other sites in that individual or to other patients. 
• Hands should be decontaminated following the removal of gloves. 
• Powdered and polythene gloves should not be used in health care facilities 
2.1.3 Glove Selection 
As with all items of personal protective equipment, the need for gloves and the selection 
of appropriate materials must be subject to careful assessment of the task to be carried out 
and its related risks to patients and health care workers. When choosing appropriate 
gloves perform risk assessment and refer to charts 1 and 2. 
2.1.4 Risk Assessment 
Risk Assessment should include consideration of: 
• Who is at risk (patient or HCW) and whether sterile or non-sterile gloves are 
required. 
• The potential for exposure to blood, body fluids, secretions and excretions.  
• Contact with non-intact skin or mucous membranes during general care and 
invasive procedures 
 
CHART 1. 
RISK ASSESSMENT AND GLOVE USE CHART 
 
 
 
 
 
 
Has the risk assessment identified that there is a risk of 
exposure to? 
• Blood/body fluids 
• Non-intact skin 
• Mucous membranes 
• Chemical/hazardous substances. 
 
YES NO 
Gloves Required Gloves not Required 
Patient risk User RIsk 
Sterile Non-sterile 
Refer to Chart 2 
CHART 2: 
MAKING THE CORRECT GLOVE CHOICE 
 
 
 
 
 
 
 
 
TYPE OF GLOVE 
Latex Synthetic alternative 
nitrile/ polychloroprene 
Vinyl Polythene 
Sterile Non 
Sterile 
Sterile Non 
Sterile 
Sterile Non 
Sterile 
Surgeons Examination 
All 
Surgery 
• All 
aseptic 
procedures with 
potential 
exposure to 
blood/body 
fluids. 
• Sterile 
pharmaceutical 
preparations 
• All procedures with 
potential exposure to 
blood/body fluids. 
• Procedures 
involving sharps. 
Handling cytoxic 
material. 
• Handling 
aldehydes (nitrile/ 
polychloprene) 
• Handling 
disinfectants 
• Tasks, which may 
pull, twist, stretch the 
glove. 
 
• Aseptic 
procedures 
where 
contact with 
blood/ bodily 
fluids is 
unlikely. 
Not 
recommended 
for clinical use 
• Tasks which 
are short and 
non-manipulative 
• Tasks with a 
low risk of blood 
and body fluid 
contamination. 
• Tasks which 
will not pull or 
twist the glove. 
• Cleaning with 
detergent. 
HC Policy : C/16 
 
 
MRSA POSITIVE WOUNDS OR ULCERS 
 
 Refer to Prison Doctor as patient may need systematic antibiotic. 
 
 Clean wound with Nacl - cleans surface organisms. 
 
 Apply Bethadine dressing to wound e.g. Inadine Tulle. 
 
 To prevent spread of infection; Apron and gloves must be worn when attending to 
dressings. 
 
 A known MRSA positive wound or ulcer should be attended to last in series of 
dressings, where possible. 
 
 Hand washing as per C/15. 
 
 Wash couch and trolley with soap and water then disinfect with hypochlorite e.g. 
Actichlor or Presept. 
 
 All staff should be advised to apply Universal Precautions. 
 
 Patient should be accommodated in a single cell where possible. 
 
 Wound should remain covered at all times when patient is recreating. 
 
 Patient should be advised re importance of him/her exercising good hand washing 
procedures. 
 
 When prisoner is moved or released, arrangements should be made to have the entire 
cell completely washed down with soap and water and disinfected with hypochlorite 
e.g. Actichlor or Presept. 
 
 
Healthcare Directorate 
September 2005 
 
 
 
 
 
 
 
 
HC Policy : C/17 
 
 
Re:  ADMINISTRATION OF EXISTING PRESCRIPTION MEDICATION TO 
PRISONERS ON COMMITTAL TO PRISON. 
 
 
Guiding Principle:  
 
To ensure the continuity of quality healthcare provision while in the custody of the prison 
service, in as safe a manner as is possible.  
 
This policy pertains to medications other than Methadone, as it is covered under a 
separate policy/ procedure (IPS Healthcare Standards - Policies C/11 and C/12. 
It is the policy of the Irish Prison Service to continue the administration of legitimately 
prescribed and dispensed medications to prisoners on committal until they are seen and 
clinically assessed by the Prison Doctor.  
 
Procedure. 
 
Where in the course of committal assessment by a member of the healthcare team it 
becomes evident that a prisoner has been, or was about to be, in receipt of medication 
legitimately prescribed and dispensed, every effort should be made to continue this 
prescription until the prisoner is seen the prison doctor.  
It is imperative for continuing health in many cases, such as treatment of insulin 
dependant diabetes that medication be continued.  
 
The following procedure should be deployed -  
 
1. Take history of medication use. 
2. Record name of prescriber, contact if possible. 
3. Record name of dispenser, contact if possible. 
4. Note any other supporting documentation. In the case of diabetes the prisoner may 
have in his possession the official record of his currently prescribed long-term 
medication (the green book). Others with long term illnesses may have similar 
documentation. 
5. In as far as is possible ensure that the medication as presented by the prisoner is 
the same as stated on the label on the prescription bottle. This may be facilitated 
by use of the Mims or BNF. 
6. Record date and time of previous administration of medication and if this 
information complies with administration schedule, administer and record, from 
the prisoners own medication supply, prescribed dosage. 
7. Prisoner should see the doctor as soon as possible for a review of all medication. 
 
 
 
This procedure is not intended to override the clinical judgement of the healthcare staff 
member involved in the assessment procedure.  It is intended to act as an aid to minimise 
the risk to the prisoner until full medical assessment occurs while continuing to provide 
care in a prison setting. The ultimate decision will, and has to, be with the person at first 
point of contact in assessing the risk. 
 
 
 
Healthcare Directorate 
13/09/2005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy C/18 
 
Re:  AVIAN FLU - POTENTIAL RISKS 
 
As you are aware there has been much media interest and publicity surrounding the 
potential risks associated with a case or outbreak of Avian Flu in this and other countries.  
While the risk is minimal at present it is undoubtedly the situation that outbreaks have 
spread from original points in East Asia to the point where there was recently a fatal 
outbreak in Turkey.   
 
Given the nature of this condition and the facility for long-distance travel now existing, it 
would seem reasonable to conclude that cases are possible closer at hand.  This would 
particularly apply in the case of people arriving in this country from one of the affected 
countries (see HSE Guidance attached) presenting with a 'flu like illness and who have 
been in contact with domestic or other fowl in the period immediately prior to their 
arrival here. 
 
The relevance of this particular matter is the possibility that individuals outlined above 
might, for whatever reason, be committed to a prison establishment here.  To assist with 
the immediate assessment of any such case I am attaching the HSE algorithm for initial 
management.  
 
As you will be aware the much greater risk to international community health is the 
possibility that mutation of the H5N1 strain may facilitate human to human transmission 
and the subsequent development of a pandemic of new variant influenza.  If this occurs it 
is likely to lead to very significant social disruption in many countries.  We have been in 
contact with the National Disease Surveillance Centre in respect of overall national plans 
to deal with such eventuality and highlighting the need for the Prison Service to be 
regarded as an essential public service in such planning.  As yet there is no definite 
advice forthcoming from the national emergency planning forum on practical steps that 
we might seek to take at this stage. 
 
Further information is available on the Health Protection Surveillance Centre (formerly 
the National Disease Surveillance Centre) website (www.ndsc.ie) which provides up to 
date clinical guidance and information in relation to questions currently being asked 
regarding these risks. 
 
As further information or advice relevant to the prison situation becomes available we 
will forward same to you. 
 
If you have any further queries on this matter please feel free to contact HC Directorate. 
 
Healthcare Directorate  
23/01/2006. 
 
 
HC Policy: C/19  
 
   PATIENT REFUSAL OF MEDICATION 
 
It has come to light that only some prisons use a disclaimer form signed by the patient            
(prisoner) in the event of a patient refusing to take his/her prescribed medication or other 
treatment. 
 
It is good practice and IPS policy, Health Care Standard 7.5.8, that all refusals of 
medication/treatment be documented on the Kardex or PMRS. It is also recommended 
that the patient also sign a refusal of medication disclaimer form. Where possible the 
patient’s signature should be witnessed by a third party.  See attached an example of a 
disclaimer form. 
 
The request for a third party signature is on foot of a recommendation from the Dublin 
City Coroner following a rider in a coroners case July of last year, this may not always be 
feasible but should be aimed for. 
 
 
Health Care Directorate 
28 February 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirmation of Investigation/ Treatment/ Medication Refusal.  
 
Name Institution_________________________________________ 
Date__________________________ 
 
I____________________________ born on___________________________ 
A prisoner in __________________________________ Prison confirm that I have 
refused to consent to the 1) Investigation.   2) Treatment, 3) Medication (please 
circle relevant item), recommended by Dr _______________________________ 
 
Specify Treatment/ Investigation, Medication. 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________ 
 
The reason(s) for refusal is/are as follows 
1.___________________________________________________________________ 
2.___________________________________________________________________ 
3.___________________________________________________________________ 
 
The consequences of this refusal have been fully explained to me and I accept full 
responsibility for any negative effects that may follow. 
 
Signature of Prisoner__________________________________________________ 
Date_____________________________ 
 
Signature of Witness___________________________________________________ 
Date_____________________________ 
 
Signature of Second Witness (where possible) 
Date_____________________________ 
 
Original to be held in prisoner's medical file. 
 
 
ADMINISTRATIVE POLICIES 
 
A/1   COMPLAINTS FROM PRISONERS REGARDING MEDICAL TREATMENT 
 
A/2  GUIDANCE FOR HEALTH CARE STAFF IN RELATION TO THE 
RESPONSIBILITY TO SAFEGUARD THE CONFIDENTIALITY OF 
MEDICAL INFORMATION CONCERNING PRISONERS 
 
A/2a GUIDANCE FOR HEALTH CARE STAFF IN RELATION TO REQUESTS 
FOR THE RELEASE OF CONFIDENTIAL MEDICAL INFORMATION 
CONCERNING PRISONERS 
 
A/3    HEALTH RESEARCH PROJECTS INVOLVING PRISONERS 
 
A/4   MEDICAL ASSESSMENT OF NEW RECEPTIONS 
 
A/5   PRIVATE MEDICAL ARRANGEMENTS BY PRISONERS 
 
A/6   ACQUISITION OF MEDICAL EQUIPMENT 
 
A/7   RECRUITMENT / ENGAGEMENT OF MEDICAL OR THERAPEUTIC 
STAFF 
 
A/8   PROVISION OF PARA-MEDICAL THERAPIES AT STATE EXPENSE 
 
A/9   REQUESTS FOR MEDICAL REPORTS ON PRISONERS 
 
A/10  REQUESTS FOR MEDICAL INFORMATION ON PRISONERS BY THE 
PAROLE BOARD 
 
A/11a FREEDOM OF INFORMATION ACT 
 
A/11b FREEDOM OF INFORMATION ACT - MEDICAL 
 
A/12   REPATRIATION OF PRISONERS UNDER THE TERMS OF THE 
EUROPEAN CONVENTION ON THE TRANSFER OF SENTENCED 
PRISONERS 
 
A/13 ANNUAL MEDICAL REPORTS 
 
A/14  EXTANT MEDICAL APPOINTMENTS ON COMMITTAL 
 
A/15 REFERRAL FOR SPECIALIST MEDICAL ASSESSMENT 
 
A/16 SPECIAL OBSERVATION LISTS (MEDICAL) 
 
A/17 NOTIFICATION OF THE IMPENDING TRANSFER OF A PRISONER TO 
HEALTHCARE STAFF. 
 
A/18 ACCESS TO MEDICAL FILES ON TRANSFER 
 
A/19  POTENTIAL CONTAMINATION OF URINALYSIS RESULTS FOR DRUGS 
OF ABUSE 
 
A/20 PEOPLE ENTERING PRISON WITH METHADONE SUPPLIES 
 
A/21 NURSING CLINICAL RECORDS 
 
A/22 PROCEDURE PENDING EMERGENCY TRANSFER TO EXTERNAL 
HOSPITAL. 
 
A/23  POLICY ON DISPOSAL OF PATIENTS LEGALLY DISPENSED 
METHADONE 
 
A/24  ARRANGEMENTS FOR THE CONTINUATION OF METHADONE 
TREATMENT FOR CLIENTS ON RELEASE FROM PRISON 
 
A/25  GUIDELINES ON SAFE AND APPROPRIATE SETTINGS FOR 
METHADONE ADMINISTRATION. 
 
A/26  GUIDELINE ON PROCEDURE TO BE FOLLOWED IN CASES OF 
ALLEGATION OF ILL-TREATMENT BY PRISONERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HC Policy A/1 
 
Re : COMPLAINTS FROM PRISONERS REGARDING MEDICAL 
TREATMENT 
 
Where prisoners make complaints directly to Healthcare Directorate significant resources 
are required to clarify information, consult with doctors or other staff, draft responses, 
etc.  It has become apparent that in many cases the local prison doctor is not aware of the 
complaint and usually would have been best placed to respond directly to the prisoner.  
This applies particularly where issues regarding appropriate treatment, external hospital 
appointments, etc., arise. 
 
1. Where a prisoner requests through Governor’s parade, half-sheet, etc., the facility 
to make complaint or seek clarification regarding any aspect of his/her medical 
treatment in prison this matter should be directed to the prison doctor or other 
appropriate member of healthcare staff in the first instance. 
 
2. Only in situations where, following the involvement of the local doctor, the 
prisoner remains dissatisfied with the situation should the matter be directed to 
Healthcare Directorate.  In such cases it is requested that the written 
comments of the doctor on the matter raised should accompany any 
correspondence forwarded. 
 
The procedure outlined above will both expedite the addressing of any concern or 
complaint a prisoner may have regarding his/her medical situation and ensure that the 
responsible doctor is appropriately involved from the outset.   
 
Your co-operation in this matter would be appreciated. 
 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 HC Policy A/2 
 
GUIDANCE FOR HEALTH CARE STAFF IN RELATION TO THE 
RESPONSIBILITY TO SAFEGUARD THE CONFIDENTIALITY OF MEDICAL 
INFORMATION CONCERNING PRISONERS 
 
 
Introduction 
 
The Irish Medical Council1, An Bord Altrainais2, and the Pharmaceutical Society of 
Ireland3 in their various guidance’s highlight the fact that confidentiality is a time 
honoured principle of professional healthcare ethics and is fundamental to the therapeutic 
relationship.  Developments in various aspects of the practice and administration of 
health care have led to reconsideration of the issues involved4,5, 6.  Various national1 and 
international statements7, 8 on the issue of ethical behaviour as applied to prisoners clarify 
that prisoners must be treated in the same way as other patients.  There is no diminution 
or derogation of professional responsibility in this respect when providing care to 
prisoners. 
 
 
Notwithstanding the fact that patient confidentiality is difficult to maintain in the prison 
setting it is, nevertheless, the responsibility of healthcare staff to ensure that a patient’s 
right to confidentiality is respected.  While a sick prisoner cannot easily prevent the 
nature of an illness being known to others sharing a cell or by prison officers this process 
should not be facilitated by unauthorised disclosure by healthcare staff.  Any presumption 
that discipline staff or others, because of their position, are entitled to unimpeded access 
to information regarding a prisoner’s health status must be clarified. 
 
 
Core Principles -  
 
1. Information relating to a prisoner’s health status should be restricted to those with 
a genuine need to know. 
 
2. Any sharing of information amongst those who do need to know should ordinarily 
be with the prisoner’s consent, though exceptions may arise (see below). 
 
3. All clinical interviews and examinations should be conducted out of the hearing 
and sight of prison officers unless the doctor or nurse concerned requests 
otherwise in a particular case. 
 
 
 
 
 
 Exceptions -  
 
1. Notification of infectious diseases under the relevant Health Acts. 
 
2. Disclosure ordered by a Court. 
 
3. Disclosure to prevent risk to the patient - should be case specific and limited to 
relevant staff. 
 
4. Disclosure to prevent risk to others - would require an real and imminent risk to 
an identified individual.  The risk would have to be considered life threatening to 
sustain a decision to disclose confidential information. 
 
5. Child protection - under terms of relevant child protection legislation.    
 
 
 
 
Healthcare Directorate 
June 2003. 
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 HC Policy A/2a 
 
GUIDANCE FOR HEALTH CARE STAFF IN RELATION TO REQUESTS FOR 
THE RELEASE OF CONFIDENTIAL MEDICAL INFORMATION 
CONCERNING PRISONERS 
 
• Best practice in the release of confidential medical information dictates that the 
consent of the patient to the release of medical information should be secured in 
advance wherever possible. 
 
• No original medical files should be released from the prison surgery except with the 
written approval of the Director of Healthcare.  However, where such approval is 
granted for the release of an original file, a complete copy of the file must be retained 
within the prison surgery. 
 
• All medical information to be released has to be requested in writing and brought to 
the attention of the prison doctor (and nurse manager, where applicable).  The request 
should ideally indicate the reason for the release and the consent of the patient where 
available. 
 
• Where legal proceedings have been formally instigated by a prisoner against the IPS, 
the rules relating to formal discovery should be applied as is implicit in the nature of 
the request.  In such cases a copy of any information released as part of legal 
proceedings should also be released under seal to the IPS legal team.  It is desirable 
that all such disclosures be governed by formal court ruling as to the nature and extent 
of the disclosure required in the circumstances. 
 
• In the event that the medical information in question is on a patient who has died, the 
information is protected by the Coroner until such time as the inquest is complete.  
All requests for the release of information in such circumstances has to be directed to 
the Coroner.  The Coroner still only ever receives a copy of the medical file.  Once 
the inquest is complete, the responsibility for the medical records reverts back to the 
doctor in the prison. 
 
• In the case of a deceased prisoner – where the inquest is completed – it is also 
reasonable to release medical information to the next of kin upon formal signed 
application. 
 
• Only members of the surgery staff may have unsupervised access to the medical files 
held in the surgery or on PMRS.  This includes access to the file room containing 
medical information on prisoners who have already left custody. 
 
Healthcare Directorate 
July 2009 
 
HC Policy A/3 
 
Re:   HEALTH RESEARCH PROJECTS INVOLVING PRISONERS 
 
All proposals or requests to undertake Healthcare related research involving prisoners 
must be referred to the IPS Research Ethics Committee for consideration in the first 
instance.  On no account should any such project be facilitated or undertaken prior to 
receiving ethical approval. 
 
While the IPS would wish to foster and encourage research which may be of benefit 
(either directly or indirectly) to prisoners or their management it is necessary to ensure 
that we are aware of any such projects together with their possible ramification for the 
management of prisoners.  It is also essential that we be in a position to ensure that any 
possible accusation that prisoners are being exploited in any way can be countered.   
 
 
 
Healthcare Directorate 
April 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/4 
 
Re :  MEDICAL ASSESSMENT OF NEW RECEPTIONS 
 
Potential difficulties have arisen in relation to the misunderstanding that it is appropriate 
to defer initial medical assessment and examination for a number of days (e.g. over a 
weekend, etc.).  All new receptions to prison should be medically examined as soon as 
possible.  In practical terms this means on the day of reception or the morning 
following such reception.  It is not appropriate to leave new receptions unexamined for a 
number of days.   
 
Among the reasons for this are - 
 
1) It is important to assess any healthcare risk (particularly possible communicable 
disease or psychological vulnerability) prior to the placement of a prisoner on a 
general prison location.   
 
2) It is important to note and assess any injuries which might be complained of at the 
time of reception.  This is important in protecting staff and others from accusation 
that such injuries might have occurred after reception into the particular prison.   
 
3) A fortunately rare occurrence is the risk of sudden illness or death occurring in a 
recently received prisoner who has not been medically assessed.  While it might 
be possible to defend such a situation where the time between reception and 
illness/death is short this would be increasingly problematic where a number of 
days had elapsed. 
 
On a practical note the Prison Doctor’s Common Contract [section 6 (d)] makes provision 
for extra payment for any work involved in medically assessing receptions at weekends 
or other times. 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
HC Policy A/5 
 
Re: PRIVATE MEDICAL ARRANGEMENTS BY PRISONERS 
 
The situation regarding the provision of medical service to prisoners is that it is policy 
that prisoners are provided with equivalent standards to other citizens.  In this context 
'equivalent' is interpreted as being the same as other citizens covered by the Health Acts 
(i.e. GMS Medical Card holders).  Effectively, prisoners are regarded as public patients, 
irrespective of their personal resources, private medical insurance cover, etc.  In relation 
to the overall smooth running of prison establishments it is felt appropriate that, to avoid 
friction and resentment, situations which might give rise to inequity (in this case access to 
preferential or more immediate healthcare) should be avoided.  While this might be 
considered disadvantageous to the (present) small minority of prisoners with the means to 
access private healthcare it is felt, on balance, to be a justifiable corollary of 
imprisonment. 
 
With regard to the matter of access to external or second medical opinion or treatment the 
following approach is advised -  
 
1. All referrals to external medical or healthcare resources should be through the 
Prison Doctor (the medical person with statutory responsibility for the primary 
healthcare of prisoners in the particular prison), based on his/her clinical 
assessment of the medical situation. 
 
2. Where a person is committed to prison with an outstanding private medical 
appointment steps should be taken to convert this to a public clinic appointment.  
If, for clinical or other reasons, this is not possible or it is considered by the Prison 
Doctor that the pre-existing private appointment should be facilitated this should 
be discussed in the first instance with Healthcare Directorate.  Where this 
situation arises an undertaking should be sought from the prisoner to be 
personally responsible for the medical costs of any private treatment.  Any 
subsequent appointments should be in a public clinic (it might be appropriate to 
clarify this with the external medical consultant or service).  Otherwise, where a 
prisoner requests private medical referral this should be refused and the reasons 
(as outlined above) explained. 
  
3. Given the statutory clinical responsibility of the Prison Doctor for prisoners while 
they are in prison it is not considered that there would be any onus on the IPS to 
facilitate any medical appointment obtained by a prisoner, by whatever means, 
independent of the knowledge or referral of the particular Prison Doctor involved. 
 
While the advice above is intended to apply to sentenced prisoners the same broad 
criteria would apply to remand prisoners.  Given the fact that remand prisoners remain 
innocent until convicted by a court there might, conceivably, arise situations where a 
remand prisoner sought, and was granted permission, to access private healthcare.  As 
indicate above clear commitment should be sought from any such prisoner to be 
responsible for the medical costs associated with such treatment. 
 
If you have any further queries on this matter please do not hesitate to contact Healthcare 
Directorate.    
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/6 
 
Re :   ACQUISITION OF MEDICAL EQUIPMENT 
 
 
Where the acquisition of medical equipment for use in surgeries, etc., is being requested 
consideration should be given to the envisaged use of the equipment requested.  The need 
for such equipment should be clearly outlined to the Governor's office / Stores, with a 
copy to Healthcare Directorate.  The provision of this information at the time of request 
will help to expedite the matter, particularly where the sanction of Finance Directorate is 
required.  This applies especially where functioning medical equipment of a similar 
nature already exists. 
 
 
 
Healthcare Directorate         
  
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/7 
 
Re : RECRUITMENT / ENGAGEMENT OF MEDICAL OR THERAPEUTIC 
STAFF 
 
Where it is necessary to consider the engagement of therapists or counsellors at   
establishment level for the purpose of providing medical or therapeutic services to 
prisoners it is suggested that the following procedure be followed.   
 
1. Where it is considered locally that a particular therapeutic need exists and a 
service input is required within the prison this matter should be raised in the first 
instance with Human Resources Directorate and any other relevant section within 
IPS HQ.  This applies both to any new service and to recruitment on the 
resignation / retirement of any existing provider.  It is particularly important 
where financial allocation has to be made to support the post that approval is 
obtained from Finance Directorate.  In all cases it should be clearly established 
that the service is required, or continues to be required, and that it cannot be 
provided from existing staff resources. 
 
2. Following discussion it may be considered advisable or appropriate to advertise 
and hold a competition to ensure that the best qualified person is obtained and to 
safeguard the IPS from subsequent accusation that a potential candidate who 
might consider him/herself suitably qualified was denied the opportunity to 
compete for a position which is paid out of the public purse. 
 
3. In all situations an appropriate selection procedure should be cleared and 
approved Human Resource Directorate. 
 
4. In all cases, whether voluntary or remunerated, it should be borne in mind that 
security clearance may be needed and steps should be taken to obtain this 
clearance. 
 
 
 
Healthcare Directorate 
April 2004 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/8 
 
 
Re : PROVISION OF PARA-MEDICAL THERAPIES AT STATE EXPENSE 
 
While it is policy that prisoners should be provided with an equivalent level of health care 
to citizens in the general community covered by the public health schemes it would 
appear that in situations have arisen where the level of treatment being provided is, 
arguably, considerably more (in terms of access, extent, duration, or frequency) than 
would pertain on the outside.  This would apply to services such as Physiotherapy, 
Chiropody, and various types of Counselling.  In general these services are provided by 
external providers with payment from the Prisons budget. 
 
Where such services are provided on the basis of medical referral it is requested that  
 
1) where an individual prisoner is receiving same for over two months there should be 
review by the referring doctor to ensure that continued provision is clinically justified 
(either on the basis of actual clinical improvement or active prevention of 
deterioration), and  
 
2) that written confirmation to this effect be provided to the Governor. 
 
Your co-operation in this respect would be appreciated. 
 
 
 
Healthcare Directorate 
April 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/9 
 
Re : REQUESTS FOR MEDICAL REPORTS ON PRISONERS 
 
On a number of occasions recently queries have arisen in relation to the procedure for the 
provision of medical reports on prisoners.  As you area aware medical opinion may be 
sought from the prison doctor in a variety of circumstances (Court, Parole Board, concern 
over fitness for imprisonment, etc.).  The disclosure of medical information requires the 
consent of the patient.  Ideally, consent should be in writing and this is particularly the 
case where there is any possibility of subsequent dispute regarding the validity of such 
consent.  Consent is only valid for the stated purpose.  In other words consent to 
disclose information to A is for that purpose alone and should not be implied as 
consenting to A passing the same information to B, C, or D. 
 
It is advised that where medical information or a report concerning a prisoner is being 
sought from a doctor or other member of the healthcare team a written request should be 
supplied indicating  -  
 
1. Who, or what body, is seeking the information; and 
 
2. For what purpose is the information or advice being sought. 
 
The provision of this information from the outset will help ensure that the appropriate 
consent is obtained and that the medical report or advice addresses the particular issues of 
concern. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/10 
 
Re : REQUESTS FOR MEDICAL INFORMATION ON PRISONERS BY THE  
PAROLE BOARD 
 
The Parole Board has been established to advise the Minister in relation to the 
administration of longer term prison sentences.  In undertaking its role it is likely that 
medical information or reports will be sought to inform and assist the deliberations of the 
Board.   
 
In relation to providing information in any requested reports I would advise that it is 
important for healthcare personnel to limit themselves to matters specifically within their 
competence, i.e. health status and health related issues.  In general comments on the 
general conduct of a particular prisoner, suitability for release or transfer, etc., are more 
appropriately addressed by other disciplines.  Where a prisoner has been seen by a 
psychiatrist, psychologist, or other therapist it is appropriate where opinion or comment is 
sought on the nature or extent of any such interaction that this be from the relevant 
professional.  
 
Should you require any further information concerning the functioning of the Parole 
Board an information leaflet for prisoners has been prepared and is available from the 
Governor. 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/11a 
 
Re : FREEDOM OF INFORMATION ACT 
 
As you are probably aware the Freedom of Information Act 1997 came into effect in 
relation to public bodies, government departments, Health Boards, public hospitals, etc., 
in 1998.  Effectively, the Act gives the right of access to personal information, including 
medical information, to the person involved.   
 
While S. 28 of the Act does allow exemption from the obligation to disclose personal 
medical or psychiatric information on the grounds that the information .... ' might be 
prejudicial to his or her physical or mental health, well being or emotional condition ' .... 
in practice the justifiable application of this clause is likely to be a rarity in the prison 
context. 
 
The net effect of this is that prisoners or ex-prisoners are entitled to seek access to their 
medical files.  In cases of requests for personal information there is no limit to how far 
back the information sought can apply.  Any such requests should be directed to the 
Freedom of Information Officer in this Department for processing rather than being 
addressed locally.  Obviously the application of this Act in no way excludes the good 
clinical practice of informing and involving any patient in relation to their own medical 
care.  As you are aware the Medical Council and medical defence bodies recommend that 
patients seeking information in relation to their medical situation should, if possible, be 
facilitated.  The new Act gives a right of access and the applicant does not have to 
indicate why access is being sought. 
 
If you have any further queries on this matter please do not hesitate to contact Healthcare 
Directorate. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/11b 
 
 
Re:  FREEDOM OF INFORMATION REQUESTS - MEDICAL 
 
All FOI Healthcare requests are to follow the guidelines set out below - 
 
1. Any request received locally (either through half-sheet or direct application to the 
prison) stating that the request is being made under the terms of the FOI Act 
should be directed without delay to the FOI Office, Department of Justice, 
Equality, and Law Reform.  This is necessary so that the request can be formally 
acknowledged and distributed to relevant sections.   
 
2. No attempt should be made to respond directly at local prison level to any FOI 
request.  This is necessary because of the formal nature of the FOI application and 
appeal process and the need to formally document the process. 
 
3. Healthcare staff should be aware that, under the FOI process, an applicant may 
request the entirety of his/her healthcare record.  Where, in the course of normal 
clinical interaction information is being provided by, or solicited from, third 
parties (relatives, etc.) it should be made clear to informants that such information 
may subsequently be divulged under FOI application. 
 
4. Where clinical information (often the prisoner’s medical file or copy) is requested 
this should be forwarded directly by local healthcare staff to Healthcare 
Directorate where a decision will be made regarding the extent of response to any 
FOI request.  This is necessary to ensure that confidential clinical information 
remains so. 
 
5. Given that FOI requests have to be responded to within 28 days of receipt (by the 
FOI Office) the need for rapid response to requests for files, etc., will be apparent. 
 
 
 
Healthcare Directorate 
27/07/2004 
 
 
 
 
 
 
 
 
 
 
HC Policy A/12 
 
Re : REPATRIATION OF PRISONERS UNDER THE TERMS OF THE 
EUROPEAN CONVENTION ON THE TRANSFER OF SENTENCED 
PRISONERS  
 
As you are probable aware the above Convention has been in operation for a number of 
years and has led to the transfer of a number of sentenced prisoners to other jurisdictions 
to complete their sentences.  In processing requests from prisoners it has been 
administrative practice to seek various reports, including medical, for transmission to the 
receiving jurisdiction.  
 
It is requested that medical reports be forwarded directly with the prisoner/patient at the 
time of transfer (rather than to the central prison healthcare administration as formerly).  
With this in mind any medical summaries or reports relating to a transferring prisoner 
being transferred under the Convention should accompany the prisoner directly at time of 
transfer rather than being forwarded in advance.   
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/13 
 
Re :  ANNUAL MEDICAL REPORTS 
 
Current Prison Rules, together with the Doctor’s Common Contract (item 5h) require that 
an annual report dealing with medical issues within the prison is forwarded on a regular 
basis.  Copies should be forwarded to HC Directorate and to the local Prison Governor. 
 
As you are aware there are very significant changes in the management of the Prison 
Service currently in train with the development of an independent authority to run the 
Prison Service.  You will be aware that a Prison Service Strategy Statement together with 
the associated Business Plans which have been prepared at establishment level will 
impact on health care provision.  In all likelihood there will, over time, be a greater 
requirement for accurate account of workloads, healthcare problems, etc.  Accurate, 
comprehensive annual reports are a necessity not only for statistical purposes but also in 
formulating longer term strategic planning of future developments in the prison 
healthcare field. 
 
For future reports it is suggested that information under the following broad headings 
should be included - 
 
  General Health of Prisoners 
 
  Mental Health of Prisoners 
 
  Infectious Diseases - in particular TB, Hepatitis B & C, and HIV. 
 
 Drug Misusers - numbers presenting, particular drugs being abused, 
management strategies, liaison with external agencies, etc.. 
 
  Deaths / Suicides 
 
 Medical Documentation - including the adequacy of standard sheets, 
transfer of medical information , etc. 
 
 Health Care Accommodation - adequacy of existing surgery 
accommodation and equipment, need or access to in-patient medical or 
psychiatric facilities. 
 
 Health Care Staffing - adequacy of number and training of staff, etc. 
 
 Visiting Specialists - numbers, frequency, adequacy of service, etc., 
 
 Health Education / Promotion - any local initiatives or plans for the 
future? 
 
 Medical Standards - any difficulties in providing prisoners with a standard 
of medical care equivalent to that available in the general community. 
 
 Other matters. 
           
While the above list may appear lengthy not all issues will pertain to each establishment.  
The benefit of a broadly standard format is that it will facilitate rapid identification of 
common issues or problems.  Furthermore, in endeavouring to obtain adequate resources 
for prison health care it will be increasingly necessary to establish and verify where 
problems exist and to what degree. 
 
Annual Reports dealing with Healthcare issues should be submitted by end-
February of the following year at latest. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/14 
 
Re: EXTANT MEDICAL APPOINTMENTS ON COMMITTAL  
 
Whenever a prisoner is received into prison initial health care screening should query 
existing medical conditions or appointments pending.   
 
Any pre-existing appointments for essential medical procedures through the public health 
system should be maintained and implemented.  Where such arrangements relate to what 
would be considered elective or non-essential treatment consideration should be given to 
postponing or deferring these arrangements until such time as the person is again at 
liberty.  Given the very significant cost of escorting prisoners to external hospitals 
together with the associated security risks all possible steps should be taken to limit 
referral to what is considered essential on clinical grounds.   
 
As it is policy to provide prisoners with access to health care on an equivalent basis to 
public patients in the general community any pre-existing arrangements for private health 
care should, if appropriate, be  converted to provision through the public health 
mechanism or, if not considered essential, deferred. 
 
Your cooperation in this matter is appreciated. 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/15 
 
Re :  REFERRAL FOR SPECIALIST MEDICAL ASSESSMENT 
 
Concern has been expressed that prisoners are being referred to specialist medical 
services, in particular in-house psychiatric clinics, without having been assessed by the 
prison doctor.   
 
Medical protocol (which will be familiar to Prison Doctors) is that access to secondary 
specialist service is following primary assessment by a general practitioner.  This 
procedure should also operate within prisons.  You will appreciate that, as the physician 
with primary healthcare responsibility for prisoners, it is necessary for the prison doctor 
to be aware and involved in referral decisions.   
 
Your co-operation in this matter would be appreciated 
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/16 
 
Re: SPECIAL OBSERVATION LISTS (MEDICAL) 
 
While Special Observation of prisoners may be indicated for a variety of reasons (many 
of which have no healthcare implication) where such observation  procedures are 
considered necessary on healthcare grounds the following procedure should be observed 
to ensure that this is only engaged in for specified reasons and for the minimum time 
possible -  
 
1) Special Observation on medical grounds must be authorised by a doctor (the 
Prison Doctor, Visiting Psychiatrist, or other appropriate doctor).  Where, on the 
grounds of urgent need, another member of staff initiates Special Observation 
procedures (citing medical reasons) the doctor must be consulted as soon as 
possible.  The doctor should review the circumstances necessitating the Special 
Observation and, if appropriate, authorise it in writing. 
 
2) The rationale for Special Obs. (on medical grounds) should be entered in the 
prisoner’s medical file and, subject to the requirements of medical confidentiality, 
be communicated to the Governor and other relevant staff.  Communication with 
staff should offer advice regarding the frequency and method of observation. 
 
3) The need for on-going (medical) Special Obs should be reviewed on a daily basis 
by the doctor. 
 
4) Where, in the opinion of the doctor, Special Obs. is no longer indicated s/he 
should enter a note to this effect in the prisoner’s medical record and 
communicate this lapsing of medical authority to the Governor. 
 
5) Where Special Obs. is maintained on a prisoner for a continuous period of 14 
days or more formal consultation should occur between the Healthcare team and 
Prison Management to assess whether medical or organisational factors can be 
brought into play to resolve such an on-going need.   
 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
HC Policy A/17 
 
Re:  NOTIFICATION OF THE IMPENDING TRANSFER OF A PRISONER TO 
HEALTHCARE STAFF. 
 
Efficient healthcare provision in prison would dictate that arrangements be in place to 
ensure that healthcare staff are informed of all impending transfers.  This is essential to 
facilitate the transfer of appropriate information and medical notes. 
 
Suitable arrangements should be in place in all establishments to ensure that this occurs. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/18 
 
Re : ACCESS TO MEDICAL FILES ON TRANSFER 
 
Where a prisoner is being transferred to a new prison the medical staff in the forwarding 
prison should ensure that information regarding medication due accompanies the 
prisoner.  Concern has been expressed that confidential medical files accompanying 
prisoners on transfer are being opened by non-medical staff in the receiving prison.  This 
applies particularly in relation to transfers to open centres which do not have 24 hour 
medical orderly cover.  Ostensibly, this practice is justified on the grounds that it is 
necessary to determine what (night) medication a prisoner might be due on arrival in the 
receiving prison.   
 
Where a prisoner is going to a centre where there is unlikely to be a medical member of 
staff on duty to receive the file on arrival it would be appropriate to attach information 
regarding medication due under separate cover to the main medical file.  While it is 
highly unlikely that the omission of a single dose of any medication that a prisoner 
suitable for an open centre might be prescribed would have a significant detrimental 
effect this procedure would obviate any need for lay staff to be seeking to access the 
confidential medical file.   
 
Your co-operation in this matter would be appreciated. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/19 
 
Re : POTENTIAL CONTAMINATION OF URINALYSIS RESULTS FOR 
DRUGS OF ABUSE 
 
As you are probably aware there is increasing resort within the prison system to 
undertaking urinalysis for various illicit drugs.  In many cases it is to determine drug use 
prior to prescribing a detoxification regime whereas in other cases it is part of an on-
going therapeutic programme.  In further cases demand for urinalysis may be court driven 
or related to security concerns within a prison establishment and so, strictly, not part of 
any medical procedure.  In these cases there may be no involvement of prison healthcare 
personnel. 
 
In this context it is essential to minimise potential challenges to the accuracy of test 
results.  One possible reason for a false-positive result is the presence of prescribed 
medication or other adulterant in a sample.  In the case of all samples submitted to an 
external laboratory for analysis it is important to indicate any prescribed medication 
which might be present.  It goes without saying that a procedure should be in place to 
ensure the integrity of all samples which may have a detrimental or other effect on a 
prisoner.   
 
If you have any further queries regarding this issue you should direct them to Mr. John 
O’Sullivan, Biochemistry Section Head at Claymon Laboratories who can be contacted at 
01- 295 8545. 
 
 
 
Healthcare Directorate 
April 2004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/20 
 
Re : PEOPLE ENTERING PRISON WITH METHADONE SUPPLIES 
 
As a safety measure and to assist in risk management it has been agreed that as and from 
1 April 2004, individuals who enter the prison system with supplies of Methadone (which 
may, of course, be in legitimate possession) should NOT have any such supply returned 
on release. 
 
Any prisoner who requests the return of such property should be advised that it will be 
necessary for him/her to attend their local community drug treatment centre for the 
renewal of prescription and supply of this medication. 
 
Any such quantities of methadone being retained in the prison system should be disposed 
of by approved means. 
 
* See A 23 Policy on Disposal of Patients Legally Dispensed Methadone* 
 
 
 
 
Healthcare Directorate 
12/03/2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/21 
 
Re : NURSING CLINICAL RECORDS - First issued 10/01/02. 
 
If not already in place, it is now policy that all health care areas maintain a nursing 
journal, similar to a ward report book. Depending on the size and operation of the 
institution, it may be appropriate for the nurses covering particular wings to maintain a 
written report for that wing; this will facilitate hand over between shifts and ensure that 
no relevant data is omitted at hand over. It is each nurses responsibility to familiarise 
themselves with the contents of the nursing journal relevant to their area of duty. 
Nursing notes regarding any aspect of patient care, (Statutory duty under Nurse’s Act 
1985) can be subpoenaed for Courts of Law and or Professional Conduct Committee or 
accessed under the Freedom of Information Act. The records are there to facilitate good 
communication and effective patient care; they also afford nurses protection if properly 
maintained. “Remember if it is not recorded it didn’t happen”. 
Records should be accurate, precise, relevant and concise, “making and keeping records, 
is an essential and integral part of care and not a distraction from its provision.” (Nursing 
and Midwifery Planning and Development Unit SEHB 2001). 
Nursing records are confidential and should be maintained in a safe area. 
 
Best Practice Guidelines for Record Keeping modified for the prison service. 
 
 Record keeping should provide a record on committal against which improvement or 
deterioration may be judged. Where present identify and record risk factors on 
committal. 
 
 Records should provide evidence of care planned, decisions made, the care delivered 
and information shared. 
 
 Records should follow in chronological order of events and reasons for decisions 
made. 
 
 Records should provide accurate, correct, comprehensive and concise information 
concerning the condition and care of the patient and associated observations. 
 
 Records should record physical, psychological and social factors that appear to affect 
the patient. 
 
 Records should be made as soon as possible after the action or event to which they 
relate. 
 
 Records should be written legibly and indelibly using the patients name and a unique 
identifier, e.g. PRIS No. 
 
 Records should be clear and unambiguous. 
 
 Records should be accurate in each entry as to date, time, (24 hr clock) and signed. 
 
 Ensure any alterations are scored through with a single line followed by the signed, 
dated and timed correct entry. A record should never be erased; Tippex or erasing 
fluid should never under any circumstances be used. 
 
 Ensure additions to existing records are individually dated, timed and signed. 
 
 Records should not include jargon or subjective statements. 
 
 Only approved abbreviations should be used. 
 
 NO abbreviations should be used on nursing documentation that is to be used for 
discharge or transfer purposes. 
 
 Records must be objective and describe what is observed. If an incident has not been 
observed but is relevant to patient care, then this must be clear e.g. Patient states..... 
   
 Pencil, red, green or coloured pens other than black or blue should not be used. 
 
 Instructions regarding patient care from a doctor via a telephone should be 
documented. If no instructions are given this should also be documented. Where 
possible a fax machine should be used and the fax signed by the doctor at the earliest 
possible opportunity and filed in the patient’s chart. 
 
 NEVER chart an action for someone else or allow someone to chart an action for you. 
 
 Abnormal test results should be charted in the patient’s medical noted and the doctor 
informed. 
 
 Records, where possible, will be written in terms the patient will be able to 
understand. 
 
 When decisions are made that your patient does not like; record the reasons for the 
decision; explain the reasons to the patient and try and ensure he/she understands. 
 
 All medications should be written up and recorded on a medical kardex prescription. 
   
 A signature bank, i.e. sample of signature and initials of all healthcare staff, should be 
maintained in each surgery and a copy in the Governors. 
 
Records are currently made in hand written form - at some stage in the future this 
may be done electronically, until that time the above guidelines are to be followed. 
This document may be amended from time to time to reflect best practice. 
Please find attached a list of approved abbreviations. 
 
  
 
AAA   Abdominal Aortic Aneurysm 
AIDS  Acquired Immune Deficiency Syndrome   LMP Last Menstrual Period 
APTTR  Activated Partial Thromboplastin Time Ratio   LIF Left lliac Fossa 
AL  Activities Of Living    LFT’s Liver Function Tests 
ARDS  Adult Respiratory Distress Syndrome   L.A. Local Anaesthetic 
ABC  Airway Breathing Circulation   L.S.C.S. Lower Segment Caesarean Section 
ABG’S  Arterial Blood Gases         
 PRN  As required 
       MRI Magnetic Resonance Imaging Scan 
       MRSA Methicillin Resistant Staphylococcus Aureus 
Ba enema  Barium Enema     MSU Midstream Specimen of Urine 
Ba meal  Barium Meal     mmHg Millimetres Mercury 
B.d.  Twice daily     MDA’s Misuse Of Drugs Act 
BPM  Beats per minute    mane Morning 
BHCG  Beta Human Chorionic Gonadotrophins   MI Myocardial Infarction 
BPD  Bipartial Diameter 
B/P  Blood Pressure    N.G.T. Naso Gastric Tube 
       NG Naso - gastric 
C.B.T.  Cognitive Behaviour Therapy   nocte Night time 
CPR  Cardiopulmonary Resusciation   NPU Not passed urine 
CVS  Cardiovascular System    NPO Nil Per Orum 
CSU  Catheter Specimen of Urine    NaCl Sodium Chloride 
CNS  Central Nervous System    NAD No Abnormality Detected 
CVP  Central Venous Pressure    N.M.S.  Neuroleptic Malignant syndrome 
CSF  Cerebro Spinal Fluid 
CVA  Cerebrovascular accident    OGD Oesophago - Gastro Duodenoscopy 
CXR  Chest Xray     O2 Oxygen 
COAD  Chronic Obstructive Airways Disease 
COPD  Chronic Obstructive Pulmonary Disease   PARA Parity 
CRF  Chronic Renal Failure    P.U. Passed Urine 
COAG Screen  Coagulation Screen    PCA Patient Controlled Analgesia 
CT  Computerised Tomography    P.O. Per Oral 
CCF  Congestive Cardiac Faliure    PR Per Rectum 
CPAP  Continuous Positive Airway Pressure   PV Per Vagina 
CABG  Coronary Artery Bypass Graft   PEG Percutaneous Endoscopic Gastrostomy 
CJD  Creutzfeldt - Jakob Disease    PEJ Percutaneous Endoscopic Jeiunostomy 
C&S  Culture and Sensitivity    P.K.U. Phenylketonuria 
CMV  Cytomegalovirus    PFA Plain Film Abdomen 
       P.O.P. Plaster of Paris 
D.V.T.  Deep vein Thrombosis    POST OP Post Operation 
DT’s  Delirium Tremens    P.P.H. Post Partum Haemorrhage 
DIC  Disseminated intravascular coagulation   KCL Potassium Chloride 
DHS  Dynamic Hip Screw    P.E.T. Pre Eclamptic Toxaemia 
D.S.H.  Deliberate self harm    PRE OP Pre Operation 
       P.I.H. Pregnancy Induced Hypertension 
ECHO  Echocardiogram    P.R.O.M. Pretem Rupture of Membranes 
ECG  Electrocardiogram    PT Prothrombin Time 
ECT  Electroconsulvant Therapy    PFT’s Pulmonary Function  Tests 
EEG  Electroencephalogram    PEARL Pupils Equal and Reacting to Light 
E.T.  Endo Tracheal     PUM Person unsound mind 
ERCP  Endoscopic Retrograde Cholangiopancreatograph 
ET tube  Endotracheal Tube    qid four times daily 
ESR  Erythrocyte Sedimentation Rate 
ERPC  Evacutation of Retained Products of Conception  RCC Red Cell Concentate 
EUA  Examination under Anaesthetic   RTI Respitatory Tract Infection 
E.D.D.  Expected Date of Delivery    R.I.P. Rest in Peace 
       RH Rhesus 
FOB  Faecal Occult Blood    RIF Right Iiiac Fossa 
FFP  Fresh Frozen Plasma    RTA Road Traffic Accident 
FBC  Full Blood Count     
       SBR Serum Bilirubin rate 
GIT  Gastrointestinal Tract    STD Sexually Transmitted Disease 
GA  General Anaesthetic    S.V.D. Spontaneous Vaginal Delivery 
G.P.  General Practitioner    SC Subcutaneous 
GUM  Genito Urinary Medicine    S/L Sublingually 
GO  Genitourinary     stat Immediately 
GCS  Glasgow Coma Scale    SLE System Lupus Erthematous 
G.T.T.  Glucose Tolerance Test 
GTN  Glyceryl Tri-nitrate    T.P.R. Temperature Pulse Respiration 
       Tid Three times daily 
HB  Haemoglobin     TEDs Thrombo Embolic Deterrent Stockings 
HC  Head Circumferance    TFT’s Thyroid Function Tests 
H.V.S.  High Vaginal Swab    TSH Thyroid Stimulating Hormone 
Hx  History     TAH Total Abdominal  Hysterectomy 
HRT  Hormone Replacement Therapy   TPN Total Parenteral Nutrition 
HCG  Human Chorionic Gonatrophin (Pregancy Test)  TURP Trans Urethral Resection Prostate 
H.I.V.  Human Immuodeficiency Virus   T.VU/S Trans Vaginal Ultrasound 
       TENS Transcutaneous Electro Nerve Stimulation 
INR  International Normalised Ratio   TIA Transient Ischaemic Attack 
I.U.G.R.  Intra Uterine Growth Retardation   RX Treatment 
       T.L. Tubal Ligation 
Im  Intramuscular     TB Tuberculosis 
I.V.  Intravenous 
IVI  Intravenous Infusion    US Ultrasound 
IVP  Intravenous Pyelogram    USS Ultrasound Scan 
IVT  Intravenous Therapy    U&E Urea and Electrolytes 
       UTI Urinary Tract Infection 
JVP  Jugular Venous Pressure 
       V.E. Vaginal Examination 
KVO  Keep Vein  Open    VQ Ventilation Perfusion Scan 
KUB  Kidney Ureter Bladder Xray    
       WBC While Blood Count 
       WCC White Cell Count 
        
       ZN Ziehl Neelsen Stain  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/22 
     
 
Re: PROCEDURE PENDING EMERGENCY TRANSFER TO EXTERNAL 
HOSPITAL  
 
It is recommended that all prisoners who are awaiting transfer to external hospitals 
(usually to A& E departments) for emergency assessment should be placed on Special 
Observation pending transfer, whether this be by ambulance or by prison escort.  This 
procedure is recommended to minimise the risk that further injury or illness occurs before 
transfer. 
 
Your co-operation in this matter is appreciated. 
 
 
 
 
Healthcare Directorate 
02/12/2005 
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POLICY ON DISPOSAL OF PATIENTS LEGALLY DISPENSED METHADONE 
 
This policy assumes that any green liquid whether labelled as Methadone or not, found on 
the person of a prisoner, is and will be treated as Methadone. 
  
1. Should a quantity of legally dispensed Methadone be found on the person of a prisoner 
on committal to prison, this should be immediately taken from the prisoner. 
 
2. It should then be taken to the surgery and handed to a member of the healthcare staff. 
 
3. The approximate volume should be estimated by the healthcare staff member. 
 
4. An entry should be made in a separate section of the Controlled Drug Register, stating: 
 
 Date received in surgery. 
 Name, DOB, PRIS of prisoner on whose person Methadone was found. 
      Name of clinic/pharmacy where supply dispensed 
 Date on which dispensed. 
 Approximate volume. 
 Signature of two members of healthcare staff. 
   
5. This supply should then be stored in the controlled drugs safe, separate from surgery 
stock. 
 
6.  Disposal - All Dublin prisons: 
 
 Pinewood Healthcare have agreed to accept, for disposal, all such Methadone stock 
from each of the Dublin prisons. 
 At regular intervals, when there is a reasonable amount of such Methadone in stock,  
      David Brannigan, Pinewood Healthcare  should be contacted on 087 8118209 
 He will then, by arrangement, call to the prison surgery to collect this Methadone. 
 He will supply the necessary paperwork, which should be completed, and signed by 
both a healthcare staff member and himself. 
 An entry should then be made in the register, stating: 
1)            Date supply collected by Pinewood. 
2)            Total quantity collected. 
3)            Signature of two staff members. 
 A copy of the completed Pinewood paperwork should be retained in the surgery, in 
the Controlled Drug Register. 
 
7. Disposal - all other prisons: 
Please inform the Co-ordinator of Pharmacy Services at 01 4616121 or 087 9292539, 
whenever there is a supply for disposal and appropriate local arrangements will be made. 
 
H/C Policy A /24                                                          
  
ARRANGEMENTS FOR CONTINUATION OF METHADONE TREATMENT 
FOR CLIENTS ON RELEASE FROM PRISON. 
 
 
 
 Methadone is subject to control under the Misuse of Drugs Regulations 1988 and 
1993 and the Misuse of Drugs (Supervision of Prescription and Supply of 
Methadone) Regulations 1998. 
 
 While prisons are not specifically include in legislation relating to the use of 
methadone, the 1998 Regulations provide for administration of methadone to 
patients while in hospital, but does not allow for supply of methadone on a take-
away basis from a hospital. Advice from the Department of Health and Children 
is that, in this regard, prisons equate with hospitals and so methadone take-aways 
for use outside the prison may not be provided from the prison. 
 
 
 In addition, in the interest of safety, methadone may only be supplied from one 
source and so when a client is released from prison further supplies must only be 
obtained from the community services. 
 
 
 Effective and efficient communication between both the IPS and the HSE is 
essential to ensure seamless care and safe and effective treatment for our patients. 
 
 
 The release of patient’s medications information must be confirmed by fax to the 
requesting service, by means of the “PRISON/COMMUNITY TRANSFER OF 
INFORMATION" form (Appendix 2) which must be completed and faxed to the 
requesting service. 
 
 Appendix 1 provides the relevant contact details in each area.  
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Appendix 1 : Community services contact details: 
 
Dublin 
Area 
GP  
Co-
ordinator 
Contact 
details 
Chief 
Pharmacist 
Contact details 
NAHB Dr Des 
Crowley 
087 
2198094 
Nihal Zayed 
2nd Floor 
PhibsboroTower 
Dublin 
 
087 2252860 
01 8820309/327 
 
nihal.zayed@mailc.hse.ie 
SWAHB Dr 
Margaret 
Bourke 
086 
8177112 
Denis 
O’Driscoll 
Bridge House 
Cherry Orchard 
Hospital 
Ballyfermot 
Dublin 10 
087 2904852 
 
 
 
denis.odriscoll@mailf.hse.ie 
ECAHB Dr Cathal 
O’Sullivan 
087 
2937570 
Helen Johnston 
Centenary 
House 
Dun Laoghaire 
Co. Dublin 
086 8543733 
01 2803335 
 
Helen.johnston@maild.hse.ie 
 
 
 
AREA Contact person: Contact details 
Midlands Dr Paul Gallagher 
The Old Maltings 
Coote Street, 
Portlaoise 
Co. Laois 
086 8511356 
 
057 8692516 (Portlaoise 
Clinic) 
Portlaoise Clinic: 
Open Tuesday afternoon 
and all day Wednesday 
Athlone Clinic : 
Open Thursday and 
Friday afternoons  
Mid-Western Rory Keane 
A/Regional  Drug Co-ordinator, 
HSE West, 
Limerick   
 
 
061 483751 
087 2464393 
 
North Eastern Liz Hoctor MPSI 
Primary Care Unit 
HSE/NE, 
Navan, Co. Meath 
046 9076400 
087 2704823 
046 9071052(fax) 
 
Paula Loughran 
Addiction Services 
Chapel St, Dundalk 
 
John Taaffe, Drogheda 
042 9357518 
 
 
 
041 9843531 
North Western Patricia Garland 
Addiction and Counselling Services 
NWHB 
12 Johnston Court 
Sligo 
 
 
 
 
071 9143316 
 
 
 
 
Southern 1. Dr Catherine Murphy 
or 
2. Willie Collins 
Co-ordinator, Drugs and Alcohol 
Services 
St Finbarrs Hospital 
Douglas Road 
Cork 
021 4923937 
 
 
021 4923135 
 
South Eastern Carlow/Kilkenny: Catherine Lawlor 
Waterford:             Pat O’Neill 
Wexford:               Chris Parnell 
Tipperary:              John Casey 
056 7784638 
051 301201 
051 426600 
052 77900 
Western Western Health Board Drugs 
Services  
West City Services 
64 Dominic Street 
Galway 
091 561299 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2:   Prison/Community Transfer of Information Form 
 
 
PRISON/COMMUNITY TRANSFER OF INFORMATION FORM 
 
This form must be faxed from the dispensing pharmacist in the community to the 
healthcare staff in the prison and vice versa as appropriate, before a new prescription is 
written or the next dose of methadone /medicines is administered. 
 
 
Client 
Name 
DOB Prison/Clinic Methadone 
dose (in 
words and 
figures) 
Date last 
dose 
dispensed 
Other 
medication 
Date last 
dispensed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
Confirmed by: 
 
 
Name:     _______________       Signature: __________________________ 
                                                                      Pharmacist/RGN/RPN/MO/GP 
 
Date:       _____________ 
 
This form must be retained as per HSE/IPS policy. 
 
 
 
 
 
 
 
 
HC Policy A/25 
 
GUIDELINES ON SAFE AND APPROPRIATE SETTINGS FOR METHADONE 
ADMINISTRATION. 
 
1. It is essential that all supervised medication administration takes place in a safe 
manner, to ensure that the right medication is given to the right patient in the right 
dose in the correct from at the correct time.  
 
2. Within the prison setting it is essential that all such medication is administered in 
a secure area and as set out in Healthcare Policy C/8 (Policy on Medication 
Administration) and that all administration is recorded appropriately in a timely 
manner. 
 
3. Due to the stricter controls governing the use of Controlled Drugs such as 
methadone, and the increased possibility of diversion/abuse of this drug, it is 
essential that administration of methadone takes place only in a secure area, (i.e. 
the prison surgery or pharmacy, or designated secure administration areas in the 
prison (i.e. behind a hatch in a dedicated room on a wing). 
 
4. All prisoners prescribed methadone should attend the surgery/designated 
administration area each day and methadone should never be taken in 
individual doses to a prisoner’s cell, except in very exceptional circumstances 
such as when, for reasons of serious ill-health, the prisoner cannot attend the 
surgery or designated area. 
 
5. Should it be necessary for a patients dose of methadone to be brought to his/her 
cell in the circumstances set out above, this should only be done at an appropriate 
time when no other prisoners are out of their cells, and there is adequate staff 
available to ensure that this can be done safely. 
 
 
 
 
Healthcare Directorate 
September 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC Policy A/26 
 
GUIDELINE ON PROCEDURE TO BE FOLLOWED IN CASES OF 
ALLEGATION OF ILL-TREATMENT BY PRISONERS . 
 
 
HC Policy A/4 ‘Medical Assessment of New Receptions’ provides guidance in relation to 
the timely assessment of new committals to prison, including the necessity to specifically 
make enquiry regarding any injuries alleged at that time, how these are alleged to have 
occurred, whether the clinical findings are consistent with the history.   
 
This present guidance is to confirm that a consistent procedure should be applied in any 
case where a prisoner alleges that s/he has been the subject of ill-treatment irrespective of 
the origin of any such treatment.  At all times it should be borne in mind that that the 
clinical findings associated with any such allegation may be the subject of subsequent 
legal proceedings.   
 
1, Any allegation of injury or ill-treatment should be clinically assessed without 
delay.   
 
2. A thorough history of the alleged injury should be documented on PMRS.  This 
will assist in confirming the timing of clinical intervention.  Assessment should 
include the means by which the injury is claimed to have occurred, the timing of 
the incident causing the injury, any other parties involved, etc. 
 
3. Any associated clinical findings, whether confirmatory or otherwise, noted at the 
time of assessment should be thoroughly documented.  It is appropriate for the 
assessing doctor to offer a qualified clinical opinion on whether the findings noted 
are consistent with the history. 
 
4. Any immediate steps deemed appropriate or necessary to safeguard the health or 
welfare of the prisoner or prisoners involved should be instigated. 
 
5. All clinical involvement by members of the prison healthcare team should be 
thoroughly documented on the basis that these may be required for subsequent 
legal proceedings. 
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